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Abstract 
 
 
Imatinib was the first targeted tyrosine kinase inhibitor (TKI) to be approved for clinical 
use, and remains first-line therapy for Philadelphia chromosome (Ph+)-positive chronic 
myelogenous leukaemia (CML). The second-generation inhibitor, nilotinib, was 
subsequently approved for treatment of CML patients that are resistant, or develop 
resistance, to imatinib. Imatinib was subsequently approved as front-line therapy for the 
treatment of gastrointestinal stromal tumours (GISTs), but failed clinical trials for 
glioblastoma multiforme (GBM). The present study shows that treatment of cultured glioma 
cells and glioma cells isolated from human biopsies with imatinib or nilotinib strikingly 
increases tyrosine phosphorylation of p130Cas, focal adhesion kinase (FAK) and paxillin 
(PXN), resulting in enhanced cell migration and three dimensional radial invasion. Imatinib 
and nilotinib-induced tyrosine phosphorylation and invasion is dependent on expression of 
p130Cas and FAK activity, and is not dependent on known imatinib and nilotinib targets 
including ABL, ARG, platelet derived growth factor receptor (PDGFR) and the collagen 
receptor DDR1. Interestingly, findings implicate the serine / threonine phosphatase PP2A in 
mediating tyrosine phosphorylation of p130Cas, FAK and PXN. Inhibition of PP2A with 
okadaic acid significantly increased basal levels of tyrosine phosphorylation of the three 
proteins. Conversely, pharmacological activation of PP2A using FTY720 strongly inhibited 
imatinib and nilotinib stimulated tyrosine phosphorylation. Imatinib and nilotinib also 
stimulate tyrosine phosphorylation and radial invasion in GIST cells, a cancer for which 
imatinib is already approved. These TKIs also stimulate tyrosine phosphorylation of 
p130Cas, FAK and PXN in hepatocellular liver carcinoma cells, and in non-transformed 
primary cell lines. Interestingly, Imatinib and nilotinib treatment of GBM cells results in 
increased serine phosphorylation of p130Cas, FAK and PXN. Findings here indicate 
important and unforeseen adverse effects of imatinib and nilotinib treatment on key 
motility-related pathways, which could be a significant contributor to the lack of clinical 
efficacy in GBM and to the development of resistance.  
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1 Introduction 
 
 
 
1.1 The tumour microenvironment 
 
1.1.1 The hallmarks of cancer  
 
In their seminal paper Hanahan and Weinberg proposed that tumour growth and metastasis 
occurs via the acquisition of the following distinct and complementary capabilities, to which 
they refer to as the “hallmarks of cancer”: resisting cell death, up-regulated proliferative 
signalling, evasion of growth suppressors, limitless replicative potential, sustained 
angiogenesis, and the ability for invasion (Fig. 1.1.1). The acquisition of these capabilities is 
dependent on alterations in the genomes of neoplastic cells. Genome maintenance systems 
govern genomic integrity in healthy cells by successfully detecting and resolving DNA 
defects. When these surveillance systems become deregulated, an accelerated mutation rate 
enables evolving premalignant cells to rapidly accumulate favourable genotypes, analogous 
to Darwinian evolution, which underpin the hallmarks of cancer (Hanahan and Weinberg, 
2000). 
 
A decade later, the two authors published an updated list of tumour hallmarks based on the 
progresses that had been made in understanding tumour biology. The revised list of 
hallmarks includes two enabling characteristics that allow for the acquisition of the six 
functional capabilities published earlier: genome instability and tumour-promoting 
inflammation (Fig. 1.1.1).  The collapse of genomic maintenance machinery and increased 
sensitivity to mutagenic agents leads to genomic instability and increased mutability. A 
higher rate of mutation enables those cells with mutant phenotypes that confer advantage to 
survive, grow and eventually dominate in a local tissue environment. Infiltrated immune 
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cells are detected in virtually all tumours at varying densities where they mimic 
inflammatory conditions that arise in non-neoplastic tissues. The presence of immune cells 
in tumours was initially regarded as a reflection of the immune system’s attempt to eradicate 
tumour cells. It later became apparent that tumour inflammation induces a paradoxical effect 
of promoting tumourigenesis and enabling the acquisition of the functional hallmarks of 
cancer. In some cancers, inflammation is detected at the earliest stages of tumour 
pathogenesis where it contributes significantly to the progression of early neoplasias into 
cancer by supplying tumour-promoting molecules to the neoplasm such as growth factors, 
proangiogenic factors and survival factors that prevent cell death (Hanahan and Weinberg, 
2011). 
 
Included in the revised list are also two emerging characteristics that are increasingly being 
recognised as important hallmarks contributing to tumour pathogenesis: the tumour cells’ 
ability to adjust energy metabolism towards a higher rate of glycolysis to meet the growing 
requirement for energy needed to sustain cell division and proliferation; and their ability to 
evade destruction by the immune system (Fig. 1.1.1)  (Hanahan and Weinberg, 2011).  
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Figure 1.1.1 Hallmarks of cancer that contribute to tumour pathogenesis. The diagram 
includes the six original hallmarks proposed by Hanahan and Weinberg in 2000 which 
enable tumour growth and spread (in blue), and the additional four emerging hallmarks 
proposed in 2011 (in grey). [Figure adapted from (Hanahan and Weinberg, 2011)] 
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1.1.2 Tumour heterogeneity 
 
Neoplasms originate from normal cells that accumulate genetic and epigenetic alterations 
required for transformation. Even though spontaneous tumours originate from a single cell, 
by the time of clinical diagnosis, most tumours display heterogeneity in their phenotypic 
features to include cellular morphology, gene expression, metabolism, motility, and 
angiogenic, proliferative, immunogenic, and metastatic potential (Marusyk and Polyak, 
2010). Although the “hallmarks of cancer” which enable tumour progression are the same, 
the particularities driving growth differ according to environmental stresses that are present. 
Tumour heterogeneity is crucial to malignancy as it impedes diagnosis and poses great 
challenges to the design and choice of effective therapies. Tumours within a single organ 
differ, and this is referred to as inter-tumour heterogeneity. Importantly, cells within the 
same tumour also differ. The tumour microenvironment affecting tumour cells is not 
homogeneous, requiring phenotypic and genetic differences for cell survival. Differences in 
oxygen pressure, access to blood vasculature, and composition of the extracellular matrix 
can all be observed within a single tumour, all of which place different pressures on cells. 
The changing tumour microenvironment leads to the emergence of different clones within a 
single tumour, referred to as intra-tumour heterogeneity (Inda et al., 2014).  
 
The existence of heterogeneity has long been recognised, but the relative contributions of 
different mechanisms is still not clear. The widely accepted Darwinian model to explain the 
progression of cancer stipulates that genetic or epigenetic mutations occur at random and 
favourable phenotypes produce clones best fit to survive environmental changes and these 
outgrow other clones. The genetic heterogeneity caused by changes in the genome translates 
into phenotypic heterogeneity. Within the framework of this model, heterogeneity could be 
explained by the presence of remaining weaker clones generated during tumour growth. In 
the context of chemo- or radiotherapy, acquiring resistance allows a population of cells to 
respond to a selection pressure, evade treatment, survive and expand (Inda et al., 2014, 
Marusyk and Polyak, 2010). Darwinian clonal evolution is supported by genome-wide 
studies and advances in next-generation sequencing. Many studies have identified genetic 
heterogeneity within individual cancers, revealing distinct clonal subpopulations that 
represent sequential clonal expansions.  (Zellmer and Zhang, 2014, Navin et al., 2011). 
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1.1.3 Cancer stem cells 
 
The view of heterogeneity based on principles of Darwinian evolution stipulates that a 
single somatic cell with a heritable mutation conferring survival advantage will proliferate 
and outlive other cells. Consequently, natural selection leads to clonal expansion, and cells 
within a tumour share common genetic abnormalities which can reflect their clonal origin. 
But single-cell analysis also shows differences in genetic and epigenetic abnormalities 
between individual cells. The major problem in cancer research is identifying the cell 
capable of initiating and sustaining growth of the neoplastic clone. More recently, the cancer 
stem cell (CSC) theory was proposed, stipulating that only a small fraction of tumour cells 
with the ability to self-renew and differentiate into “non-stem” cells are responsible for the 
maintenance of tumours (Marusyk and Polyak, 2010, Dick, 2008). Both the CSC theory and 
the clonal evolution model have been proposed to explain intra-tumour heterogeneity. The 
CSC theory proposes that a subset of cells with stem cell properties drive tumour initiation 
and progression. By contrast, the Darwinian clonal evolution model proposes that cells are 
subject to natural selection. A malignant cell accumulates hereditary changes over time that 
confer survival advantage that allow it to survive and expand (Michor and Polyak, 2010). 
 
The term “cancer stem cell” refers to the distinct cell within the neoplastic clone that is 
capable of initiating and sustaining tumour growth in vivo (Wang and Dick, 2005). The CSC 
model stipulates that a small number of phenotypically distinct tumorigenic cells form the 
majority of non-tumorigenic and phenotypically diverse cells that comprise the cancer. The 
now widely accepted CSC model of cancer evolution and heterogeneity was postulated 
initially for hematopoietic malignancies. Research into acute myeloid leukaemia (AML) 
revealed that cells have limited proliferative capacity, which suggested the malignant clones 
are maintained by a rare population of stem cells (Sawyers et al., 1991). Pluripotent stem 
cells in the bone marrow had been established, expressing high levels of cell surface marker 
CD34 (Civin et al., 1984). The subsequent development of xenotransplantation protocols 
using immunodeficient mice enabled the in vivo detection of stem cells capable of initiating 
cancer. It was discovered that distinct leukaemic cells derived from the peripheral blood or 
bone marrow of AML patients could reconstitute the disease when transplanted into 
immunodeficient mice; whereas all other leukaemic cells could not. These cells were found 
to express CD34 and lack CD38. Expression of CD38 on CD34-positive cells is a marker 
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for lineage commitment, suggesting that the cells able to reconstitute AML in mice were 
immature bone marrow cells (Lapidot et al., 1994).  
 
The ability to purify and analyse distinct CSCs has pointed to the presence of distinct 
heterogeneous types of stem cells with differing proliferative, differentiating, and self-
renewal capacities. The presence of CSCs provides evidence that non-heritable sources of 
tumour heterogeneity exist, by contrast to the Darwinian model of clonal evolution that 
relies on acquired genetic and epigenetic mutations. Importantly, the two models are not 
mutually exclusive and both are relevant to cancer initiation and progression. Tumour cell 
plasticity is an additional non-heritable source of heterogeneity, defining the phenotypic 
differences that arise due to changes in tumour microenvironment. In contrast to the CSC 
model, it has been found that heterogeneity in melanoma is driven by reversible phenotypic 
changes in vivo, whereby both the melanoma cells expressing and lacking specific cell 
surface markers are able to form tumours, and that the tumours exhibit similar heterogeneity 
of marker expression (Quintana et al., 2010, Shackleton et al., 2009, Inda et al., 2014).  
 
The interaction of tumour cells with their surrounding microenvironment shapes tumour 
progression and malignancy. Tumour cell plasticity enables cells to adapt to differences in 
the microenvironment by producing diverse phenotypes. Confounding diagnosis and 
treatment further, is the concept of inter-clonal cooperativity. This model stipulates that 
clones which possess a pro-oncogenic microenvironmental phenotype may alter the 
microenvironment through the secretion of extracellular factors to promote the growth of 
other clones (Inda et al., 2014). 
 
Clonal heterogeneity remains a poorly explored phenomenon. The co-existence of diverse 
clones within a tumour leads to complicated signalling network between the clones and the 
microenvironment and amongst the clones. Tumours are treated as complex systems, the 
complexity of which confounds diagnosis and impedes treatment. A particularly malignant 
type of cancer is glioblastoma multiforme. This glioma exhibits relentless progression via 
aggressive invasion and resistance to therapy as a result of widespread heterogeneity.  
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1.1.4 Glioblastoma multiforme 
 
Gliomas are glial malignancies, classified based on histopathological characteristics, 
according to World Health Organization (WHO) classification, into astrocytomas, 
oligodendrogliomas, or mixed oligoastrocytomas with morphological features of both 
astrocytes and oligodendrocytes. Tumours are then graded on a WHO scale of I-IV 
according to their level of malignancy (Furnari et al., 2007). Gliomas exhibit genetic 
differences as well as different cells-of-origin. However, they are similar in their ability to 
aggressively invade surrounding tissue (Cuddapah et al., 2014). 
 
Primary brain tumours account for 7% of lives lost yearly from cancer before the age of 70 
(Furnari et al., 2007). Glioblastoma multiforme (GBM) is a WHO Grade IV astrocytoma, 
and represents more than 15% of all primary brain tumours (Persano et al., 2013, Hou et al., 
2006). GBMs are heterogeneous masses that are made up of glioma cells, hyper-
proliferative endothelial cells, macrophages and trapped cells of the normal brain structures 
(Holland, 2001). GBM is the most aggressive malignant glioma, characterised by 
uncontrolled proliferation, diffuse infiltration, angiogenesis, resistance to apoptosis, and 
high genomic instability (Furnari et al., 2007).  
 
An increasing amount of genetic alterations often correlates with increasing severity of 
clinical outcome. Genetic mutations largely fall into two distinct categories, altering either 
signal-transduction pathways downstream of tyrosine kinase receptors, or disrupting cell-
cycle arrest pathways. The expression of growth factors and receptors that control glial cell 
differentiation are frequently elevated in gliomas, such as platelet-derived growth factor 
(PDGF), platelet-derived growth factor receptor (PDGFR), or epidermal growth factor 
receptor (EGFR) which is amplified in 30-50% of malignant gliomas. Excessive production 
of growth factor and growth factor receptors results in autocrine stimulation and increased 
downstream signalling (Holland, 2001). The p53 tumour suppressor represses abnormal cell 
proliferation and growth. It controls the arrest of the cell in the G1 phase, initiates DNA 
repair, induces programmed cell death, and promotes cellular differentiation (Louis, 1994). 
The gene encoding p53, TP53, is mutated in approximately 40% of GBM (Holland, 2001). 
 
More than 22,000 people a year are diagnosed with a malignant glioma in the USA alone. 
Therapy consists of a maximal tolerable surgical resection followed by radiation and 
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chemotherapy. However, this adds only several months of additional survival and the 
median patient survival time is only 12 to 18 months, with 95% of patients dying within 5 
years. Treatment remains ineffective because of the high intrinsic ability of GBM to invade 
surrounding tissue and by strong inter- and intra-tumour heterogeneity. Tumour cells 
aggressively diffuse into surrounding brain area, and recurrence after surgical intervention is 
inevitable. Gliomas show excessive intra-organ invasion but, by contrast to other cancers 
such as small-cell lung carcinoma or prostate cancer, less than 2% metastasise beyond the 
brain. But the high intrinsic ability to invade neighbouring tissue and to infiltrate the brain 
parenchyma renders GBM highly resistant to traditional therapeutic approaches  (Cuddapah 
et al., 2014, Hou et al., 2006).  
 
A large effort has been made to understand GBM cell migration and invasion with a large 
number of studies being designed to delineate the molecular mechanisms underlying these 
processes. Development of clinically relevant tumour model systems for understanding 
GBM is essential for the advancement of basic biology and translational medicine. 
Numerous cell line models of GBM have been established which contain genetic 
abnormalities typical of primary cancers and provide the basis of significant biological 
insight into the disease (Clark et al., 2010). 
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1.1.5 Glioblastoma multiforme heterogeneity  
 
Glioblastoma multiforme is characterised by high levels of intra-tumour heterogeneity, as 
the term multiforme suggests. After the brain develops, a population of stem cells persists in 
the subventricular zone (SVZ), the structure situated throughout the walls of the lateral 
ventricles. These stem cells proliferate and retain the capacity to generate neurons and glial 
cells following embryonic development. The SVZ stem cells have been identified as a 
source of a brain tumours and can give rise to tumours with diverse histological phenotypes. 
Deletion of the tumour suppressors p53 and retinoblastoma protein (Rb) in the mouse SVZ 
leads to the development of a malignant neural crest tumour. Deletion of p53 and PTEN in 
the mouse SVZ stem cells results in a tumour that resembles human anaplastic 
oligoastrocytoma, which is a tumour that arises from the rapid proliferation of 
oligodendrocytes and astrocytes. By contrast, mouse astrocytes with deletion of 
Rb/p53/PTEN, Rb/p53 or PTEN/p53 proliferated strongly in vitro but did not generate 
tumours in vivo, suggesting that the pathways that generate tumours from SVZ stem cells do 
not form tumours from astrocytes (Jacques et al., 2010). These findings support the role of 
stem cells in initiating malignancy, and suggest that the combination of stem cell genetic 
mutations underpins the specific phenotype of a tumour. 
 
Glioma stem cells (GSCs) reside in specific tumour niches and are capable of generating 
new tumours when transplanted. They share properties to normal stem cells, are driven by 
microenvironmental factors such as hypoxia, and are able to initiate and maintain a 
malignant tumour. GSCs are responsible for tumour maintenance, enabling resistance to 
chemo- and radiotherapy, and are important in recurrence after resection (Persano et al., 
2013).  
 
GSCs were initially defined by the expression of the glycoprotein CD133 (prominin-1) 
(Singh et al., 2004). But CD133-negative cells are also able to form tumours in 
immunodeficient mice, suggesting the presence of other markers that need to be delineated 
(Inda et al., 2014). More recently, a population of glioma cells expressing high levels of 
CD44 and the DNA-binding protein-1 were identified that confer poor prognosis in GBM 
patients and display a stem-like phenotype (Anido et al., 2010).  
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Clusters of proliferating neural stem cells have been found to occupy a vascular niche in 
gliomas and contain proliferating endothelial precursors, suggesting a role for angiogenesis. 
In addition, endothelial cells secrete factors that can stimulate these stem cells to proliferate. 
It has been reported that subsets of glioma cells retain stem cell like properties and that 
retroviral delivery of oncogenes, such as PDGF, into neural progenitors is sufficient to 
induce a diffusely infiltrating tumour that mimics human glioma (Farin et al., 2006).  
 
There is also evidence of GBM inter-clonal cooperativity. Simultaneous engraftment of 
cells over-expressing wildtype EGFR (wtEGFR) and mutated EGFRvIII resulted in GBM 
tumours that expressed wtEGFR in much larger quantity than the mutated receptor. The 
study revealed that a paracrine mechanism driven by EGFRvIII is the major cause for 
wtEGFR-expressing cell recruitment. The EGFRvIII-positive cells express specific 
cytokines, which activate wtEGFR in neighbouring cells. The deletion of these cytokines 
abolishes cross-talk between cells and significantly attenuates tumour growth (Inda et al., 
2010). 
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1.2 Cell motility 
 
The acquired ability for invasion and metastasis enables cancer cells to escape the primary 
tumour and occupy a new area in the body where nutrients and space are not limiting. The 
resulting distant settlements of tumour cells represent the cause of approximately 90% of 
human cancer-related deaths (Hanahan and Weinberg, 2011).  
 
Invasion and metastasis accounts for the difference between benign and malignant tumours. 
Invasiveness refers to the combined active invasion and destruction of tissue. Metastasis 
refers to the capability to leave a primary tumour and form a secondary tumour (Leber and 
Efferth, 2009). Tumours metastasise in two ways: they spread to other organs, usually via 
the blood or the lymphatic system; and they metastasise locally to form new tumours within 
the same organ (Cuddapah et al., 2014). 
 
Metastasis is caused by invasion and migration of individual cells, which detach from the 
primary tumour and invade surrounding healthy tissue. Malignant cells then attach to 
endothelial cells via adhesion molecules and secrete enzymes that allow them to infiltrate 
blood vessels and enter the blood circulation. Particularly aggressive and resistant cells will 
survive the toxic concentration of oxygen and lymphocytes. Tumour cells will get stuck in 
the capillaries of organs and will penetrate the endothelium of the organ by proliferating and 
utilizing proteolytic enzymes. Cells colonise the organ by proliferating and inducing 
angiogenesis, or they may coopt existing host blood vessels, to ensure vascularisation for 
survival. This cascade of events results in the formation of distant secondary tumours (Leber 
and Efferth, 2009).  
 
Invasion and metastasis are complex processes, the precise biochemical and genetic 
determinants of which remain poorly understood. The pathways which govern healthy 
cellular motility become deregulated causing excessive migration, invasion and metastasis. 
Growth factor receptors are at the top of downstream signalling cascades that regulate 
fundamental cellular processes including migration, as well as proliferation, metabolism, 
differentiation, and programmed cell death. Cell migration depends on growth factor 
stimulation via binding to receptor tyrosine kinases (RTKs), integrin receptor activation, and 
	 26	
subsequent activation of downstream signalling molecules including non-receptor tyrosine 
kinases (NRTK), adaptor and scaffold proteins, and small GTPases (Fig 1.2). 
 
Activation of RTKs leads to increased tyrosine phosphorylation of key signalling molecules 
required for motility. Among these are p130Cas, focal adhesion kinase (FAK) and paxillin 
(PXN). For example, p130Cas tyrosine phosphorylation is increased by PDGF, vascular 
endothelial growth factor (VEGF), epidermal growth factor (EGF), hepatocyte growth 
factor (HGF), and insulin-like growth factor (IGF). Tyrosine phosphorylation of p130Cas 
plays a critical role in PDGF-induced migration of U87MG glioma cells and vascular 
smooth muscle cells (Barrett et al., 2014). 
 
Focal adhesions are transient self-assembling complexes that enable the cell to make contact 
and interact with the extracellular matrix (ECM) and facilitate the connection between the 
ECM and actin cytoskeleton. Focal adhesion dynamics (assembly and disassembly) is a 
continuous process, and involves fibronectin, filamin and integrin association, that together 
with adaptor proteins such as p130Cas and PXN, and signalling proteins such as Src and 
FAK, structurally and functionally control the cell’s morphology and are required for cell 
motility (Fig.1.2) (Campbell, 2008, Hu et al., 2014). NRTKs Src and FAK form a signalling 
complex in response to integrin or growth factor receptor stimulation. This complex 
promotes GTPase activation through the phosphorylation of two major adaptor proteins, 
PXN and p130Cas (Arregui et al., 2013). Knock-out mutations in Src or FAK, or adaptor 
proteins p130Cas or PXN, results in embryonic lethality attributed to the failure of cell 
migration (Sharma and Mayer, 2008). 
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Figure 1.2 Key motility signal transduction pathways. p130Cas co-localises with 
proteins that make up focal adhesion complexes –paxillin, FAK, and Src. Paxillin, FAK, Src 
and p130Cas are activated via either integrin receptor or tyrosine kinase receptor 
stimulation. Receptor tyrosine kinases are activated by growth factor (GF) binding. 
Activated receptors phosphorylate FAK, which leads to recruitment and binding of 
Src. Activated receptor tyrosine kinases also phosphorylate Src, which then binds to a Src-
binding site located in the carboxy-terminal domain of p130Cas and is responsible for the 
direct phosphorylation of p130Cas in response to numerous growth factors. Crk adaptor 
proteins link p130Cas to downstream effectors which catalyse the activity of small 
GTPases, bringing about changes in the actin cytoskeleton to facilitate cell motility.  RAS is 
activated by receptor tyrosine kinases and recruits RAF to the membrane. RAF 
phosphorylates and activates MEK, which then phosphorylates and activates ERK (Barrett 
et al., 2013, Heidorn et al., 2010). 
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1.2.1 Focal adhesions 
1.2.1.1 Integrins 
Integrins are transmembrane receptors that enable cells to sense their environment. They are 
cell adhesion molecules implicated in cell motility that transmit signals bi-directionally 
across the plasma membrane to mediate cell–cell, cell–extracellular matrix (ECM) and cell–
pathogen interactions (Fig.1.2) (Cuddapah et al., 2014).  Integrin adhesion receptors span 
the cell membrane to link the ECM with intracellular signalling proteins. The cytoplasmic 
protein talin regulates integrin affinity and provides a mechanical link between integrins and 
the actin cytoskeleton. Each integrin subunit contains a large extracellular domain, a single 
transmembrane domain and a short cytoplasmic tail. 18 α subunits and 8 β subunits dimerise 
to form 24 different integrins that display distinct binding affinities for particular ligands. 
For example, integrins containing subunits α7, β1, and β3 have been shown to induce 
p130Cas phosphorylation (Luo and Springer, 2006, Campbell, 2008, Ye et al., 2014).  
Integrin receptor activation following adhesion to the ECM is considered the initial trigger 
to activate downstream signalling cascades mediated by non-receptor tyrosine kinases. Cell 
adhesion to ECM proteins such as fibronectin and vitronectin initiates integrin activation, 
which in turn leads to the FAK autophosphorylation at tyrosine residue Y397, which 
recruits Src and p130Cas (Sharma and Mayer, 2008). Integrin-mediated phosphorylation of 
p130Cas is Src-dependent and often results in the establishment of Cas-Crk complexes. The 
C10 regulator of kinase (Crk) is an adaptor protein with Src-homology 2 (SH2) and SH3 
domains that couple to effectors p130Cas and PXN (Bouton et al., 2001, Barrett et al., 
2013). The cooperative signalling between integrins and growth factor receptors accessing 
the intracellular signalling space modulates this complex and regulates downstream 
signalling involved in cell proliferation, differentiation and motility (Eke and Cordes, 2014).  
Changes in integrin expression are evident in invasive and metastatic cells, with shifts in the 
spectrum of integrin α or β subunits displayed by the migrating cells (Hanahan and 
Weinberg, 2000). β1 integrin (ITGB1) is often up-regulated in human malignancies and is 
implicated in tumour progression and metastasis. For example, up-regulation of ITGB1 has 
recently been found to significantly induce proliferation and invasion of human colorectal 
cancer cells  (Song et al., 2014). 
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1.2.1.2 Adaptor proteins 
Adaptor proteins, also known as scaffold proteins, provide structural framework to facilitate 
the concurrent binding of proteins within particular signalling pathways. Adaptor proteins 
are composed of multiple protein-binding domains that mediate the association of various 
binding partners. By linking specific proteins together, cellular signals can be propagated to 
achieve a response to particular environmental cues. Specificity in signalling is achieved by 
the type of protein binding domains encoded by the adaptor protein, the sequence of 
domains that dictates specificity in binding, subcellular localisation and proximity of 
binding partners. Adaptor proteins are positioned to regulate cell signalling in a spatial and 
temporal manner and enable sequential activation of individual components of signalling 
pathways (Flynn, 2001). 
1.2.1.2.1 Paxillin 
Paxillin (PXN) is a 559 amino acid protein that localises to focal adhesions, the sites at 
which the cell makes contact and interacts with the ECM (Fig.1.1). Its primary function is to 
serve as a scaffold protein, providing multiple docking sites at the plasma membrane for 
signalling and structural proteins. PXN recruits various cytoskeletal and signalling proteins 
into a complex, including Src and FAK, which are activated as a result of adhesion or 
growth factor stimulation, thus enabling the coordination of downstream signalling that 
results in cell motility (Schaller, 2001, Turner, 2000b).  
The N-terminal half of PXN contains five copies of an eight-amino-acid leucine-rich 
sequence known as the LD motifs (LD1-5), which serve as binding sites for proteins (Fig. 
1.2.1.2.1). FAK binds PXN at LD2 and LD4. The focal adhesion-associated protein vinculin 
that functions to link the actin cytoskeleton to focal adhesions was the first PXN binding 
partner to be identified and associates with LD1, LD2 and LD4  (Schaller, 2001). The C-
terminal half of paxillin is comprised of four LIM domains (LIM1-4), each of about 50 
amino acids and arranged in tandem. LIM domains are double zinc-finger motifs that 
function mainly to anchor PXN at the plasma membrane. Phosphorylation on serine and 
threonine residues of PXN LIM2 and LIM3 domains during cell adhesion or growth-factor 
stimulation potentiates the localisation of paxillin to focal adhesions (Turner, 2000a). 
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PXN has been shown to be a cellular target for tyrosine kinases that are activated as a result 
of integrin and growth factor signalling. Phosphorylation of PXN is associated with the 
coordinate formation of focal adhesions and is important for their association with actin 
filaments. FAK, in association with Src that binds FAK at Y397, phosphorylates PXN at 
tyrosine residues Y31 and Y118. Phosphorylation at these sites generates two functional 
SH2-binding sites for members of the Crk family of SH2-SH3 adaptor proteins. Crk binds 
p130Cas following its phosphorylation by Src. The association of Crk with p130Cas and 
PXN is important in mediating cell motility (Turner, 2000a). Overexpression of paxillin 
mutants in bladder tumour cells in which tyrosine Y31 and/or tyrosine Y118 are replaced by 
phenylalanine prevents the formation of PXN-Crk complexes and impairs cell motility (Petit 
et al., 2000). 
 
Negative regulators of signalling pathways involved in migration also bind PXN, including 
CSK (an inhibitor of Src activity) and PTP-PEST (a phosphatase that dephosphorylates 
p130Cas). By binding to PXN they are brought into close proximity with their targets 
(Turner, 2000b).  
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Figure 1.2.1.2.1 Structure of paxillin. The adaptor protein PXN serves as a scaffold for the 
recruitment of many signalling proteins to the plasma membrane. Human paxillin isoform 1 
contains 559 amino acids and the amino acid sequence numbers are represented beneath the 
figure (Turner, 2000a). The N-terminal domain contains five eight-amino-acid leucine-rich 
sequences known as LD motifs (LD1-5), which function as binding sites for proteins. FAK 
binds to LD2 and LD4. The C-terminal half of PXN is made up of four LIM domains 
arranged in tandem, which are double zinc-finger motifs, each of about 50 amino acids, that 
function mainly to anchor PXN at the plasma membrane. FAK in association with Src 
phosphorylates (P) PXN at two main sites – tyrosine residues Y31 and Y118, generating 
two functional SH2-binding sites for members of the Crk family of SH2-SH3 adaptor 
proteins. This enables the formation of PXN-Crk complexes, important for linking p130Cas 
(Schaller, 2001, Turner, 2000a).  [Figure adapted from (Turner, 2000a)] 
559 1 326 
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1.2.1.2.2 p130Cas 
p130cas (also known as BCAR1) is a member of the Cas (Crk-associated substrate) family 
of adaptor proteins, which includes NEDD9 and BCAR3. It is a 130 kDA protein which 
lacks a kinase domain, but contains various protein-protein interaction domains that mediate 
associations with a number of binding partners (Fig 1.2.1.2.2). p130Cas possesses an amino 
(N)-terminal SH3 domain, followed by a proline-rich region (PRR) and a substrate domain. 
FAK interacts and co-localises with p130Cas at focal adhesion complexes by binding to the 
p130Cas SH3 domain. The substrate domain is comprised of 15 repeats of the YxxP 
consensus phosphorylation motif for Src family kinases. These YxxP motifs create docking 
sites for SH2-containing effectors, forming interactions with motility-related proteins such 
as Crk. Following the substrate domain is the serine-rich region (SRR), which forms a four-
helix bundle. This acts as a protein-interaction motif, and is the site where the 
serine/threonine phosphatase PP2A interacts with p130Cas. The remaining carboxy-terminal 
sequence contains a bipartite Src-binding domain (residues 681–713) able to bind both the 
SH2 and SH3 domains of Src. The coordinated coupling and uncoupling of p130Cas–Crk 
complexes is critical for motility (Bouton et al., 2001, Barrett et al., 2013, Shin et al., 2004). 
ABL negatively regulates cell migration by uncoupling p130Cas-Crk complexes. ABL 
phosphorylates tyrosine residue Y221 on Crk which results in decreased p130Cas-Crk 
association (Kain and Klemke, 2001). 
The regulation of p130Cas, via phosphorylation and dephosphorylation, has downstream 
consequences that govern many cellular processes. In particular, p130Cas has been 
demonstrated to play a critical role in cell motility (Fig. 1.2). p130Cas becomes 
phosphorylated via RTK stimulation and upon integrin interaction with ECM components, 
including fibronectin, vitronectin, laminin and collagen. p130Cas exists at focal adhesions 
in a macromolecular complex with FAK and Src. Src directly phosphorylates p130Cas in 
response to numerous growth factors, as well as in response to integrin-mediated 
stimulation. The assembly results in the activation small GTPases, bringing about changes 
in the actin cytoskeleton to facilitate cell motility. Phosphorylation of p130Cas and 
p130Cas-Crk coupling leads to activation of Rac1, which promotes membrane ruffling, 
lamellipodium formation and actin reorganisation (Barrett et al., 2013, Sharma and Mayer, 
2008). In glioma cells, tyrosine residue Y410 is phosphorylated in response to PDGF and 
HGF and is important in driving glioma cell motility (Fig 1.2.1.2.2) (Evans et al., 2011). 
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Figure 1.2.1.2.2 Structure of p130Cas. The adaptor protein p130Cas lacks a kinase 
domain but is made up of several domains that serve as docking sites for various proteins. 
FAK binds p130Cas via its amino-terminal SH3 domain. Src binds p130Cas via its carboxy-
terminal binding domain. Src is responsible for the direct phosphorylation of YxxP motifs in 
the p130Cas substrate domain, which enables p130Cas to interact with Crk. ABL regulates 
p130Cas– Crk coupling, by phosphorylating (P) the inhibitory tyrosine Y221 of Crk which 
results in complex uncoupling. p130Cas is regulated by the phosphatases protein tyrosine 
phosphatase-1B (PTP-1B) and PTP-PEST that interact with the p130Cas SH3 domain. The 
serine / threonine phosphatase PP2A regulates serine dephosphorylation via interaction with 
the p130Cas serine-rich region (SRR). Human p130Cas isoform 1 contains 916 amino acids 
and the amino acid sequence numbers are represented beneath the figure (Barrett et al., 
2013). Phosphorylation (P) at tyrosine residue Y410, located in the proline-rich region 
(PRR) is important for driving glioma cell motility (Evans et al., 2011). [Figure adapted 
from (Barrett et al., 2013)] 
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The importance of p130Cas in mediating cell migration is exemplified by the severe 
consequences caused by aberrant protein expression or activation. p130Cas-/- embryos die in 
utero and show systemic congestion and growth retardation. p130Cas-/- primary fibroblasts 
contain disorganised, short actin filaments (Honda et al., 1998), and show decreased 
migration in wound healing assays and decreased invasion through a three-dimensional 
collagen matrix (Bouton et al., 2001, Honda et al., 1999). p130Cas-/- mouse embryo 
fibroblasts also exhibit cell spreading and migration defects that are rescued by wildtype 
p130Cas but not by p130Cas substrate domain-deletion mutants (Shin et al., 2004).  
Increased expression of p130Cas has been found to correlate with more advanced stages of 
disease in several cancers, including breast, prostate and ovarian. p130Cas functions as a 
crucial mediator of transformation in several cancers, including breast cancer and chronic 
myeloid leukaemia (CML) (Cabodi et al., 2010, Dai et al., 2011, Barrett et al., 2013). Our 
lab has previously shown that tyrosine phosphorylation of p130Cas plays a critical role in 
PDGF-induced migration of U87MG glioma cells and vascular smooth muscle cells (Barrett 
et al., 2014); and that p130Cas activity is important for three-dimensional glioma cell 
invasion (Frankel et al., 2008). Increased tyrosine phosphorylation of p130Cas has also been 
detected in glioma cells in response to VEGF and HGF (Evans et al., 2011). Tyrosine 
residue Y410 of p130Cas is phosphorylated in response to PDGF- and HGF-mediated 
migration of U87MG glioma cells (Evans et al., 2011). 
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1.2.1.3 The ERK signalling pathway 
The RAS–ERK (mitogen-activated protein kinase 1, also known as MAPK) signalling 
pathway is made up of the RAS small guanine-nucleotide binding protein and the protein 
kinases RAF, MEK, and ERK (Fig 1.2). RAS is attached to the plasma membrane and can 
be activated by growth factor, cytokine, and hormone receptors. Activated RAS recruits 
RAF to the membrane, which subsequently phosphorylates and activates MEK, which then 
phosphorylates and activates ERK (Heidorn et al., 2010, Viala and Pouyssegur, 2004). 
There is growing evidence that the ERK MAPK signalling is implicated in cell motility. 
ERK has been found to be a target of Src-FAK signalling and found to be associated with 
PXN near the membrane. ERK contributes to cell motility by regulating small GTPases 
Rac1 and RhoA, which regulate actin cytoskeletal and adhesion dynamics, and enable the 
formation of cellular protrusions (Viala and Pouyssegur, 2004).  
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1.2.2 Tyrosine kinases and phosphatases 
Protein phosphorylation regulates virtually every aspect of eukaryotic cell biology. It is a 
reversible and dynamic process, and is mediated by protein kinases and phosphoprotein 
phosphatases. Protein tyrosine phosphorylation is fundamental to the maintenance of many 
biological functions, including gene expression, cell growth, differentiation, migration, 
adhesion, and apoptosis (Soulsby and Bennett, 2009).  
Protein kinase enzymes are classified into the following categories based on the residues 
which they phosphorylate: protein-serine/threonine kinases, protein-tyrosine kinases, or dual 
specificity kinases (e.g. MEK) (Roskoski, 2005). Tyrosine kinases (TKs) are a family of 
enzymes that selectively catalyse the phosphorylation of tyrosine residues in different 
substrates using ATP. The human kinome contains 518 kinases, of which 90 are protein 
tyrosine kinases (Jabbour and Lipton, 2013, Manning et al., 2002, Hantschel et al., 2008). 
Intracellular signalling pathways mediated by tyrosine phosphorylation are controlled 
through the balanced and opposing actions of TKs and protein tyrosine phosphatases 
(PTPs). Whereas kinases transfer a phosphate group from ATP to the hydroxyl group of 
serine, threonine and tyrosine residues, PTPs hydrolyse the phosphoester bond resulting in 
protein dephosphorylation (Lillo et al., 2014). It is critical to maintain homeostatic control 
of tyrosine phosphorylation and the imbalance between TK and PTP activity results in the 
development of diverse pathophysiological conditions, including cancer and metabolic, 
neural and immunological disease (Soulsby and Bennett, 2009, Lee et al., 2014b). 
Kinases are defined by their ability to catalyse the transfer of the terminal phosphate of ATP 
to substrates, most often on serine, threonine or tyrosine residues. Kinases typically share a 
conserved arrangement of secondary structures, arranged into 12 subdomains that fold into a 
bi-lobed catalytic core, with ATP binding in a deep cleft located between the lobes. All 
kinases have a conserved activation loop which can assume a number of conformations, 
from catalytically competent and usually phosphorylated (“active conformation”), through 
to the “inactive conformation” in which the loop blocks the ATP binding site  (Zhang et al., 
2009).  
	 37	
1.2.2.1 Receptor tyrosine kinases 
 
Tyrosine kinases are primarily classified into receptor tyrosine kinases (RTKs) e.g. EGFR, 
VEGFR, PDGFR, and non-receptor tyrosine kinases (NRTKs) e.g. Src, ABL, FAK (Paul 
and Mukhopadhyay, 2004). 90 tyrosine kinases have been identified in the human genome, 
58 of them encoding RTKs and the remainder encoding NRTKs. Tyrosine kinases play an 
important role in the development of disease, representing a common class of oncogenes 
and found deregulated in most types of cancerous malignancies (Robinson et al., 2000). 
 
RTKs are cell surface transmembrane receptors that display enzymatic activity. All RTKs 
have an extracellular ligand binding domain, which is connected to the cytoplasmic domain 
by a transmembrane helix. With the exception of the insulin receptor, all known RTKs exist 
as monomers in the cell membrane. They are activated by ligand binding to the extracellular 
domain which enables dimerisation and trans-phosphorylation in the cytoplasmic domain. 
The autophosphorylation is critical for the recruitment and activation of effector signalling 
proteins. Most of the phosphorylated tyrosine residues are located in the non-catalytic 
regions of the receptor, and function as binding sites for SH2 (Src homology 2) and PTB 
(phosphotyrosine binding) domains of a variety of proteins. The recruitment of proteins to 
these sites enables the formation of signalling complexes that enable downstream signalling. 
RTKs are critical in mediating most fundamental cellular functions, including the cell cycle, 
migration, metabolism, survival, differentiation and proliferation (Schlessinger, 2000). 
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1.2.2.2 Non-receptor tyrosine kinases 
 
NRTKs are cytoplasmic proteins, whose activation is more complex, involving heterologous 
protein-protein interaction (Paul and Mukhopadhyay, 2004). NRTKs regulate many 
physiological processes such as cell migration, differentiation, proliferation, and survival, 
by interacting with and phosphorylating a large number of substrates simultaneously. Three 
NRTKs of interest to this study implicated in tumour progression are discussed below.  
 
1.2.2.2.1 Src 
 
The Src family of protein tyrosine kinases (SFKs) is made up of nine proteins, of which Src 
is the founding member. SFKs play a key role in mediating signal transduction by a variety 
of cell surface receptors, including growth factor receptors and integrins. SFKs regulate 
many fundamental cellular processes, including cell survival, growth, differentiation, and 
motility (Parsons and Parsons, 2004). In 1911 Rous provided evidence that avian sarcoma 
could be transmitted between chickens by a non-cellular element (Rous, 1911), 
subsequently identified as the retrovirus now known as the Rous sarcoma virus. The first 
recognised transforming protein, v-Src, was identified as the gene encoded by Rous sarcoma 
virus. This led to the discovery of its cellular proto-oncogene homolog in the vertebrate 
genome, c-Src, and the discovery that both v-Src and c-Src are tyrosine kinases (Martin, 
2001, Jones et al., 2000).  
 
Subsequent research revealed that Src activity is regulated by tyrosine phosphorylation; and 
that the SH2 and SH3 domains of Src mediate protein–protein interactions with sequences 
containing phosphotyrosine and proline-rich motifs. Research also revealed that Src was a 
member of a large family of nine structurally related kinases: the ubiquitously expressed 
Fyn, Yes and Yrk; Lck expressed in the brain and T cells; Lyn expressed in the brain, B 
cells and myeloid cells; Blk, Fgr, Hck, expressed in B cells and myeloid cells. SFKs share a 
conserved domain organisation and are made up of a N-terminal segment, followed by SH3, 
SH2, linker and tyrosine kinase domains, and a short C-terminal tail (Parsons and Parsons, 
2004).  
 
Src kinase activity is regulated by phosphorylation of two tyrosine residues, the activating 
Y416 residue and the inhibitory Y527 residue. Autophosphorylation at Y416 in the 
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activation loop promotes kinase activity, whereas phosphorylation of Y527 by the 
cytoplasmic tyrosine kinase C-terminal Src kinase (CSK) inactivates Src. When Y527 is 
phosphorylated by CSK, Src undergoes a conformational change whereby Y527 interacts 
with its own SH2 domain rendering the protein catalytically inactive (Jones et al., 2000, 
Roskoski, 2005).  
Src is located in the cytoplasm at sites of integrin clustering. Following integrin receptor 
activation, FAK is autophosphorylated and recruits Src via its SH2 domain, and recruits 
p130Cas via its SH3 domain. This enables the formation of the Src-FAK-p130Cas complex. 
Src is a critical player of the cell motility pathway that activates several downstream 
signalling proteins. Amongst the substrates of Src is Src itself (autophosphorylation at 
tyrosine Y416), FAK, p130Cas and PXN (Sharma and Mayer, 2008, Jones et al., 2000).  
Src mediates cell-cell adhesion by interacting with p120-catenin, which subsequently 
interacts with cadherins (Parsons and Parsons, 2004). Src regulates the activation of Rho-
family GTPases and increases the synthesis and secretion of proteases that degrade the 
extracellular matrix (Martin, 2001). Src also phosphorylates PI3 kinase (PI3K), which is 
involved in growth factor receptor-mediated signalling (Brown and Cooper, 1996). Src 
phosphorylates ABL to activate Rho GTPase, which stimulates actin-myosin contractility. 
In this way Src can promote transforming signalling cascades that result in augmented cell 
migration. Src activates ABL by phosphorylating its tyrosine residue Y412 in the activation 
loop of the catalytic SH1 domain (Krishnan et al., 2012). 
Src has a role in a variety of signal transduction pathways which result in many endpoints 
important for the development of malignancy including cell motility, cell invasion, cell 
adhesion, and cell spreading (Jones et al., 2000). When deregulated, Src activity can 
influence the transformation of healthy cells into malignant ones. Src enhances the 
mitogenic response of the EGFR to EGF, and upregulated Src activity is an early event in 
colon carcinogenesis (Martin, 2001). Importantly, FAK has been found to cooperate with 
Src family kinases to regulate invasion (Frame, 2002). FAK was initially discovered in the 
early 1990s as a tyrosine-phosphorylated protein in Src-transformed cells. FAK activates 
signalling pathways associated with cell adhesion, mitogenesis, and oncogenic 
transformation (Jones et al., 2000). p130Cas, the binding partner of FAK, was also first 
identified as a tyrosine-phosphorylated protein in Src-transformed cells (Frame, 2002). 
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1.2.2.2.2 FAK 
 
Much progress has been made in the last two decades since the initial identification of focal 
adhesion kinase (FAK) as a highly phosphorylated substrate of the viral Src oncogene 
product v-Src localised to the integrin cluster of focal adhesions (Hanks et al., 1992, 
Schaller et al., 1992).  
 
FAK is ubiquitously expressed and functions as a cytoplasmic non-receptor tyrosine kinase 
as well as a scaffold protein, mediating signals initiated at sites of integrin-ECM attachment 
and signals triggered by growth factor receptors. The protein is now recognised to play a 
critical role in diverse signalling pathways that regulate focal adhesions, cell adhesion, cell 
migration, cell survival and transformation. Its role across these numerous signal 
transduction pathways can result in enhanced tumour progression, and FAK expression is 
increased in many cancers, such as breast and prostate (Jones et al., 2000, Slack-Davis et al., 
2007, Lee et al., 2014a). 
 
FAK is a 125-kDa protein composed of an N-terminal FERM domain, a central kinase 
domain, proline-rich regions and a C-terminal focal-adhesion targeting (FAT) domain. The 
FERM domain mediates the recruitment of FAK to membrane-linked proteins, including 
RTKs such as EGFR and PDGFR. FAK contains three proline-rich regions (PRR1–3) that 
bind SH3 domain-containing proteins. The C-terminal PPR2 and PRR3 bind p130Cas (Fig. 
1.2.2.2.1)(Mitra et al., 2005).  
 
Early studies found that FAK could be activated either by the ECM or by growth factors. 
FAK activation leads to autophosphorylation at its tyrosine residue Y397 (Nakamura et al., 
2001). FAK influences both focal adhesion assembly and disassembly. Phosphorylation of 
FAK in response to integrin engagement leads to the formation of phosphotyrosine docking 
sites for a number of signalling molecules involved in motility. The phosphorylation on 
tyrosine Y397 creates a high-affinity binding site for the SH2 domain of Src family kinases 
and leads to the recruitment and activation of Src (Parsons, 2003, Jones et al., 2000). 
Subsequent Src phosphorylation of FAK at Y576 and Y577 promotes maximal FAK 
activity. Active FAK–Src enables binding of p130Cas SH3 domain to FAK and subsequent 
phosphorylation of p130Cas by FAK (Tachibana et al., 1997, Mitra et al., 2005). Src 
phosphorylation of the Y861 site enhances FAK binding to p130Cas (Lee et al., 2014a, 
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Mitra et al., 2005). As well as directing the phosphorylation of p130Cas, FAK also directs 
the phosphorylation of PXN. Tyrosine phosphorylation of FAK at residue Y861 is strongly 
observed during cell migration, and Y861-phosphorylated FAK localises with 
phosphorylated forms of PXN and p130Cas in mouse mammary gland cells (Nakamura et 
al., 2001). In transformed mammary epithelial cells, FAK deletion leads to impaired 
migration, invasion and spreading. This is accompanied by reduced phosphorylation of Src, 
PXN and p130Cas (Lahlou et al., 2012).  
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Figure 1.2.2.2.1 Structure of focal adhesion kinase. FAK contains an N-terminal FERM 
domain, a central kinase domain and a C-terminal focal adhesion targeting (FAT) domain. 
Human FAK isoform 1 contains 1052 amino acids and the amino acid sequence 
numbers are represented beneath the figure (Golubovskaya and Cance, 2007). The 
FERM domain mediates interactions of FAK with receptor tyrosine kinases, such as the 
epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor 
(PDGFR). FAK is autophosphorylated (P) on Y397 in response to integrin or growth 
factor stimulation. This creates a docking site for the SH2 domain of Src. Src-mediated 
phosphorylation of FAK at Y576 and Y577, which promotes FAK catalytic activity. Src 
phosphorylation of the Y861 site enhances FAK binding to p130Cas. Active FAK-Src 
enables p130Cas binding to FAK via the p130Cas SH3 domain. Three proline-rich 
regions (PRR1–3) bind SH3 domain-containing proteins. PRR2 and PRR3 bind 
p130Cas. Src phosphorylates FAK at Y861, and this is associated with increased binding of
p130Cas to the PRR2 and PRR3 regions of FAK. (Mitra et al., 2005, Nakamura et al., 
2001). [Figure adapted from (Mitra et al., 2005)] 
1052 1 424 676 
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1.2.2.2.3 ABL 
 
Abelson tyrosine kinase (ABL, also known as c-Abl) is a NRTK that has a role in the 
regulation of the actin cytoskeleton important for various cellular functions including cell 
adhesion, proliferation, growth, and development (Kain and Klemke, 2001). Importantly, 
ABL negatively regulates motility by inhibiting p130Cas–Crk coupling. p130Cas-Crk 
complexes form in response to integrin or growth factor receptor stimulation via FAK 
and/or Src activation. The formation of the complex occurs through the interaction of the 
SH2 domain of Crk with the phosphotyrosine residues in the substrate domain of p130Cas. 
ABL interacts with the SH3 domain of Crk and phosphorylates Crk inhibitory tyrosine 
Y221 (Fig. 1.2.1.2.2). This causes Crk to functionally fold such that the SH2 domain binds 
its phosphorylated Y221 residue, prohibiting further p130Cas interaction (Kain and Klemke, 
2001). This is reversed by phosphatase PTP-1B- mediated Crk dephosphorylation (Barrett et 
al., 2013). 
 
However, the role of ABL in cell migration across different cell types remains unclear. 
Embryonic fibroblasts isolated from animals genetically deficient for ABL showed 
significantly enhanced cell migration and increased p130Cas-Crk complexes (Kain and 
Klemke, 2001). In smooth muscle cells, ABL has been reported to mediate cell motility via 
interaction with β1-integrin. This leads to actin filament rearrangement and stimulates cell 
migration. Conversely, actin cytoskeleton remodelling promotes recruitment of ABL to the 
cell edge (Cleary et al., 2014). There is also evidence that ABL promotes motility of 
myeloid cells (Baruzzi et al., 2010) and cancer cells (Khusial et al., 2010).  
 
The constitutively active BCR-ABL fusion protein is the cause of disease in ∼95% of 
patients with CML (Seeliger et al., 2007). CML is a stem cell disease caused by the 
translocation between band q34 of chromosome 9, which contains the ABL proto-oncogene, 
and band q11 of chromosome 22, which contains the breakpoint cluster region (BCR) gene 
(Jabbour and Lipton, 2013). The expression of the Philadelphia chromosome 
[(t9;22)(q34;q11)] and fused oncoprotein BCR-ABL results in constitutive ABL tyrosine 
kinase activity, critical for the oncogenic transformation of haematopoietic stem cells 
(Hantschel et al., 2008).  
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1.2.2.3 Protein phosphatases 
Signalling mediated by tyrosine phosphorylation is tightly regulated by the opposing actions 
of TKs and PTPs. PTPs hydrolyse the phosphoester bond to dephosphorylate proteins (Lillo 
et al., 2014). Protein phosphatases have been less studied than protein kinases and were 
originally considered housekeeping enzymes with no important regulatory functions. 
However, PTPs are now recognised as important regulators, enabling the homeostatic 
control of phosphorylation and dephosphorylation.  
p130Cas is regulated by the protein tyrosine phosphatase-PEST (PTP-PEST; also known as 
PTPN12). PTP-PEST associates with the SH3 domain of p130Cas and dephosphorylates 
phosphotyrosine residues, resulting in decreased p130Cas–Crk association and decreased 
pro-migratory signalling. Cells expressing activated PTP-PEST exhibit defects in cell 
migration that coincide with significantly reduced levels of tyrosine phosphorylated 
p130Cas (Barrett et al., 2013, Defilippi et al., 2006). PTP-PEST also regulates cell 
spreading and migration via interaction with PXN. PTP-PEST binds PXN in fibroblasts and 
signals through PXN tyrosine Y31 and Y118 residues. PXN is essential for PTP-PEST-
dependent regulation of cell spreading and motility in these cells (Jamieson et al., 2005).  
PTP1B (also known as PTPN1) plays a role in integrin-mediated adhesion signalling, and its 
absence in fibroblasts results in attenuated cell spreading (Cheng et al., 2001). PTP1B is a 
cytosolic phosphatase that is expressed in most cells and functions as a Src Y527 
phosphatase (Roskoski, 2005). PTP-PEZ (also known as PTPN14) is also known to interact 
with p130Cas (Barrett et al., 2013). The SHP-2 tyrosine phosphatase (also known as 
PTPN11 mediates activation of Ras and MAPK by various mitogens and cell adhesion. 
Inhibition of SHP-2 has been found to increase the rate of cell spreading, which was 
accompanied by the enhancement of adhesion-induced tyrosine phosphorylation of PXN 
and p130Cas (Inagaki et al., 2000). PTEN phosphatase expression leads to tyrosine 
dephosphorylation of FAK and inhibition of cell migration. Overexpression of FAK 
partially antagonises the effects of PTEN (Bouton et al., 2001, Tamura et al., 1998).  
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1.3 Tyrosine kinases in cancer 
 
Approximately 518 kinases are encoded in the human genome and they are implicated in 
nearly all signal transduction pathways, suggesting that targeting kinase activity 
therapeutically could elicit a physiological response (Zhang et al., 2009). Research has 
generated a substantial amount of evidence to show that receptor tyrosine kinases (RTKs) 
are involved in the processes that govern the transformation of normal cells to malignant 
cells. When mutated, overexpressed, or structurally altered, RTKs can become ‘oncogenic’ 
and stimulate downstream signalling responsible for enhanced migration, proliferation, 
angiogenesis and survival of cancer cells (Dong et al., 2011, Paul and Mukhopadhyay, 
2004). 
 
Aberrant RTK activation in transformed cells has been discovered in a large number of 
human cancers, including breast cancer, gastrointestinal stromal tumours, non-small-cell 
lung cancer (Gschwind et al., 2004). Notable examples include the human epidermal growth 
factor erbB-2 tyrosine kinase (HER2) that is amplified in 20% of breast cancer (Osborne et 
al., 2004), and EGFR that is implicated in breast, lung and glioma malignancies (Zhang et 
al., 2009). EGFR, PDGFRα, PDGFRβ, c-Kit and c-Met, have all been reported to be altered 
in GBM, with EGFR altered at the highest frequency (>40%) (Jones et al., 2000, Lee et al., 
2014a, Roth and Weller, 2014, Farin et al., 2006). Because RTK activity is often implicated 
in the pathology of disease, particularly in tumour progression, targeting them can have 
significant therapeutic benefit in the treatment of malignancy.   
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1.3.1 Targeting cancer with small-molecule kinase inhibitors 
Considerable efforts have been made to develop small-molecule inhibitors targeting kinases 
for a number of disorders, most notably for cancer. Between 2001, when the first small-
molecule kinase inhibitor imatinib was developed, and 2015, 28 small-molecule kinase 
inhibitors were approved by the U.S. Food and Drug Administration (FDA), the majority of 
which are tyrosine kinase inhibitors (TKIs)  (Wu et al., 2016). There are over 80 inhibitors 
that have been advanced to some stage of clinical evaluation (Zhang et al., 2009). Most of 
the kinase inhibitors developed compete with ATP for the ATP-binding site. The majority 
of these ATP-competitive inhibitors are Type 1 inhibitors, meaning that they recognise the 
active conformation of the kinase. The other type of competitive inhibitors are Type 2 
inhibitors, which recognise the inactive conformation of the kinase. Movement of the 
activation loop to the inactive conformation exposes an additional hydrophobic binding site 
directly adjacent to the ATP-binding site. Conformational shapes are numerous, and the 
active site can be modelled to accommodate a variety of inhibitors (Zhang et al., 2009). 
However, because of the high level of sequence conservation of the ATP-binding site and 
the large number of kinases, it has proven difficult to design kinase-selective Type 1 and 
Type 2 competitive inhibitors. There are exceptions, such as lapatinib which targets HER2; 
but on the whole, inhibitors have a spectrum of targets that increases as their concentration 
increases (Liu et al., 2013). The third class of kinase inhibitors are allosteric inhibitors that 
bind outside the ATP-binding site. These inhibitors are typically more selective because 
they make use of binding sites that are unique to the kinase (rather than the conserved 
activation loop). The fourth class of inhibitors are covalent inhibitors that irreversibly block 
ATP binding to the kinase. Although irreversible kinase inhibitors have been designed, there 
is concern over their use in the clinic due to the possibility of toxicity that can arise if 
unexpected targets are also irreversibly blocked (Zhang et al., 2009). 
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1.3.2 Chronic myeloid leukaemia 
Chronic myeloid leukaemia (CML) is a myeloproliferative disease characterised by the 
proliferation of myeloid cells in the bone marrow and blood. CML accounts for about 20% 
of adult leukaemias, with about 5000 cases each year in the United States (Packer et al., 
2011, O'Dwyer and Druker, 2001). CML is a stem cell disease in which neoplastic cells 
express a specific chromosomal translocation (9; 22) (q34; q11). This translocation between 
the long arms of chromosomes 9 and 22 generates a shortened chromosome 22, referred to 
as the Philadelphia (Ph)  chromosome (O'Dwyer and Druker, 2001). The molecular 
consequence from this translocation is the chimeric BCR-ABL gene consisting of the ABL 
gene fused head-to-tail with 5’ exons of the BCR gene (Heisterkamp et al., 1990).  
The Ph chromosome results in the expression of the fused oncoprotein BCR-ABL. BCR-
ABL is expressed in all patients with Ph chromosome-positive (Ph+) CML, and its 
expression in animal models identified it as the sole oncogenic event that induces 
leukaemia. The infection of murine bone marrow with a retrovirus encoding BCR-ABL and 
subsequent transplantation into irradiated mice was sufficient to induce a myeloproliferative 
syndrome that resembles the chronic phase of human CML (Daley et al., 1990). Similarly, 
transgenic mice expressing BCR-ABL develop and die of leukaemia (Heisterkamp et al., 
1990).  
The constitutive tyrosine kinase activity of BCR-ABL is essential for the transforming 
properties of the protein.  The fusion of ABL and BCR drives transformation and 
leukaemogenesis via upregulated phosphorylation of substrates such as Crk and activation 
of pathways such as the RAS/RAF/MEK/ERK and PI3K/Akt pathways. This results in cell 
proliferation, prevention of apoptosis and subsequent CML cell survival (Packer et al., 
2011, Puissant et al., 2012, Steelman et al., 2004).  
CML follows a predictable progression involving three distinct clinical stages: chronic 
phase, accelerated phase, and blast crisis. The chronic phase lasts 3-4 years and is 
characterised by myeloid hyperplasia, with excessive production of differentiated 
granulocytes. This is followed by acceleration of the disease (6-28 months) that ultimately 
leads to the terminal acute blast phase. The blast crisis stage lasts several months, during 
which patients accumulate excessive amounts of immature cells of the myeloid lineage 
known as blast cells (Dick, 2008, Calabretta and Perrotti, 2004). 
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1.3.3 Target-based drug discovery for the treatment of chronic 
myeloid leukaemia 
 
The identification of the leukaemic oncogene BCR-ABL as the causative molecular 
pathogenetic event in Ph+ CML provided the rationale for targeting the protein for the 
treatment of the disease and allowed for the development of the first fusion gene-targeted 
drug, imatinib mesylate (Gleevec®, STI-571). The rationally designed tyrosine kinase 
inhibitor, imatinib, was approved in 2002 for the treatment of CML in any phase, and 
remains frontline therapy. Imatinib blocks the ATP-binding site of BCR-ABL, thereby 
preventing ATP from binding. This inhibits BCR-ABL tyrosine kinase activity and blocks 
downstream signalling (Druker, 2008).  
 
Prior to the approval of imatinib, the standard therapy for CML consisted of recombinant 
interferon-a alone, or in combination with the chemotherapy agent cytarabine. However, 
this combined approach led to a major cytogenetic response in only 6-25% of patients 
(Waller, 2010). The cytogenetic response (CyR) refers to the reduction of cells in the bone 
marrow expressing the fused Ph chromosome (O'Brien et al., 2003).  
 
A phase I clinical trial with imatinib was launched in 1998 to determine the maximally 
tolerated dose and to delineate side effects, with clinical benefit as the secondary endpoint. 
Patients with chronic phase CML who had failed therapy with interferon-a were enrolled 
(Druker et al., 2001). Three open-label phase II studies were subsequently initiated using 
imatinib as a single therapeutic and looking at over one thousand Ph+ CML patients in 
chronic phase, accelerated phase, and blast crisis. In 532 patients with chronic phase CML 
who had failed interferon-a therapy, 95% of patients reached a complete haematologic 
response, that is the normalisation of white blood cell counts. Over 80% of patients in the 
accelerated phase showed some haematologic response, with over 50% reaching complete 
haematologic response. Over 50% of patients in blast crisis exhibited some haematologic 
response to imatinib. The results of these phase I and phase II trials led to the U.S. FDA 
approval of imatinib in 2001 for the treatment of CML in advanced phase and after failure 
of interferon-a therapy (Waller, 2010, O'Brien et al., 2003).  
 
The landmark IRIS (International Randomized Study of IFN and STI571) open-label phase 
III clinical trial looked at the combination of interferon-a and cytarabine compared with 
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imatinib. 1106 patients across 16 countries were randomly assigned to treatment with either 
400 mg/day of imatinib, or interferon-a and cytarabine (553 in each group). After a median 
follow-up of 19 months, patients treated with imatinib had significantly better complete 
haematologic response, major cytogenetic response, and complete cytogenetic response 
(CCyR), meaning that no cells with the Ph+ chromosome were found in the bone marrow. 
This was accompanied by a significantly better progression-free survival compared to 
patients treated with the traditional anticancer agents (O'Brien et al., 2003). Study results 
were disclosed early as a consequence of such promising outcomes and most patients being 
treated with interferon-a and cytarabine were transferred over to the imatinib group (Waller, 
2010). 
In the IRIS five-year follow-up study, the 553 patients in the initial imatinib group were 
assessed for response to the tyrosine kinase inhibitor. It was found that by 60 months, 87% 
of patients achieved CCyR. Importantly, nearly all patients (97%) with a CCyR within 12 
months after starting treatment did not progress to the accelerated phase or blast crisis by 60 
months. The estimated overall survival rate at 60 months was 89%. As well as a 
significantly positive response to imatinib, patients exhibited acceptable side effects with 
few severe grade 3 or 4 adverse effects (Druker et al., 2006).  
It took less than 15 years from the identification of the critical role of the BCR-ABL 
oncoprotein to develop imatinib, which is now the standard of care for patients with CML. 
Imatinib provided validation that targeting kinases with the newer class of anticancer drugs, 
the so-called “small-molecule” inhibitors, could have significant therapeutic benefit without 
major side effects. The gene-to-drug approach employed in the development of imatinib has 
validated the impact of rational target-based drug design for the treatment of cancer and has 
raised expectations for subsequent drug discovery.  
In the absence of imatinib, ATP is bound to BCR-ABL and transfers its terminal phosphate 
to a substrate, which becomes activated and able to bind downstream effectors (Fig. 
1.3.3A). Imatinib is a Type 2 inhibitor, binding with high affinity to the ATP binding site in 
the inactive form of the tyrosine kinase domain. Imatinib prevents ATP from binding, and 
leads to the inhibition of kinase activity by preventing the transfer of phosphate to tyrosine 
residues on substrate proteins (Fig. 1.3.3B) (Waller, 2010). In vitro studies have shown that 
imatinib potently inhibits all of the ABL tyrosine kinases, including ABL, viral ABL (v-
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ABL), BCR-ABL, as well as the closely related kinase ARG (also known as ABL2). 
Imatinib also potently inhibits the stem cell growth factor receptor (c-Kit), platelet derived 
growth factor receptor beta (PDGFRβ), the collagen receptor discoidin domain receptor 
tyrosine kinase 1 (DDR1), and the non-kinase NAD(P)H:quinone oxidoreductase NQO2 
(Fig. 1.3.3C) (Rix et al., 2007, Hantschel et al., 2008, Deininger et al., 2005).  
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Figure 1.3.3 Mechanism of action of imatinib. (A) ATP occupies the pocket of the ABL 
component of BCR-ABL and is able to transfer its terminal phosphate (P) to a substrate, 
phosphorylating an activating tyrosine (Y) residue. The substrate is activated, detaches from 
BCR-ABL and makes functional contact with a downstream effector. (B) When imatinib 
occupies the ATP binding site, it prevents the phosphorylation and subsequent activation of 
the substrate. The substrate cannot bind downstream effectors and downstream signalling 
pathways that would otherwise promote cell proliferation and cell survival are inhibited. (C) 
The known targets that imatinib binds to with high specificity.  
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1.3.4 Development of resistance to imatinib in chronic myeloid 
leukaemia 
The development of a highly selective and safe drug shifted the paradigm for molecular 
targeted cancer therapy – it showed that you can successfully target an oncoprotein that is 
the driver of malignancy to effectively treat disease without severe side effects. Imatinib is 
the current standard of care for patients with Ph+ CML. However, a number of patients 
develop resistance leading to relapse, or intolerance leading to discontinuation of treatment. 
Despite exhibiting an overall response rate of about 80%, imatinib faces significant 
challenges in the clinic that are imposed by drug resistance and lack of inhibitor efficacy 
(Zhang et al., 2009). 
The response to imatinib in CML is maintained by selective inhibition of the BCR-ABL 
ATP binding domain. The most prevalent cause of resistance is the occurrence of point 
mutations within the kinase domain which interferes with drug binding. Nearly 100 different 
mutations conferring varying degrees of resistance have been identified in vitro and in vivo 
(Quintas-Cardama et al., 2010, Hantschel et al., 2008).  
The efficacy of imatinib is astounding for those patients in chronic phase CML, where the 
rate of complete haematologic response approaches 100%. But for those patients in 
accelerated phase and blast crises phase, the efficacy of imatinib is significantly lower 
(Quintas-Cardama et al., 2010). And even though initial response rates to imatinib are high, 
the TKI fails in up to 40% of patients with prolonged treatment, most often because of 
mutations in the BCR-ABL kinase domain. Less frequently, imatinib is discontinued as a 
result of adverse side effects (Cortes et al., 2013). The overall failure rate of imatinib at the 
5-year follow up in the IRIS study was 17% (Druker et al., 2006). In the accelerated and
blast crisis phases, the combination of high numbers of proliferating tumour cells coupled
with genomic instability leads to secondary genetic alterations that are independent of BCR-
ABL. The clones that acquire a genetic alteration conferring resistance to imatinib are
selected by the drug (von Bubnoff et al., 2002). Three second generation tyrosine kinase
inhibitors were developed with enhanced potency towards wildtype BCR-ABL for the
purpose of targeting cells resistant to imatinib: nilotinib and dasatinib both now approved
for first-line therapy, and bosutinib approved for CML patients with resistance to other
TKIs.
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1.3.5 Second- and third-generation small-molecule inhibitors for 
chronic myeloid leukaemia 
 
Nilotinib (Tasigna, AMN107) is the second-generation TKI rationally designed and 
approved in 2010 as first-line treatment of CML and for those patients that become resistant 
or intolerant to imatinib. Similar to imatinib, nilotinib is a Type 2 competitive inhibitor, and 
was designed on the basis of crystallographic studies that looked at the interaction of 
imatinib and the ABL kinase domain. Nilotinib has an improved affinity and specificity 
against BCR-ABL when compared to imatinib: it is 20- to 30-fold more potent against 
wildtype (unmutated) BCR-ABL in vitro with an IC50 (50% inhibitory concentration) of 25 
nm (Jabbour and Lipton, 2013, Quintas-Cardama et al., 2010). Importantly, nilotinib is also 
strongly active against most imatinib-resistant BCR-ABL mutants harbouring point 
mutations (Weisberg et al., 2006). Like imatinib, nilotinib also potently inhibits ARG, 
PDGFR, c-Kit, and DDR1 and NQO2 (Hantschel et al., 2008). 
 
Successful outcomes from phase I and II studies looking at patients with CML resistant or 
intolerant to imatinib led to the accelerated approval of nilotinib for CML after imatinib 
failure. The phase I study looking at 119 patients with imatinib-resistant CML established a 
safe 400 mg twice-daily dose of nilotinib for phase II trials. The same study found that 
nilotinib induced a CCyR in 53% of chronic phase patients, 48% of accelerated phase, and 
27% of blast crisis phase (Quintas-Cardama et al., 2010).  
 
In the phase III, randomised, open-label, multicentre trial, efficacy and safety of nilotinib 
(300 or 400 mg twice daily) was compared with that of imatinib (400 mg once daily) in a 
total of 846 patients with newly diagnosed Ph+ CML in the chronic phase. The primary end 
point was the rate of major molecular response at 12 months, defined as a BCR-ABL 
transcript  level of £ 0.1% in the peripheral blood; and the secondary end point was the rate 
of CCyR at 12 months. By 12 months, rates of major molecular response were significantly 
higher in patients receiving 300 mg of nilotinib (44%) or 400 mg of nilotinib (43%) twice 
daily than in those receiving imatinib (22%). The rates of CCyR were also higher among 
patients receiving 300 mg nilotinib (80%) and 400 mg nilotinib (78%) compared to those 
receiving imatinib (65%). Severe grade 3 and 4 adverse effects were uncommon in all 
patients. Overall, nilotinib was superior to imatinib in both primary and secondary end 
points. And the transformation to the accelerated phase or blast crisis was significantly 
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lower in both nilotinib groups than in the imatinib group (Saglio et al., 2010). The recent 
five-year follow up identified that more 50% of patients in the nilotinib groups achieved a 
molecular response compared to 31% of patients treated with imatinib. But cardiovascular 
events, and elevations in blood cholesterol and glucose level, were more frequent in patients 
receiving nilotinib (Hochhaus et al., 2016). However, overall the long-term results support 
the use of nilotinib 300 mg twice daily as frontline therapy for patients with chronic phase 
CML. 
Nilotinib was active against 32/33 imatinib-resistant BCR-ABL mutants studied, but had no 
significant effect against the T315I mutant (Weisberg et al., 2006). The T315I mutation 
confers resistance against imatinib, and second-generation TKIs nilotinib, dasatinib and 
bosutinib. This is because the “gatekeeper” T315 residue is located within the ABL kinase 
binding site and mediates access to the hydrophobic pocket to which the inhibitors bind. The 
isoleucine residue conferred by the mutation is bulky and obstructs the inhibitors’ ability to 
bind (Quintas-Cardama et al., 2010, Weisberg et al., 2006, Cortes et al., 2012). The so-
called “gatekeeper” T315I mutation accounts for 4-20% of all mutations that are associated 
with TKI resistance, and stem cell transplantation is considered the first-line option for 
CML patients with the T315I mutation (Xu et al., 2016). 
The second-generation TKI dasatinib is approved for patients with Ph+ CML resistant or 
intolerant to imatinib. Dasatinib is about 300 times more potent than imatinib in cells 
expressing unmutated BCR-ABL in vitro. Dasatinib also potently inhibits SRC-family 
kinases, c-Kit, PDGFR, DDR1, and ephrin receptor kinase. At least 30 additional kinases 
have been found to bind to dasatinib and the broad spectrum of targets may account for the 
unique side effects that have been observed in a large proportion of patients (Lindauer and 
Hochhaus, 2010, Hantschel et al., 2008). Bosutinib is another dual Src-BCR-ABL kinase 
inhibitor approved for Ph+ CML resistant or intolerant to imatinib (Keller et al., 2010). 
Even second-generation TKIs nilotinib, dasatinib and bosutinib, are not successful in all 
patients that discontinue imatinib. Between 37-52% of patients treated with the second-
generation inhibitors do not respond, and an additional ~25% of patients have an initial 
major CyR that is lost within 2 years (Cortes et al., 2012, Kantarjian et al., 2011). Second-
generation TKIs consistently fail in those patients with the gatekeeper T315I mutation 
(Jabbour et al., 2015). Ponatinib, a third-generation TKI designed using a computation and 
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structure-based approach, is active against the T315I mutation. In a phase I trial looking at 
patients with haematologic cancers for whom no standard care was available, ponatinib 
caused a complete haematologic response in 98% of patients with chronic phase CML, and 
a CCyR in 63% of patients (Cortes et al., 2012). In a multi-centre phase II trial, the rate of 
major CyR in response to ponatinib in patients with the T315I mutation was 70% for 
chronic phase, 50% for accelerated phase, and 29% for blast crisis phase (Cortes et al., 
2013). However, the long-term response and side effects are still not known because of 
short-term follow up.  
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1.3.6 Mechanisms underlying resistance 
Resistance to TKIs includes primary resistance, i.e. de novo resistance, describing patients 
that do not respond to the drug from the start of treatment and do not achieve a partial 
remission; and secondary resistance, i.e. relapse after initial response. Both primary and 
acquired resistance can be caused by alterations to drug metabolism (uptake and efflux) or 
by modifications of the drug target (Zahreddine and Borden, 2013). 
Almost all tumours are heterogeneous, consisting of mixed populations of cells. Acquired 
resistance can arise due to the presence of pre-existing resistant subclones that survive 
treatment and expand after therapy, or due to the acquisition of mutations in response to 
treatment that render certain cells resistant (Oxnard, 2016). Patients with non-small cell lung 
cancer with activating mutations in the EGFR kinase domain usually respond well to the 
tyrosine kinase inhibitors gefitinib and erlotinib. However, patients typically develop 
resistance and relapse after about a year. In a lot of cases resistance is caused by the 
acquisition of the “gatekeeper” secondary kinase domain mutation, T790M (Godin-
Heymann et al., 2008). 
Multidrug resistance is a big contributing factor to the development of resistance to 
anticancer drugs. Anticancer drugs may kill drug-sensitive cells, but the proportion of drug-
resistant cells that are left behind will survive, proliferate and eventually render the tumour 
resistant to treatment (Persidis, 1999). Resistance is correlated to the presence of several 
drug transporters, the so-called molecular “pumps”, that serve as efflux pumps and remove 
drugs from tumour cells. The pumps commonly found to confer resistance are ATP-binding 
cassette (ABC) drug transporters: P-glycoprotein (encoded by ABCB1), multidrug 
resistance-associated protein (encoded by ABCC2) and ABCG2. These are important 
multidrug-resistance genes, conferring simultaneous resistance to unrelated drugs that do 
not necessarily have the same mechanism of action  (Persidis, 1999, Lou and Dean, 2007). 
Cancer stem cells are inherently highly resistant to chemotherapeutic drugs and contribute 
to resistance. Not only do CSCs possess the ability to self-renew and differentiate into cells 
that help maintain a tumour, they also express high levels of ABC transporters (Lou and 
Dean, 2007). For example, ABCG2 is highly expressed in haematopoietic stem cells. It has 
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been proposed that chemotherapy drugs used in combination with ABC transporter 
inhibitors would more efficiently target CSCs  (Dean et al., 2005). 
 
In imatinib-sensitive Ph+ CML white blood cells, imatinib is available at a sufficient 
quantity to inhibit all BCR-ABL molecules. Resistance can arise as a result of 
overexpression of BCR-ABL, whereby some BCR-ABL molecules are not bound to 
imatinib. In this scenario, the leukaemic cell is able to maintain a baseline level of signalling 
sufficient for cell survival. Specific mutations within the BCR-ABL kinase domain can also 
confer resistance by preventing the binding of imatinib and enabling ATP binding. Genomic 
instability can lead to the acquisition of additional mutations that may contribute to BCR-
ABL-independent growth and / or survival of malignant clones (von Bubnoff et al., 2002). 
Genomic instability, or clonal evolution, leads to gene amplification, mutation, and 
additional genetic changes in the leukaemic cell, suggesting that genomic instability would 
contribute to resistance in more than one way.   
 
Another possible reason for the failure of RTK inhibitor monotherapy is the presence of 
other activated RTKs in the same tumour that are not being targeted by the drug. In this 
scenario, targeting a single RTK is not effective because other RTKs will drive tumour 
growth and maintain activation of signalling pathways instead. This phenomenon known as 
“RTK-switching” supports the idea that combinational therapies may be required for the 
treatment of malignancy (Inda et al., 2014).  
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1.3.7 Targeting glioblastoma multiforme with tyrosine kinase 
inhibitors 
 
The current standard treatment for GBM consists of surgical resection followed by 
chemotherapy and radiotherapy. However, tumour cells are able to evade surgery and 
chemoradiotherapy, and recurrence is inevitable, typically occurring within 1-2 cm from the 
original border (Cuddapah et al., 2014). Following the success of imatinib for the treatment 
of CML, small-molecule inhibitors that inhibit kinase activity were developed for solid 
cancers. For example, the EGFR and HER2 inhibitor, lapatinib, was developed for HER2-
positive breast cancer, and the RAF, PDGFR, VEGFR and c-Kit inhibitor, sorafenib, for 
hepatocellular carcinoma (De Witt Hamer, 2010). However, there are still no small-
molecule kinase inhibitors for glioblastoma that show significant efficacy.  
 
Tyrosine kinases play a fundamental role in signal transduction that becomes deregulated in 
GBM. Migration and proliferation of GBM cells can be stimulated by the action of growth 
factors and their tyrosine kinase receptors, which often appear to be over-expressed or 
constitutively active in this cancer. The epidermal growth factor receptor (EGFR, also 
known as HER1 or ERBB1) is amplified, mutated, and/or rearranged in more than 40% of 
GBM. PDGFRα, PDGFRβ, c-Kit and c-Met, are also reported to be altered in GBM at lower 
frequencies (Roth and Weller, 2014).  
Because GBM remains incurable and kinases play an integral role in driving pathology, the 
application of small-molecule kinase inhibitors for the treatment of GBM is an obvious 
strategy. Targeting the EGFR is regarded as a particularly promising therapeutic strategy for 
GBM and small-molecule inhibitors, such as erlotinib, having been investigated. However, 
only 10 to 20% of patients benefit from current EGFR-directed strategies (erlotinib, or 
monoclonal antibodies): mutations, poor tumour perfusion, and the blood-brain barrier all 
present significant challenges and many patients do not respond or develop resistance (Roth 
and Weller, 2014).  
 
Overexpression and activation of PDGFR may contribute to the transformed phenotype of 
gliomas. PDGF A / B ligands and PDGFR α / β receptors are expressed in nearly all 
cultured glioma cell lines and in astrocytomas resected from patients (Kilic et al., 2000). 
Dominant-negative PDGF mutants block the proliferation of glioma cells in vitro and in 
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vivo (Shamah et al., 1993). In a glioma cell line with constitutively activated PDGF 
signalling pathway, the application of PDGF antibodies inhibited colony growth, diminished 
DNA synthesis and reversed the transformed morphology of tumour cells (Vassbotn et al., 
1994). However, anti-PDGFR therapy has so-far failed in GBM patients in the clinic 
(Stommel et al., 2007). 
Within the context of inhibiting tyrosine kinase activity, imatinib has been shown to inhibit 
the growth of glioma cells in vitro and in vivo in an intracranial GBM mouse model (Kilic et 
al., 2000). However, despite encouraging clinical results for CML, imatinib has failed 
clinical trials for glioblastoma, where it shows no significant inhibition of tumour growth or 
extension of survival. The North American Brain Tumor Consortium phase I/II trial of 
patients with recurrent malignant glioma found that single-agent imatinib has minimal 
activity and may be associated with a higher risk of intratumoural haemorrhage (Wen et al., 
2006). Another single-arm, phase II trial involving 112 patients with malignant 
astrocytomas (51 patients with GBM) also found that imatinib shows no significant 
antitumour activity in patients with recurrent gliomas (Raymond et al., 2008). 
As mentioned, only 10 to 20% of patients benefit from current EGFR-directed strategies, 
and anti-PDGFR therapy has failed in GBM patients (Roth and Weller, 2014, Stommel et 
al., 2007). The small-molecule imatinib has also failed.  In fact, a systemic review of 
clinical studies looking at the use of small-molecule inhibitors for GBM found that the 
efficacy of the inhibitors examined does not warrant switching from the standard of care for 
adult patients (De Witt Hamer, 2010).
GBM is characterised by strong intratumoural heterogeneity, and imatinib is likely to have 
failed because multiple kinases would be exerting pathogenic effects. Heterogeneous pattern 
of RTK amplification has been observed in GBM. The three receptors most commonly 
amplified are EGFR, PDGFR and c-Met, with evidence that tumour cells present varying 
amplification patterns within a single tumour (Inda et al., 2014). Aberrant kinase receptor 
activity may condition the response of GBM cells to targeted therapies. The absence of 
well-known mutations that predict the response to tyrosine kinase inhibitors and the 
presence of compensatory pathways prevent potent anti-glioma effects of drugs that target 
these receptors (Roth and Weller, 2014, Stommel et al., 2007). 
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1.3.8 Imatinib for the treatment of gastrointestinal stromal 
tumours  
 
Imatinib has also been approved for use in gastrointestinal stromal tumours (GIST), where 
mutated c-Kit (also known as CD117) has been found to play a critical role in the 
pathogenesis of the disease. c-Kit is expressed in a variety of human cancers, including 
neuroblastoma, melanoma, small cell lung cancer, breast and ovarian cancer, as well as 
GIST (Waller, 2010). For most of these cancers, the precise role of c-Kit is not defined. 
However, in the case of GIST, gain-of-function mutations in KIT are found in 95% of 
tumours and these mutations cause the kinase to become a proto-oncogene. c-Kit becomes 
constitutively active, which leads to uncontrolled cell proliferation and resistance to 
apoptosis (Demetri et al., 2002, Din and Woll, 2008).  
 
GISTs are soft tissue sarcomas of the gastrointestinal tract, originating from the neoplastic 
transformation of the intestinal cells of Cajal. KIT mutations result in the constitutive 
activation of the kinase leading to the activation of downstream effectors that deregulate cell 
proliferation and survival (Fukuda et al., 2013). The stem-cell factor (SCF) binds the 
extracellular SCF-binding domain of the transmembrane c-Kit receptor, leading to 
homodimerization and autophosphorylation of intracellular tyrosine residues. This creates 
docking sites for signal transduction effectors, leading to the activation of downstream 
signalling cascades involving MAPK, PI3K and RAS, which mediate c-Kit-induced 
mitogenesis and differentiation (Joensuu et al., 2002). GISTs range from small non-
malignant tumours curable with surgery to aggressive malignant cancers. About 20-30% of 
GISTs are malignant and the median survival from the time of diagnosis of metastatic or 
recurrent disease ranges from 12 to 19 months (Dagher et al., 2002, Joensuu et al., 2002).  
 
Surgery is the standard initial treatment for non-metastatic GISTs. For aggressive cancers, 
the standard of care prior to imatinib was chemotherapy. However, this was ineffective in 
the treatment of malignant unresectable GISTs. In one study only 7% of GIST patients 
responded to chemotherapy with two anticancer agents; and in another study involving five 
anticancer drugs, only 5% of patients responded (Joensuu et al., 2002).  
 
The tumour volume of the first GIST patient ever to receive imatinib shrunk by more than 
70% after 8 months of treatment (Joensuu et al., 2001). Imatinib's accelerated approval for 
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the treatment of advanced or metastatic GIST in February 2002 was based on response rate, 
an endpoint judged to likely predict clinical benefit. Response rate was calculated by 
carrying out a 24-month single open-label phase II trial of 147 patients with metastatic 
and/or unresectable malignant GIST. The study found that 38% of patients responded to 
imatinib, with pharmacokinetics similar to CML patients  (Dagher et al., 2002).  
Accelerated approval allows patient access to promising drugs but requires a follow-up 
study to demonstrate clinical benefit. Imatinib subsequently received accelerated full 
approval for primary treatment of patients with KIT-positive GIST in 2008 based on the 
positive findings from two large open-label, multicentre, randomised phase III studies which 
looked at a total of 1640 patients. The median progression-free survival time was 
approximately 20 months and the median overall survival time was approximately 49 
months (Cohen et al., 2009). The finding that c-Kit expression is altered in GIST and the 
development of imatinib has revolutionised the diagnosis and treatment of GIST, with 
overall response rates to the drug in excess of 80% (Din and Woll, 2008). 
However, treatment with imatinib is not uniformly successful. Although the 2-year survival 
rate for imatinib treatment of GIST ranges from 70-80%, between 10 and 20% of patients 
exhibit primary resistance to imatinib (Bauer et al., 2007, Bauer et al., 2005). The clinical 
outcome of imatinib is genotype-dependent in regards to both primary and secondary 
mutations that render c-Kit unresponsive to the TKI. One study that aimed to correlate 
clinical response to imatinib with tumour genotype found that tumours harbouring mutations 
in exon 11 were twice as likely to exhibit a partial response to imatinib (³50% decrease in 
tumour diameter) than tumours with mutations in exon 9 (Heinrich et al., 2003). A rare 
mutation in exon 17 has been found to confer resistance to imatinib in one patient and there 
are other rare mutations whose clinical outcome remain unknown (Spitaleri et al., 2015).
Although more than 80% of patients benefit significantly from imatinib treatment, most of 
these will eventually develop resistance and their disease will progress. In one study 12 
patients were selected for surgery to resect residual disease following imatinib treatment. 
Out of the 11 specimens from patients for whom complete resection was possible, 10 were 
found to contain viable tumour cells (Bauer et al., 2005, Bauer et al., 2007). This suggests 
that imatinib is not able to produce a complete response.  Nilotinib is not currently used for 
the treatment of GIST. The open-label phase III trial of nilotinib versus imatinib as front-
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line therapy for GIST patients was discontinued by Novartis in 2011 because interim results 
indicated that nilotinib would not be superior to imatinib. In a phase III trial of patients with 
advanced GIST who had previously been treated with imatinib and sunitinib, nilotinib did 
not show any advantages in progression-free or overall survival compared with renewal of 
imatinib treatment (Reichardt et al., 2012). 
 
The mechanisms underpinning primary and secondary resistance to imatinib remain 
unknown. However, most patients with imatinib resistance continue to express activated c-
Kit, suggesting that the c-Kit signalling pathway should remain a useful therapeutic target. 
But alternative small-molecule inhibitors have shown only a minor efficacy when used in 
GIST patients with secondary imatinib resistance. Secondary KIT mutations acquired during 
treatment have been reported, particularly in the kinase domain. But it is unclear whether 
these mutations simply block imatinib binding or whether they also hyper-activate c-Kit, 
which would lead to hyper-activation of downstream signalling (Bauer et al., 2007).  
 
The limited efficacy of other c-Kit kinase inhibitors may result from heterogeneity of 
mutations within individual patients. In this scenario any single drug would unlikely inhibit 
a broad range of mutations found in a patient, suggesting that a combinational approach 
targeting downstream effectors of c-Kit may help overcome the problem of resistance. The 
same signalling pathways are activated in imatinib-resistant GISTs as in untreated GISTs, 
notably the PI3K/AKT and ERK pathways. One approach to tackle imatinib resistance may 
be to target downstream signalling proteins. This is supported by findings that additive 
effects have been observed in GIST using imatinib together with either an mTOR inhibitor, 
PI3K inhibitor, or a MEK inhibitor. In imatinib-sensitive GIST, imatinib-induced inhibition 
of c-Kit is accompanied by significant decreases in phosphorylation of mTOR, AKT, and 
ERK (Heinrich et al., 2006). In a subsequent study, mTOR inhibition using a 
pharmacological inhibitor in conjunction with imatinib produced additive effects, inhibiting 
proliferation and apoptosis more than when either of the inhibitors were used alone (Bauer 
et al., 2007). As expected, imatinib induced almost no apoptosis and only minor 
antiproliferative effects in two GIST cells lines established from patients with imatinib-
resistance. However, a PI3K inhibitor induced strong antiproliferative effects (40-75% 
inhibition of proliferation) and apoptosis (three- to four-fold increase), suggesting that 
targeting downstream effectors may be of therapeutic benefit for the treatment of imatinib-
resistant GIST (Bauer et al., 2007). 
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1.4 Aims of the project  
 
Many of the motility-related proteins involved in migration are tyrosine kinases, including 
FAK, Src, c-Abl, and RTKs at the cell membrane. The target spectrum of imatinib and 
nilotinib include key kinases involved in motility (Fig. 1.3.3C). Therefore, the effects of 
imatinib and nilotinib on GBM motility in vitro were investigated. Surprisingly, preliminary 
results showed increases in tyrosine phosphorylation of the adaptor proteins p130Cas and 
PXN, and of the tyrosine kinase FAK, in response to stimulation with either imatinib or 
nilotinib (Fig 1.4). The preliminary unforeseen effects of TKIs on glioma cell tyrosine 
phosphorylation set the foundation of this project. The residues that were identified to be 
phosphorylated on p130Cas, FAK and PXN play a key role in driving glioma motility. I 
wanted to identify the effects of imatinib and nilotinib on glioma cellular signalling in vitro. 
 
 
 
Figure 1.4 Imatinib and nilotinib induce tyrosine phosphorylation of three key 
motility-related proteins. Cells (~80% confluent) were incubated in SFM for ~18hr prior 
to treatment with either serum free medium (SFM) & DMSO vehicle control (C), or 10 µM 
imatinib or 10 µM nilotinib for 20 minutes. Cell lysates were then prepared, blotted, and 
probed with the indicated antibodies. 
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p-p130Cas 
(Y410) 
Total	p130Cas 
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Importantly, despite encouraging clinical results for CML and for GIST, imatinib has failed 
clinical trials for GBM, where it shows no significant inhibition of tumour growth or 
extension of survival. The molecular mechanisms of action of imatinib in GBM is still not 
well understood. Imatinib and nilotinib are reported to cause activation of intracellular 
kinases including PI3K, Akt and ERK (Fenouille et al., 2010, Mokhtari et al., 2013, Packer 
et al., 2011, Dong et al., 2011). The activation of alternative pathways may contribute to the 
lack of clinical efficacy of imatinib in GBM trials. It was proposed that given the 
preliminary findings of enhanced activation of key motility-related proteins, imatinib and 
nilotinib may be exerting undesirable stimulatory effects on glioma migration. It was also 
proposed that using imatinib and nilotinib in a GBM model would help delineate the 
mechanisms of tumour development driving glioma pathology and would help identify 
targets for therapeutic intervention.  
 
Although the target selectivity, pharmacokinetic profiles, and toxicity profiles are well 
defined for imatinib and nilotinib, the precise molecular outcomes of drug treatment are not 
defined, and subsequently, neither is their clinical management. Inhibition of other TKs and 
co-activation of signalling pathways may account both for the development of imatinib 
resistance in Ph+CML and GIST. The aim of this project was to identify the target(s) and 
alternative downstream pathways being activated by imatinib and nilotinib. Identifying the 
effects of imatinib and nilotinib on cell functions modulating tumour behaviour is essential 
for understanding critically important aspects of drug treatment including non-
responsiveness, the development of resistance, and the occurrence of side effects. The 
identification of novel pathways being activated by imatinib and nilotinib could help 
identify new targets for combinational treatment.  
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2 Materials and methods 
 
 
2.1 Materials 
 
2.1.1 General consumables, chemicals and reagents  
 
Dulbecco’s Modified Eagle’s Medium (DMEM), Ham’s F-10 medium, DMEM (10X), 
Lipofectamine 2000, NuPAGE® Bis-Tris gels, Invitrolonä polyvinylidene difluoride 
membranes, NuPAGE® Transfer Buffer, NuPAGE® Electrophoresis Apparatus, Opti-
MEM, and 2.5% trypsin solution were from Invitrogen Life Technologies Ltd (Paisley, 
UK). Bovine serum albumin (BSA), Ethylenediaminetetraacetic acid (EDTA), Foetal 
bovine serum (FBS), Dimethyl sulphoxide (DMSO), Methanol, NP40, Penicillin-
Streptomycin, RIPA, 4X SDS Sample buffer, Phosphatase Inhibitor Cocktail 1, Phosphatase 
Inhibitor Cocktail 2, TWEEN®20 and Methyl cellulose were from Sigma-Aldrich (St. 
Louis, USA). Spectra Multicolor Broad Range Protein Ladder was from Thermo Scientific 
(Waltham, USA). cOmplete Protease EDTA-free Inhibitor Cocktail Tablets were from 
Roche Applied Science (West Sussex, UK). ECL Western Blotting Detection Reagent and 
Amersham Hyperfilm ECL were from GE Healthcare (Little Chalfont, UK). Falcon tissue 
culture dishes, Falcon tissue culture plates, Non-tissue culture treated u-bottom 96 well 
plates, Transwell inserts, Tissue culture flasks and Bovine Pituitary Extract (354123) were 
from BD Bioscience (Oxford, UK). MITO+ serum extender (355006) was from Corning 
Inc. (Corning, USA). PureCol® bovine collagen was from CellSystems Biotechnologie 
Vertrieb GmbH (Troisdorf, Germany). Paraformaldehyde and Triton X-100 were from 
Sigma. Vectashield Microscope Mounting Medium with DAPI was from Jackson 
Immunoresearch Laboratories (Luton, UK). 
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2.1.2 siRNA 
The AllStars Negative Control was purchased from Qiagen (Crawley, UK). Refer to Table 
2.1.2 for a list of all siRNa used.  
Table 2.1.2 List of siRNA used. 
TARGET GENE COMPANY SEQUENCE (5’ à3’) 
ABL1 (#10) Qiagen ACGCACGGACAUCACCAUGAA 
ABL2 (Arg; #8) Qiagen AACCCUGUCCUUAAUAACUUA 
BCAR1 (p130Cas; #1) Life Technologies GAGUUUGAGAAGACCCGAUU 
BCAR1 (p130Cas; #2) Dharmacon GGUCGACAGUGGUGUGUAU 
BRAF (#1) Qiagen AACAUAUAGAGGCCCUAUUGG 
CRAF (#5) Qiagen AAGACGUUCCUGAAGCUUGCC 
CSK Qiagen AAGUACAAUUCCACGGCACU 
DDR1 (#9) Qiagen ACGGUGUGAAUCACACAUCCA 
ITGB1 (#1) Dharmacon GAACAGAUCUGAUGAAUGA 
ITGB1 (#2) Dharmacon CAAGAGAGCUGAAGACUAU 
ITGB3 (#1) Dharmacon CUCUCCUGAUGUAGCACUUAA 
ITGB3 (#2) Dharmacon CACGUGUGGCCUGUUCUUCUA 
PDGFRβ Qiagen GGAACGUGCUCAUCUGUGA 
PTPN14 (PTP-Pez; #1) Ambion CGAGUAGAGCUGAUACCAA 
PTPN14 (PTP-Pez; #2) Ambion CCACGAAGUUUCGAACGGA 
PTPN12 (PTPPEST; #7) Qiagen UUGCAGGUUAUCAGAGAUCAA 
PTPN12 (PTPPEST; #8) Qiagen AAGCUUAAUGAGGAAAUAUCA 
PTPN11 (SHP2; #5) Qiagen AAGGUGGUUUCAUGGACAUCU 
PTPN11 (SHP2; #6) Qiagen CAGAAGCACAGUACCGAUUUA 
PTPN1 (PTP1B; #6) Qiagen GUCAGUCCCUUUGACCAUA 
PTPN1 (PTP1B; #7) Qiagen GGAGAAAGGUUCGUUAAAA 
PTPRA (#5) Qiagen CAGAGUGAUCAUUCCAGUUAA 
PTPRA (#6) Qiagen CCGGAGAAUGGCAGACGACAA 
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2.1.3 Antibodies 
Antibodies to DDR1, ABL1, c-Kit, ERK, FAK, NCK (15B9), Phospho-p130Cas (Y410), 
Phospho-p130Cas (Y165), Phospho-ERK (T202/Y204), Phospho-Paxillin (Y118), Phospho-
Src (Y416), PP2AC, PTP1B, PTP-PEST (AG10), Phospho-PTPRA (Y789), Phospho-Src 
(Y416), SHP2, and Alexa Fluor® 488 were from Cell Signaling Technology Inc. (Danvers, 
MA, USA). Antibodies to PDGFR-b, b1 Integrin (P5D2), b3 Integrin (H-96), CSK 
(CSK-04), CRAF, BRAF, p130Cas (C-20), Paxillin (H-114), Pez (G20) and GAPDH 
(V-18) were from Santa Cruz Inc. (Heidelberg, Germany). Secondary antibodies to mouse 
(SC-2005), goat (sc-2010) and rabbit (sc-2004) were also from Santa Cruz Inc. Antibody to 
p130Cas (Mouse) and FAK (Mouse) were from BD Transduction Laboratories (Oxford, 
UK).  Antibody to Phospho-p130Cas (Y128) was from Generon (Maidenhead, UK). 
Antibody to ABL2 (N1N3) was from GeneTex (Irvine, USA). Antibodies to Phospho-FAK 
(Y861) and Phospho-FAK (Y397) were from Life Technologies Ltd. (Paisley, UK). 
Antibody to Phospho-Paxillin (S126) was from Abcam (Cambridge, UK). Anti-
phosphoserine antibody (AB1603) was from Millipore. Please refer to Table 2.1.3 for the 
dilutions of primary antibodies that were most commonly used for Western blotting. 
Secondary antibodies were all used at a dilution of 1:10,000. 
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Table 2.1.3 List of antibodies and dilutions used for Western blot. BD, BD Transduction 
Laboratories; CST, Cell Signaling Technology Inc.; LT, Life Technologies Ltd.; SC, Santa 
Cruz Inc. 
TARGET MANUFACTURER HOST DILUTION 
ABL1 CST Rabbit 1:1000 
ABL2 GeneTex Rabbit 1:1000 
BRAF SC Rabbit 1:1000 
c-Kit CST Mouse 1:1000 
CRAF SC Rabbit 1:1000 
CSK SC Mouse 1:1000 
DDR1 CST Rabbit 1:1000 
ERK CST Rabbit 1:1000 
ERK phospho T202/Y204 CST Rabbit 1:1000 
FAK CST Rabbit 1:1000 
FAK BD Mouse 1:1000 
FAK phospho-Y397 LT Rabbit 1:1000 
FAK phospho-Y861 LT Rabbit 1:000 
GAPDH SC Goat 1:5000 
NCK1 CST Rabbit 1:1000 
p130Cas BD Mouse 1:5000 
p130Cas SC Rabbit 1:1000 
p130Cas phospho-Y128 Generon Rabbit 1:1000 
p130Cas phospho-Y165 CST Rabbit 1:1000 
p130Cas phospho-Y410 CST Rabbit 1:2000 
Paxillin SC Rabbit 1:4000 
Paxillin phospho-S126 Abcam Rabbit 1:1000 
Paxillin phospho-Y118 CST Rabbit 1:1000 
PDGFRβ CST Rabbit 1:1000 
PEZ (PTPN14) SC Goat 1:1000 
PP2AC CST Rabbit 1:1000 
PTP-PEST CST Mouse 1:1000 
PTP1B CST Rabbit 1:1000 
PTPRA phospho-Y789 CST Rabbit 1:1000 
SHP2 CST Rabbit 1:1000 
Src phospho-Y416 CST Rabbit 1:1000 
β1 Integrin SC Mouse 1:500 
β3 Integrin SC Rabbit 1:1000 
69	
2.1.4 Inhibitors 
The FAK inhibitor PF-573228 was purchased from Tocris Bioscience (Bristol, UK). PDGF-
BB was purchased from PeproTech (London, UK). Dimethyl sulphoxide (DMSO) and 
lipopolysaccharide (LPS; L4130) were purchased from Sigma. The MEK1/MEK2 inhibitor 
U0126 (ABE2893), imatinib (Gleevec®, STI-571), and nilotinib (Tasigna ®, AMN-107) 
were from Source Bioscience (UK). The PP2A inhibitor okadaic acid (OA; 495609) was 
purchased from Millipore. The PP2A activator FTY720 (1006292) was from Cayman. The 
Src inhibitor PP2 (529576) was from Calbiochem. 
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2.1.5 Stock solutions and buffers used for immunoblotting 
Cell lysis buffer per 10ml 
RIPA (Sigma; 150 mM NaCl, 1.0% IGEPAL CA-630, 0.5% 
sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) 
10ml 
cOmplete™ mini EDTA-free protease inhibitor tablet 1 tablet 
Phosphatase inhibitor cocktail 1 10µl 
Phosphatase inhibitor cocktail 2 10µl 
PBST (phosphate-buffered saline with tween) per 1000ml 
PBS tablets (Gibco; Phosphate 10nM, KCl 2.68nM, NaCl 
140nM) 
2 tablets 
TWEEN®20  1000µl 
Water  1000ml 
NP40 Buffer per 10ml 
NP40  (150mM NaCl, 50mM Tris-HCl pH8, 0.5% NP40) 10ml 
cOmplete™ mini EDTA-free protease inhibitor tablet 1 tablet 
Phosphatase inhibitor cocktail 1 10µl 
Phosphatase inhibitor cocktail 2 10µl 
Transfer Buffer per 1000ml 
NuPAGE® Transfer buffer 20X 100ml 
Methanol 100ml 
Water  800ml 
MOPS per 1000ml 
NuPAGE® MOPS 20X (50 mM MOPS, 50 mM Tris Base, 0.1% 
SDS, 1 mM EDTA, pH 7.7) 
50ml 
Water  950ml 
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2.2 Methods 
2.2.1 Routine cell culture 
All tissue culture was performed in sterile conditions using biological safety class II vertical 
laminar flow cabinets. Cells were grown in 37°C incubators maintained at 5% CO2. 
U87MG, U251MG and  U118MG glioma cells were purchased from ATCC (Manassas, 
USA). Hepatocellular carcinoma HEPG2 cells were a gift from Professor Steve 
Humphries, UCL. All these cells were cultured in DMEM containing 10% (vol/vol) foetal 
bovine serum (FBS) supplemented with Pen/Strep (1:100). GIST882 and GIST48 
gastrointestinal cells were a gift from Professor Bart Vanhaesebroeck, UCL. 
GIST882 and GIST48 were cultured in Ham’s F-10 medium containing 10% (vol/
vol) FBS, supplemented with Pen/Strep (1:100), 1.25 ml MITO+ serum extender and 
7.5 mg Bovine Pituitary Extract. 
2.2.2 Culture of human glioblastoma stem cells 
Human glioma stem cells (GSCs) were kindly provided by Professor Sebastian Brandner at 
the UCL Institute of Neurology. All patients gave informed consent before the surgical 
intervention. The storage of human tissue is governed by the Human Tissue Act (UK; HTA 
License #’s 12054). The National Hospital (part of University College London Hospitals 
NHS Foundation Trust) Ethics Committee has approved the use of the tissue (Ethical 
Approval LREC 08/0077 NHNN, HTA License #12054).  
GSCs can be stimulated to proliferate by exposing them to growth factors in tissue culture to 
generate non-adherent spherical clusters of cells, referred to as neurospheres, that can be 
plated and expanded (Bez et al., 2003, Vescovi et al., 1993). The following describes how 
the GSCs used in this project were initially derived by Professor Brandner’s lab, as 
described in (Jacques et al., 2010). All tumours were diagnosed as glioblastoma (WHO 
grade 4) by neuropathologists. The samples were taken directly from the operating theatre 
and placed in cold Dulbecco’s Modified Eagle’s Medium/Ham’s F12 (DMEM/F12; 
Invitrogen). The samples were finely minced, erythrocytes lysed by ACK (Ammonium-
Chloride-Potassium) buffer (Invitrogen) and tissue dissociated using Trypsin/EDTA. The 
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resulting suspension was centrifuged and pellets re-suspended in DMEM/F12 medium 
supplemented with B-27 (17504-044, Invitrogen), EGF (recombinant mouse, 315-09, 
PeproTech, 20 ng/ml), bFGF (recombinant human, 100-18B, PeproTech, 20 ng/ml) and 
Pen/Strep (1:100). For the first week, cells were cultured free-floating to form spheres and 
subsequently transferred into Laminin-coated dishes (L2020, Sigma, 0.01 mg/ml) in which 
they grow adherently. Cells were kept in 37°C incubators maintained at 5% CO2.  
GSCs exhibit diverse morphologies across patient samples and across clones from the same 
cell line (Zorniak et al., 2012). The morphology of the cells from three human-derived 
glioblastoma tumours used in this project is shown below (Fig. 2.2.2). The GSCs used here 
appear more astrocytic (Zorniak et al., 2012), with triangular cell bodies and multiple short 
projections. 
Figure 2.2.2 Morphology of three patient-derived GSCs used in this project. Cells and 
images were provided by Professor Brandner at the UCL Institute of Neurology. The 
IncuCyte ZOOM® brightfield imaging microscope was used. 
NH10-1123 NH10-1124 NH12-1206 
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2.2.3 siRNA transfection 
Cells at 60% confluence were transfected with Lipofectamine 2000 using 25 nM final 
concentration of siRNA. Table 2.1.2 provides details of all siRNA used for this project. 
Opti-MEM was used to dilute Lipofectamine 2000. Cells were transfected in 6-well tissue 
culture plates. The final volume used per well was 500 µl Opti-MEM and 6µl
Lipofectamine 2000 with 25 nM final concentration of siRNA, added to 1.5 ml DMEM 
supplemented with 10% FBS. Cells were left for 48 hours following which they were 
shifted overnight with serum-free DMEM, before treating with drugs and harvesting.  
2.2.4 Preparation of protein extracts 
Cells were seeded in 6-well tissue culture plates, treated as indicated and washed twice with 
ice-cold PBS. Cells were harvested in RIPA or NP40 lysis buffer containing the cOmplete 
protease inhibitor cocktail from Roche, and phosphatase inhibitor cocktails 1 and 2 from 
Sigma (80 µl RIPA per well of a 6-well plate). The cells were scraped off the plate and the 
lysates transferred to 1.5ml centrifuge tubes.  The samples were centrifuged for 15 min at 
16,000 g at 4°C to pellet the insoluble material.  The supernatant containing the protein 
lysate was removed and kept on ice, or at -20°C for longer-term storage.  
2.2.5 Immunoprecipitation 
Immunoprecipitation (IP) uses antibodies specific to a protein to remove those proteins from 
solution. The antibody-protein complexes were precipitated out of solution with the addition 
of an insoluble form of antibody binding proteins. Cells were washed with PBS, lysed in 
NP40 (50 mM Tris–HCl pH8, 150 mM NaCl, 0.5% NP40) containing cOmplete protease
and phosphatase inhibitors and centrifuged for 15 min at 16000 g at 4 °C. Immune 
complexes were collected using antibody and rotating at 4˚C overnight. 20 µl of anti-mouse 
or anti-rabbit IgG agarose beads were added for an additional 1 hour. The beads were 
collected by centrifuging at 16000 g for one minute and washed three times with ice-cold 
lysis buffer, and once with ice-cold PBS. Samples were eluted with 20µl of 2x SDS sample 
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buffer and heated for 2 min at 80oC. Samples were separated and immunoblotted as 
described in the next section. The following beads were used: Anti-Rabbit IgG (whole-
molecule)-Agarose, antibody produced in goat (Sigma; A8914); Control Rabbit IgG-
Agarose (Sigma; A2909), Anti-Mouse IgG (whole-molecule)-Agarose, antibody produced 
in goat (Sigma; A6531); Control Mouse IgG-Agarose (Sigma; A0919). 
 
 
2.2.6 Immunoblot analysis 
 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was carried out 
to separate proteins according to their molecular weight. Equal concentration of protein 
samples were reduced in 4x SDS-PAGE sample buffer followed by heating at 80˚C for 3 
minutes. After centrifugation, protein samples were resolved on precast polyacrylamide gels 
(4-12% NuPAGE Bis-Tris) immersed in MOPS SDS running buffer. Pre-stained Spectra 
Multicolor Broad Range Protein Ladder was loaded to the first well of the gel while the 
protein samples were loaded to the subsequent wells. The gel was run for 45 minutes at 200 
V to allow for the separation of proteins. Proteins were electrotransferred onto Invitrolonä 
PVD membranes (0.45 µm pore) in Nu-PAGE transfer buffer containing 10 % methanol at 
room temperature for 1 hour at 30 V. Successful transfer was indicated by full transfer of 
the molecular weight markers onto the membrane. Membranes were blocked with 5% 
(wt/vol) non-fat dry milk and 0.1% (vol/vol) TWEEN®20 in phosphor-buffered saline 
(PBST) for 1 hr at room temperature at gentle rocking, before being probed with the 
primary antibody by overnight incubation at 4°C. The membranes were washed 3 times for 
10 minutes each in PBST before adding appropriate horseradish peroxidise (HRP) 
conjugated anti-immunoglobulin G (IgG) secondary antibody diluted in 5 % milk/PBST 
solution for 1 hour. After secondary antibody incubation, membranes were washed and 
detected using the enhanced chemiluminescence (ECL) Western Blotting Detection Reagent 
following the manufacturer’s protocol.  Chemiluminescent images of immunodetected 
bands were recorded on Amersham Hyperfilm chemiluminescence film and developed 
using the Kodak® X-Omat Model 2000 processor. Immunoblots were quantified by 
scanning films with a calibration strip and analysed by densitometry using Image J (US 
National Institutes of Health; http://rsb.info.nih.gov/ij). Results, were normalised to total 
protein levels to account for loading errors or incomplete transfers.  
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2.2.7 Immunofluorescence 
For immunofluorescent staining, cells were fixed in 4% paraformaldehyde (PFA) for 20 min 
followed by permeabilisation in 0.2% Triton X-100 for 30 min and washed in Tris Buffered 
Saline (TBS) with 0.1% Triton X-100. After blocking with 2% BSA/0.1% Triton X-
100/TBS for 1 hour at room temperature, cells were incubated with primary antibodies 
overnight at 4oC (dilutions shown below). Primary antibody incubation was followed by 
three washes with TBS with 0.1% Triton X-100 and subsequent incubation with secondary 
antibodies conjugated to Alexa 488 fluorescent dye for 45 minutes. Cells were washed three 
times and mounted on glass slides using immunofluorescence Vectashield mounting medium 
with DAPI. Confocal imaging was performed using an Olympus FV1000 confocal 
microscope. Images were obtained with a x60 magnification oil-immersion objective. 
The following dilutions were used for immunofluorescence: Anti-phospho FAK 
Y861, anti-phospho p130Cas Y410, anti-phospho Paxillin Y118, and Alexa Fluor® 488 
were used at 1:200.
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2.2.8 Spheroid invasion assay 
 
Methyl cellulose was dissolved in distilled water, shaken vigorously overnight at 37oC and 
autoclaved (stored at 4oC). Cells were trypsinised and counted using the ADAM MC 
automated cell counter (NanoEnTek Inc., Newton, USA). A total of 5X104 cells/ml were 
suspended in a 4:1 (vol/vol) mixture of 10% FBS in DMEM and methyl cellulose. 100µl of 
mixture was pipetted and plated per one well of a non-tissue culture treated u-bottom 96-
well plate and incubated for 24 h (37oC, 5% CO2). The next day the collagen mixture was 
prepared on ice containing the following per 1000µl: 700µl of collagen, 200µl of 5XDMEM 
and 100µl distilled water. The collagen mixture was divided into falcon tubes and 
supplemented with control DMSO or various inhibitors, mixed well, and left on ice. 500µl 
of collagen + treatment was transferred per well of a 12-well plate and left to solidify in an 
incubator at 37oC for 1 hour. The medium in the 96-well plate containing the spheroids was 
carefully aspirated, making sure the spheroids were left at the bottom of the well. 100µl of 
the collagen mix + treatment was added to each spheroid. The tip of 1000µl tip was cut with 
sterilised scissors and used to pick up the spheroids with collagen mix and added to the 
solidified collagen in the 12-well plate. 5 spheroids per condition were added. Spheroids 
were left to invade for 48h following which they were fixed with 4% PFA and images were 
taken using a phase contrast microscope. Invasion was determined by measuring the circular 
area of the spheroid core and the rim of the invasion using Image J (Fig. 2.2.8).  
 
 
 
 
 
 
 
Figure 2.2.8 Example of a spheroid generated using the spheroid invasion protocol. 
The core and rim of invasion used for quantification are shown. 
 
Spheroid core 
Rim of invasion 
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2.2.9 Transwell migration assay 
 
Transwell migration assays are used for the study of motility of different types of cells. 
Permeable migration inserts are placed in a well of a tissue-coated plate, creating two 
chambers on either side of the insert. Cells placed in the top chamber can sense 
chemoattractant(s) placed on the other side and can diffuse across the permeable insert. 
Cells which migrate across can be counted to assess the effect of the chemoattractant on 
motility. Transwell cell culture inserts made of transparent, low-pore-density polyethylene 
terephthalate with an 8 µm pore size were inserted into a 24-well plate. Serum free medium 
supplemented with vehicle or imatinib was added to the bottom chamber, and U87 glioma 
cells in suspension (1.5 x 105 cells/well in serum free DMEM) were added to the top 
chamber and incubated at 37˚C for 6h. Cells that had not migrated or had only adhered to 
the upper side of the membrane were removed before membranes were fixed and stained 
with a Reastain Quik-Diff kit (IBG Immucor Ltd, West Sussex, UK) and mounted on a glass 
slide.  Cells that had migrated to the lower side of the membrane were counted in four 
random fields per well at x20 magnification using an indexed eyepiece graticule. 
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2.2.10 Wound healing assay  
 
The wound healing assay, also known as the scratch assay, allows for the study of two-
dimensional migration in vitro. By creating an artificial gap (the so-called “wound” or 
“scratch”) on a monolayer of cells, the cells on the edge of the gap will move toward the 
other edge to close the gap. The rate of wound closure can be calculated by capturing 
images at the beginning and at regular intervals thereafter (Fig.2.2.10).  
 
U251MG cells were seeded to confluence in a tissue culture flat-bottom 96-well plate. Cells 
were shifted and treated with imatinib, nilotinib, or vehicle control. The IncuCyteTM 
WoundMakerTM (Essen Bioscience, UK) was used to mechanically create a homogenous 
700-800 µm wide scratch in the cell monolayer evenly across all wells of the 96-well plate. 
The rate of migration was measured using the IncuCyte ZOOM® live cell imaging machine 
(Essen Bioscience, UK) by analysing the gap over time. Photos were taken every hour for 
30 hours. A minimum of six separate wells were analysed per condition in each experiment.  
 
 
 
 
 
 
Figure 2.2.10 Example images of wound closure captured using the IncuCyte ZOOM® 
live cell imaging machine. U251MG cells seeded to confluence in a 96-well tissue culture-
treated plate formed a monolayer. Cells were scratched and placed into the IncuCyte 
ZOOM®.  Images were acquired at 0 h (A), 12 h (B), and 24 h (C).  
 
  
A B C 
	 79	
2.2.11 Proliferation assay 
 
Our lab has previously transfected U87MG cells with the human histone H2B gene fused to 
green fluorescent protein (H2B-GFP). The H2B-GFP fusion protein is incorporated into 
nucleosomes, the building blocks of chromatin. U87MG stably expressing H2B-GFP were 
seeded in 96-well plates at a density of 2,000 cells / well. Proliferation was determined by 
assessing the total cell fluorescence intensity per well in living cells using the IncuCyte 
ZOOM® for up to 96 hours. 
 
 
2.2.12 Statistical analysis 
 
For the Western blot results, data was obtained from at least three separate experiments and 
representative blots are shown to present protein expression. For the spheroid assay results, 
data was obtained from three separate experiments, with at least three different spheroids 
measured per condition. Statistical analysis was performed using Prism (GraphPad) on 
normalised data by one- or two-way analysis of variance (ANOVA) followed by the Student 
Newman Keuls test for multiple comparisons used to find differences. The level of accepted 
statistical significance was P<0.05. The data displayed on the graphs are means, with error 
bars representing the standard error of the mean (SEM). P<0.05 is denoted with * and 
P<0.01 is denoted with **. 
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3 Imatinib and nilotinib stimulate tyrosine 
phosphorylation and promote tumour 
cell migration in human GBM cells 
 
 
 
3.1 Imatinib and nilotinib treatment of human GBM 
cells leads to increased p130Cas, FAK and PXN 
tyrosine phosphorylation 
 
Access to readily available cell models is critical for the study of GBM. U87MG is a well-
characterised and commonly studied GBM cell line that has been used for research for 
decades and is included in over 1900 publications. The U87MG cell line was initially 
derived from a primary brain tumour from a 44-year-old Caucasian woman. The cells are 
easy to procure and to maintain for multiple passages (Clark et al., 2010, Xiang et al., 2015, 
Xie et al., 2015). U87MG cells used in this project were previously purchased by our lab. 
The cells are well characterised and are known to express both PDGF-A and PDGF-B, and 
high levels of PGFRa  and  b receptor. They have mutations in the p14, p16 and PTEN 
tumour suppressors (Shamah et al., 1993, Kilic et al., 2000, Ishii et al., 1999). 
Tyrosine phosphorylation of p130Cas at Y410, FAK at Y861 and PXN at Y118 play 
important roles in cell migration and invasion. Tyrosine residue Y410 of p130Cas is 
phosphorylated in response to PDGF- and HGF-mediated migration of U87MG glioma cells 
(Evans et al., 2011). Src phosphorylation of Y861 enhances FAK binding to p130Cas (Mitra 
et al., 2005). Phosphorylation of PXN at tyrosine residue Y118 is required for the formation 
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of focal adhesions and for optimum motility. Tyrosine phosphorylation at residue Y118 (and 
Y31) generates a functional SH2-binding site for members of the Crk family of SH2-SH3 
adaptor proteins (Petit et al., 2000).  
U87MG cells were treated with imatinib or nilotinib to investigate their effects on key 
signalling proteins required for tumour cell motility and invasion, p130Cas, FAK and PXN. 
Tyrosine residues Y410, Y861 and Y118 were used as readouts of activation of p130Cas, 
FAK and PXN, respectively. Treatment with 10 μM imatinib or 10 μM nilotinib caused a 
striking increase in tyrosine phosphorylation of p130Cas, FAK and PXN (Fig. 3.1.1). The 
effects observed were dose-dependent, with a significant increase detected at 1 μM and a 
maximal response at 10 μM for both imatinib and nilotinib (Fig. 3.1.2). The effects of 
imatinib and nilotinib on tyrosine phosphorylation of p130Cas, FAK and PXN are rapid and 
sustained with a significant increase observed at 10 min, reaching a maximum at 30 min, 
which are maintained for up to 1 hour (Fig. 3.1.3). After 4 hours, p130Cas tyrosine 
phosphorylation declined to near basal level, whereas FAK and PXN tyrosine 
phosphorylation remained strongly elevated.  
Imatinib and nilotinib were also found to increase tyrosine phosphorylation of additional 
p130Cas residues. Phosphorylation of p130Cas at tyrosine residue Y128 is critical for 
migration of colorectal cancer cells (Zhang et al., 2013) and phosphorylation at Y165 
promotes p130Cas association to FAK in cortical neurons (Liu et al., 2007a). Treatment 
with imatinib and nilotinib led to an increase in phosphorylation of tyrosine residues Y128 
and Y165 (Appendix Fig. A1A). One of the earliest steps of the signalling transduction 
pathway mediating motility is the autophosphorylation of FAK at tyrosine residue Y397 
(Sharma and Mayer, 2008). Treatment with imatinib or nilotinib also led to an increase in 
tyrosine phosphorylation of FAK at residue Y397 (Appendix Fig. A1B). 
Immunofluorescence confocal microscopy was performed in order to examine the effect of 
imatinib and nilotinib treatment on the localisation of the phosphorylated motility-related 
proteins p130Cas, FAK and PXN. Our lab previously generated U87MG cells with 
fluorescently labelled actin cytoskeleton that stably express mCherry-LifeAct (Riedl et al., 
2008). To confirm that imatinib and nilotinib cause similar effects in the U87MG LifeAct 
cells, the outcome of drug treatment on tyrosine phosphorylation was examined. Imatinib 
and nilotinib treatment of LifeAct U87MG cells induced similar increases in tyrosine 
phosphorylation of Y410, Y861, and Y118 (Fig. 3.1.4), confirming that the LifeAct cells 
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behave similarly to the parental cell line. Subsequent immunofluorescence revealed that the 
levels of phosphorylated p130Cas (Tyr 410) increased in both imatinib and nilotinib treated 
cells after 20 min. A striking redistribution of phoso-p130Cas to the cell membrane was also 
observed, localising along what appear to be membrane ruffles (Fig. 3.1.5). Similar 
increases and redistribution were observed for phospho-FAK (Y861) (Fig. 3.1.6) and 
phospho-PXN (Y118) (Fig. 3.1.7). 
To confirm the effects of imatinib and nilotinib on tyrosine phosphorylation in GBM, the 
effect of drug treatment on additional well-established glioma cell lines was examined. 
U251MG derived from a 75-year-old male, and U118MG derived from a 50-year-old male 
are GBM cell lines characterised by mutations in  PTEN, p53, p14 and p16 tumour 
suppressors (Ishii et al., 1999). 20-minute treatment with 10 μM nilotinib caused a 
significant increase in phosphorylation of p130Cas. Treatment with 1 μM or 10 μM 
nilotinib also led to a significant increase in phosphorylation of FAK and PXN. Treatment 
with 10 μM imatinib led to a significant increase in FAK phosphorylation (Fig. 3.1.8).  
Imatinib and nilotinib treatment caused similar increases in tyrosine phosphorylation in 
U118MG cells. 20-minute nilotinib treatment at 10 μM led to a significant increase in 
phosphorylation of all three proteins. Treatment with 10 μM imatinib led to a significant 
increase in phosphorylation of PXN (Fig. 3.1.9). The results from additional glioma cell 
lines support the initial findings in U87MG that two well-established TKIs induce tyrosine 
phosphorylation of key motility-related proteins in glioma cells. 
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Figure 3.1.1 Imatinib and nilotinib treatment of human U87MG GBM cells leads to 
increased p130Cas, FAK and PXN tyrosine phosphorylation. U87MG cells (~80% 
confluent) were incubated in SFM for ~18hr prior to treatment with either SFM & DMSO 
vehicle control (C), or 10 μM imatinib or 10 μM nilotinib for 20 minutes. Cell lysates were 
then prepared, blotted, and probed with the indicated antibodies. Quantification of tyrosine 
phosphorylation shown here and in all subsequent figures was performed by densitometry 
using Image J. In each panel, data from four independent experiments are presented as 
phosphorylation relative units (RU) (means +/- s.e.m.) normalised to total protein levels; 
*p<0.05, **p<0.01 compared to vehicle control (C).  
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Figure 3.1.2 Imatinib and nilotinib induce tyrosine phosphorylation in a dose-
dependent manner. U87MG cells (~80% confluent) were incubated in SFM for ~18hr 
prior to treatment with either SFM & DMSO vehicle control (C), imatinib or nilotinib at 
indicated concentrations for 20 minutes. Cell lysates were then prepared, blotted, and 
probed with the indicated antibodies. Data from three independent experiments are 
presented as phosphorylation relative units (RU) (means +/- s.e.m.) normalised to total 
protein levels; *p<0.05, **p<0.01 compared to vehicle control (C). 
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Figure 3.1.3 Time course of imatinib- and nilotinib-induced tyrosine phosphorylation. 
U87MG cells (~80% confluent) were incubated in SFM for ~18hr prior to treatment with 
either SFM & DMSO vehicle control (C), or 10 µM imatinib or 10 µM nilotinib for the 
indicated amount of time. Cell lysates were then prepared, blotted, and probed with the 
indicated antibodies. Data from three independent experiments are presented as 
phosphorylation relative units (RU) (means +/- s.e.m.) normalised to total protein levels; 
*p<0.05, **p<0.01 compared to vehicle control (C).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.4 Imatinib and nilotinib treatment of human LifeAct GBM cells leads to 
increased p130Cas, FAK and PXN tyrosine phosphorylation. LifeAct GBM cells (~80% 
confluent) were incubated in SFM for ~18hr prior to treatment with either SFM & DMSO 
vehicle control (C), or 10 μM imatinib (I) or 10 μM nilotinib (N) for 20 minutes. Cell 
lysates were then prepared, blotted, and probed with the indicated antibodies.  
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Figure 3.1.5 Imatinib and nilotinib treatment leads to a rapid increase of phospho-
p130Cas at the cell membrane. Immunofluorescence confocal microscopy was performed 
on U87MG cells stably transfected with LifeAct®–TagRFP. Cells were seeded on glass 
cover slips and incubated in SFM for ~18h prior to treatment with vehicle control, or 10 µM 
imatinib or 10 µM nilotinib for 20 minutes. Phosphorylated p130Cas (Y410) staining is in 
green, actin in red, and DAPI in purple. Arrows point to areas of increased phosphorylated 
p130Cas (Y410) localisation to the membrane upon treatment.  
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Figure 3.1.6 Imatinib and nilotinib treatment leads to a rapid increase of phospho-
FAK at the cell membrane. U87MG LifeAct cells were seeded on glass cover slips and 
incubated in SFM for ~18h prior to treatment with vehicle control, or 10 µM imatinib or 10 
µM nilotinib for 20 minutes. Phosphorylated FAK (Y861) staining is in green, actin in red, 
and DAPI in purple. Arrows point to areas of increased phosphorylated FAK (Y861) 
localisation to the membrane upon treatment.  
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Figure 3.1.7 Imatinib and nilotinib treatment leads to a rapid increase of phospho-
PXN at the cell membrane. U87MG LifeAct cells were seeded on glass cover slips and 
incubated in SFM for ~18h prior to treatment with vehicle control, or 10 µM imatinib or 10 
µM nilotinib for 20 minutes. Phosphorylated PXN (Y118) staining is in green, actin in red, 
and DAPI in purple. Arrows point to areas of increased phosphorylated PXN (Y118) 
localisation to the membrane upon treatment.  
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Figure 3.1.8 Imatinib and nilotinib treatment of human U251MG GBM cells leads to 
increased p130Cas, FAK and PXN tyrosine phosphorylation. U251MG cells (~80% 
confluent) were incubated in SFM for ~18hr prior to treatment with vehicle control (C), or 
imatinib and nilotinib at specified concentrations for 20 minutes. Cell lysates were then 
prepared, blotted, and probed with the indicated antibodies. Data from three independent 
experiments are presented as phosphorylation relative units (RU) (means +/- s.e.m.) 
normalised to total protein levels; *p<0.05, **p<0.01 compared to vehicle control (C). 
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Figure 3.1.9 Imatinib and nilotinib treatment of human U118MG GBM cells leads to 
increased p130Cas, FAK and PXN tyrosine phosphorylation. U118MG cells (~80% 
confluent) were incubated in SFM for ~18hr prior to treatment with vehicle control (C), or 
imatinib and nilotinib at specified concentrations for 20 minutes. Cell lysates were then 
prepared, blotted, and probed with the indicated antibodies. Data from three independent 
experiments are presented as phosphorylation relative units (RU) (means +/- s.e.m.) 
normalised to total protein levels; *p<0.05, **p<0.01 compared to vehicle control (C). 
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3.2 Imatinib and nilotinib treatment of human GBM 
cells leads to enhanced two-dimensional and three-
dimensional migration  
 
Signalling via p130Cas, FAK and PXN plays a critical role in the regulation of motility, and 
tyrosine phosphorylation at Y410, Y861 and Y118, respectively, are indicators of protein 
activation. Given the implication of p130Cas, FAK, and PXN in migration, the effects of 
imatinib and nilotinib treatment on glioma cell motility was examined. It was predicted that 
imatinib and nilotinib would stimulate migration. Assays for examining both two-
dimensional (2D) wound healing and three-dimensional (3D) migration were employed.  
The wound healing assay (also known as the scratch assay) allows for the study of 2D cell 
migration in vitro. The assay involves creating an artificial gap, the so-called “scratch”, on a 
confluent cell monolayer. The cells on either side of the outer edge of the scratch will 
migrate towards the opposite edge until new cell-cell contacts are made in order to close the 
gap. The rate of closure is measured by taking images at the start and at regular intervals 
thereafter.  
 
U87MG grow on top of each other and do not form a clear monolayer. By contrast, 
U251MG cells form a monolayer (Fig. 2.2.10) and were used for the wound-healing assay. 
The assay revealed that either 10 µM imatinib or 1 µM nilotinib treatment results in 
increased rates of wound closure compared to control vehicle-treated cells (Fig. 3.2.1). 
Nilotinib was used at 1 µM because 10 µM nilotinib precipitated out of solution after 
several hours.   
The transwell chemotactic migration assay is a useful tool for looking at the effect of a drug 
on chemotaxis, which refers to the migration of cells in response to a stimulus. Permeable 
inserts placed in a 6-well plate create two chambers on either side of the insert. Serum free 
medium supplemented with or without drug can be added to the bottom chamber, and 
U87MG cells can be suspended in medium in the top chamber. Cells that diffuse across the 
insert are counted to assess the effect of the drug on migration. Transwell migration assays 
performed by my supervisor, Dr. Paul Frankel, show that imatinib acts as a chemo-attractant 
and stimulates migration of U87MG cells (Appendix Fig. A2). 
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Figure 3.2.1 Imatinib and nilotinib treatment of U251MG results in enhanced rates of 
wound closure. U251MG cells were grown to confluence in a 96-well plate and a uniform 
scratch was made along the centre of each well. Cells were washed with SFM and incubated 
with SFM containing either DMSO control, 10 µM imatinib, or 1 µM nilotinib. Rate of 
wound closure was monitored in an IncuCyte ZOOM® with images captured every hour for 
a total of 30 hours. Data is representative of n=3 experiments. 
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Invasion of tumour cells into surrounding healthy tissue is a key hallmark of malignant 
tumours. GBM is a particularly malignant type of cancer with high invasive capability. The 
radial tumour spheroid invasion assay enables a rapid and reproducible method for 
investigating three-dimensional migration in vitro. Spheroids from U87MG, U251MG and 
U118MG GBM cell lines were generated and embedded in collagen plugs supplemented 
with serum free medium containing either vehicle control, 10 µM imatinib or 1 µM 
nilotinib. Treatment with either imatinib or nilotinib alone for 48 hours resulted in a striking 
increase in radial invasion compared to the vehicle control spheroids (Fig. 3.2.2A–C).  
A proliferation assay was performed to confirm that the observed effects of imatinib and 
nilotinib on motility are not a result of enhanced proliferation. Proliferation can be assessed 
by labelling chromosomes in living cells with a fluorescent tag attached to a histone gene. 
As cells divide and proliferate the amount of fluorescent signal increases and this can be 
quantified using the IncuCyte ZOOM®. The effect of imatinib and nilotinib on cell 
proliferation was assessed by using U87MG stably expressing the histone H2B gene fused 
to green fluorescent protein (GFP) that were previously generated in our lab. Treatment with 
10 µM imatinib or 1 µM nilotinib had no significant effect on cell proliferation (Fig. 3.2.3). 
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Figure 3.2.2 Imatinib and nilotinib treatment of human GBM cells leads to increased 
3D radial invasion. (A) U87MG. (B) U251MG. (C) U118MG. (A - C) Equal amounts of 
cells were used to generate spheroids as described in Materials and Methods.  24 hours after 
spheroid production, spheroids were imbedded in a collagen gel and incubated in serum free 
medium supplemented with vehicle (control), 10 µM imatinib or 1 µM nilotinib. Spheroids 
were fixed in 4% paraformaldehyde (PFA) and invasion was determined by measuring the 
area corresponding to the invasion rim minus the area of the core for at least 3 different 
spheroids per condition. Data from three independent experiments are presented as relative 
area units (RU) (means +/- s.e.m.); **p<0.01 compared to control. 
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Figure 3.2.3 Imatinib and nilotinib treatment does not affect U87MG cell proliferation.  
Proliferation was measured using U87MG cells stably expressing H2B-GFP. Values are 
means from 5 replicate wells per experiment and 5 independent experiments (n=5) ± s.e.m, 
expressed as the relative fluorescence intensity per well.  
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3.3 Discussion  
 
The effects of two tyrosine kinase inhibitors, imatinib and nilotinib, on tyrosine 
phosphorylation were examined, as well as their effect on glioma cell migration. Findings 
presented here show that treatment of multiple human glioma cell lines with imatinib or 
nilotinib produces a rapid and significant increase in tyrosine phosphorylation of p130Cas, 
FAK and PXN at residues implicated in the signalling pathways governing motility.  
The peak plasma/serum concentrations of imatinib and nilotinib are approximately 4.6 μM 
(Druker et al., 2001) and 3.6 μM (Weisberg et al., 2007), respectively. Data presented here 
indicate that observed effects occur at clinically relevant concentrations. The finding that 
imatinib and nilotinib treatment stimulates tyrosine phosphorylation as early as 10 minutes 
indicates that this is an immediate response of a direct drug effect on signalling components 
distal to p130Cas, FAK and PXN pathways, and not the result of long-term effects such as 
altered gene expression. Localisation of tyrosine phosphorylated p130Cas, FAK and PXN to 
the cell membrane is also rapid, occurring after 20 minutes of drug stimulation. 
p130Cas, FAK and PXN are important signalling nodes involved in signal transduction 
pathways that result in enhanced motility, as outlined in the introduction (Barrett et al., 
2013, Parsons, 2003). Functional experiments were carried out to investigate the effect of 
imatinib and nilotinib on motility. Findings show that, consistent with increases in tyrosine 
phosphorylation and localisation of phosphorylated proteins to the membrane, imatinib and 
nilotinib strikingly increase motility in 2D and 3D models using multiple glioma cell lines. 
The effects appear to be specific to cell motility because proliferation was unaffected by 
drug treatment.  
Given that tyrosine phosphorylation of p130Cas at tyrosine residues Y128 and Y165 is 
associated to motility, the identification that imatinib and nilotinib stimulate 
phosphorylation at these sites support the functional data showing that both TKIs promote 
migration. FAK is activated and undergoes autophosphorylation at tyrosine residue Y397 in 
response to integrin receptor activation (Sharma and Mayer, 2008). The finding that 
imatinib and nilotinib treatment leads to increased phosphorylation at Y397 further supports 
their ability to stimulate the motility pathway and promote migration.   
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GBM is a highly malignant tumour that is dependent on augmented tumour cell motility. 
Results provide evidence of unexpected off-target effects of the use of imatinib and nilotinib 
treatment on GBM cell lines. This suggests a potential adverse effect of imatinib and 
nilotinib treatment on tumour progression, which will be further discussed in Chapter 7. 
Imatinib has previously failed clinical trials for the treatment of GBM, where it shows no 
significant inhibition of tumour growth or extension of survival (Wen et al., 2006). A 
previous study found that imatinib inhibited the growth of U87MG cells in vitro and in vivo 
in an intracranial mouse model of GBM generated by injecting U87MG cells into mice 
(Kilic et al., 2000). Findings here, however, present important and unforeseen adverse 
effects of imatinib and nilotinib on tumour cell motility, which could significantly 
contribute to the lack of clinical efficacy observed in these trials. Results point out the 
importance of screening imatinib, nilotinib, and other TKIs of interest, on multiple modes of 
cell motility and on different types of cancers for which they are being investigated. 
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4 Investigating the mechanism of imatinib 
and nilotinib effects in GBM cells 
 
 
The molecular mechanism of action of imatinib on glioma cells is poorly understood, and 
the reason for its failure in the clinic remains unclear.  Imatinib and nilotinib are reported to 
cause activation of intracellular kinases including PI3K, Akt and ERK (Fenouille et al., 
2010, Mokhtari et al., 2013, Packer et al., 2011, Dong et al., 2011). The delineation of 
signalling pathway(s) affected by drug treatment in glioma may help to explain not only 
why it failed in GBM trials, but also to identify novel targets for the improvement of clinical 
efficacy.  
Acquired resistance is common in patients receiving TKIs for the treatment of cancers. This 
occurs over months or years as cells accumulate mutations in the kinase domain, or reduce 
their dependency on the target kinase via the activation of other kinases or signalling 
pathways. It is critical to develop synergistic inhibitor combinations, with the simultaneous 
inhibition of multiple targets, either one or more kinase and / or downstream signalling 
effectors. The identification of novel pathways being activated by imatinib and nilotinib 
could help identify new targets for combinational treatment. To start with, I wanted to 
investigate whether one or more of the known targets that imatinib and nilotinib bind to with 
high specificity could be mediating observed drug effects. The known targets that imatinib 
and nilotinib bind to with high specificity are ABL1, ABL2, PDGFR, DDR1, and c-Kit 
(Hantschel et al., 2008, Deininger et al., 2005). 
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4.1 Evaluating the role of the major targets of   
imatinib and nilotinib in mediating the 
observed increases in phosphorylation 
of p130Cas, FAK and PXN 
Imatinib and nilotinib are both ABL1 and ABL2 (also called ARG) kinase inhibitors. 
Furthermore, ABL has been reported to mediate p130Cas coupling to adaptor protein Crk, 
an important interaction for downstream signalling mediating motility (Fig. 1.2) (Barrett et 
al., 2013). It was therefore reasoned that ABL1 and/or ABL2 could be mediating the 
imatinib- and nilotinib-induced stimulation of phosphorylation and migration.  
U87MG cells were treated with siRNA to ABL1 and ABL2 either individually or in 
combination, and subsequently treated with 10 μM imatinib, 10 μM nilotinib or vehicle 
control (Fig. 4.1.1). A reduction in total levels of p130Cas and PXN make it difficult to 
evaluate the effect of the knockdown. Nevertheless, densitometric analysis of the data 
revealed that there is no significant effect of knockdown on imatinib- and nilotinib-induced 
tyrosine phosphorylation of p130Cas and PXN. However, knockdown has a significant 
effect on drug-induced tyrosine phosphorylation of FAK. Interestingly no decrease in basal 
phosphorylation of FAK in the control treated cells was detected. 
Imatinib and nilotinib also inhibit three additional tyrosine kinases at physiologically 
relevant concentrations: the platelet derived growth factor receptor (PDGFR), the stem cell 
growth factor receptor (c-Kit), and discoidin domain receptor tyrosine kinase 1 (DDR1)
(Hantschel et al., 2008). However, silencing of PDGFRβ and DDR1 had no effect on 
increased tyrosine phosphorylation in response to imatinib and nilotinib (Fig. 4.1.2 A&B). c-
Kit was not detected in U87MG cells, whereas we could readily detect c-Kit in human 
coronary artery smooth muscle cells (HCASMCs) (Fig. 4.1.2 C). This indicates that c-Kit is 
not significantly expressed in U87MG cells and so cannot be mediating the imatinib- and 
nilotinib-induced effects. 
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Figure 4.1.1. The effect of silencing ABL1 and ABL2 on observed imatinib- 
and nilotinib-induced tyrosine phosphorylation. U87MG cells were transfected with 
siRNA targeting ABL1 (siABL1), ABL2 (siABL2) or together at a concentration of 25 nM, 
or with 25 nM of a control scrambled siRNA (siScr). 48hr post transfection, cells were 
incubated in serum-free medium (SFM) for ~18hr prior to treatment with SFM & DMSO 
vehicle control (C), or 10 µM imatinib or 10 µM nilotinib for 20 minutes. Cell lysates were 
then prepared, blotted, and probed with the indicated antibodies. Densitometric analysis 
was followed by application of a Two-way ANOVA and the Student Newman Keuls post 
hoc test. Data from three independent experiments are presented as phosphorylation 
relative units (RU) (means +/- s.e.m.) normalised to total protein levels; *p<0.05 
compared to imatinib and nilotinib siScr respectively. 
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Figure 4.1.2 PDGFRb, DDR1 and c-Kit are not required for imatinib and nilotinib 
stimulated increases in p130Cas, FAK and PXN tyrosine phosphorylation. U87MG 
cells were transfected with siRNA targeting (A) PDGFR Beta (siPDGFRb) or (B) DDR1 
(siDDR1). Cells were transfected at a concentration of 25 nM siRNA, or with 25 nM of a 
control scrambled siRNA (siScr). 48hr post transfection, cells were incubated in SFM for 
~18hr prior to treatment with SFM & DMSO vehicle control (C), or 10 µM imatinib or 10 
µM nilotinib for 20 minutes. Cell lysates were then prepared, blotted, and probed with the 
indicated antibodies. (C) U87MG cells, human umbilical vein endothelial cells (HUVECs) 
and human coronary artery smooth muscle cells (HCASMCs) were blotted for c-Kit and 
GAPDH (as a loading control). Only the smooth muscle cells expressed detectable levels of 
c-Kit.  
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4.2 Increased p130Cas, FAK and PXN tyrosine 
phosphorylation is dependent on p130Cas 
expression and FAK kinase activity 
By contrast to the findings that drug-induced increases in tyrosine phosphorylation are not 
dependent on known targets, observed increases in phosphorylation are dependent on 
p130Cas expression. Targeted knockdown of p130Cas with two different 
siRNAs significantly reduced tyrosine phosphorylation of FAK and PXN induced by
imatinib and nilotinib (Fig. 4.2.1). Furthermore, drug-induced 3D invasion of U87MG 
cells is also dependent on p130Cas expression. Spheroids were generated using cells treated 
with siRNA to p130Cas, which significantly reduced radial invasion induced by imatinib 
and nilotinib (Fig. 4.2.2). 
To assess whether FAK is required for observed increases in tyrosine phosphorylation 
U87MG cells were treated with PF-573228 (PF-228), a potent inhibitor of FAK. PF-228 
inhibits FAK phosphorylation on tyrosine residue Y397 with an IC50 of 30–100 nM and 
displays a 50-250-fold selectivity for FAK over other kinases (Slack-Davis et al., 2007). 
Treatment of U87MG cells with the FAK inhibitor PF-228at 5 µM significantly reduced the
imatinib and nilotinib stimulated increases in p130Cas and PXN tyrosine phosphorylation 
(Fig. 4.2.3). Treatment with PF-228 also significantly reduced 3D radial invasion induced 
by imatinib and nilotinib (Fig. 4.2.4).  
Because p130Cas and FAK are reported to exist in multi-protein complexes that are 
required for cell motility (Barrett et al., 2013), their association in glioma cells was 
examined. Immunoprecipitation of p130Cas and subsequent immunoblotting showed that 
FAK and PXN are both constitutively complexed with p130Cas in U87MG cells. These 
complexes are not affected by imatinib or nilotinib treatment (Fig. 4.2.5).  
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Figure 4.2.1 Increased p130Cas, FAK and PXN tyrosine phosphorylation is dependent 
on p130Cas expression. U87MG cells were transfected with siRNA targeting p130Cas 
(sip130Cas) at a concentration of 25 nM, or with 25 nM of a control scrambled siRNA 
(siScr). 48hr post transfection, cells were incubated in SFM for ~18hr prior to treatment 
with SFM & DMSO vehicle control (C), or 10 µM imatinib or 10 µM nilotinib for 20 
minutes. Cell lysates were then prepared, blotted, and probed with the indicated antibodies. 
Data from three independent experiments are presented as phosphorylation relative units 
(RU) (means +/- s.e.m.) normalised to total protein levels; *p<0.05, **p<0.01 compared to 
imatinib and nilotinib siScr respectively. 
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Figure 4.2.2 Imatinib- and nilotinib-induced radial invasion is dependent on the 
expression of p130Cas. Spheroids were generated using U87MG cells treated with siRNA 
to p130Cas (sip130Cas) or control scrambled siRNA (siScr). 24 hours after spheroid 
production, spheroids were imbedded in a collagen gel and incubated in either SFM & 
DMSO vehicle control (C) or 10 µM imatinib or 1 µM nilotinib for an additional 48 hours. 
Spheroids were fixed in 4% PFA and invasion was determined by measuring the area 
corresponding to the invasion rim minus the area of the core for at least 3 different 
spheroids per condition. Data from three independent experiments are presented as relative 
area units (RU) (means +/- s.e.m.); **p < 0.01 compared to imatinib and nilotinib siScr 
respectively.  
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Figure 4.2.3 Increased p130Cas and PXN tyrosine phosphorylation is sensitive to 
treatment with a FAK kinase inhibitor. U87MG cells (~80% confl uent) were 
incubated in SFM for ~18hr prior to pre-incubation for 30 min with 5 µM PF-228 
or 0.05% DMSO vehicle (Veh) prior to treatment with SFM & DMSO control (C), or 
10 µM imatinib or 10 µM nilotinib for 20 minutes. Cell lysates were then prepared, 
blotted, and probed with the indicated antibodies. Data from three independent 
experiments are presented as phosphorylation relative units (RU) (means +/- s.e.m.) 
normalised to total protein levels; *p<0.05, **p<0.01 compared to imatinib and nilotinib 
DMSO vehicle respectively.
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Figure 4.2.4 Imatinib- and nilotinib-induced increases in radial invasion are sensitive 
to treatment with a FAK kinase inhibitor. Spheroids derived from U87MG cells were 
imbedded in collagen containing either SFM & DMSO vehicle control (Veh) or 5 µM 
PF-228 with either DMSO control (C), 10 µM imatinib, or 1 µM nilotinib. After 48 hours 
spheroids were fixed in 4% PFA and invasion was determined by measuring the area 
corresponding to the invasion rim minus the area of the core for at least 3 different 
spheroids per condition. Data from three independent experiments are presented as relative 
area units (RU) (means +/− s.e.m.). **p < 0.01 compared to imatinib and nilotinib 
DMSO vehicle control respectively. #p>0.05 compared to control DMSO vehicle.  
 Veh  PF-228 (5 µM) 
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Figure 4.2.5 Co-immunoprecipitation of p130Cas, FAK, and PXN in U87MG cells. 
U87MG cells (~80% confluent) were incubated in SFM for ~18hr prior to treatment with 
either SFM & DMSO vehicle control (C), 10 µM imatinib or 10 µM nilotinib for 20 
minutes. Cell lysates were then immunoprecipitated with anti-p130Cas antibody. Purified 
complexes and corresponding total cell lysates were separated by SDS-PAGE, and probed 
with the indicated antibodies. IgG control and a whole cell lysate (WCL) were also 
included.  
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4.3 Increased tyrosine phosphorylation is not 
affected by modulation of the RAS / RAF /
MER / ERK signalling pathway
Following the finding that known targets of imatinib and nilotinib are not required for drug-
induced increases in tyrosine phosphorylation, the potential involvement of other key 
components of the pathways mediating motility was investigated.   
It has recently been reported that imatinib and nilotinib treatment leads to the activation of 
MEK and ERK in colorectal, pancreatic, lung and melanoma cancer cell lines at 
physiologically relevant concentrations (Packer et al., 2011). ERK signalling is also 
implicated in meditating signalling pathways required for migration of glioma cells (Lind et 
al., 2006, Zohrabian et al., 2009). The effect of imatinib and nilotinib treatment on ERK 
activation in U87MG cells was examined. Although imatinib treatment increased levels of 
phosphorylated ERK, nilotinib treatment had no effect (Fig. 4.3.1A). U0126 is a selective 
MEK-1 and MEK-2 direct inhibitor (Favata et al., 1998). Even though U0126 completely 
abolished levels of phosphorylated ERK in all samples treated, it had no effect on imatinib 
and nilotinib stimulation of p130Cas, FAK, and PXN tyrosine phosphorylation (Fig. 
4.3.1A). U0126 treatment had no significant effect on radial invasion in imatinib and 
nilotinib treated spheroids, although U0126 alone resulted in a small but significant increase 
in radial invasion compared with SFM vehicle control (Fig. 4.3.2). 
RAS is a small GTPase, which causes downstream activation of tyrosine kinases RAF, 
MEK, and ERK. RAS genes (HRAS, KRAS, NRAS) are mutated in about 30% of human 
cancers. It has been reported that imatinib and nilotinib can bind to BRAF and CRAF 
leading to the formation of RAF hetero- and homo-dimers, and stimulate paradoxical 
activation of BRAF and CRAF in the presence of activated RAS (Packer et al., 2011). The 
possibility of a RAF-dependent, MEK/ERK-independent pathway leading to increased 
tyrosine phosphorylation of p130Cas, FAK and PXN, was therefore considered. However, 
silencing of BRAF or CRAF either alone or together had no effect on imatinib and nilotinib 
stimulated increases in tyrosine phosphorylation (Fig. 4.3.1B). 
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Figure 4.3.1 Pharmacological inhibition of ERK or treatment with BRAF and CRAF 
siRNA does not  affect imatinib- and nilotinib-induced increases in p130Cas, FAK 
and PXN tyrosine phosphorylation. (A) U87MG cells (~80% confluent) were incubated 
in SFM for ~18hr prior to pre-incubation for 30 min with 10 µM U0126 or DMSO 
vehicle (Veh) prior to treatment with SFM & DMSO vehicle control (C), or 10 µM 
imatinib or 10 µM nilotinib for 20 minutes. (B) U87MG cells were transfected with 
siRNA targeting BRAF (siBRAF), CRAF (siCRAF) or together at a concentration of 
25 nM, or with 25 nM of a control scrambled siRNA (siScr). 48hr post transfection, 
cells were incubated in SFM for ~18hr prior to treatment with SFM & DMSO vehicle 
control (C), or 10 µM imatinib or 10 µM nilotinib for 20 minutes. Cell lysates were 
then prepared, blotted, and probed with the indicated antibodies. 
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Figure 4.3.2 Imatinib- and nilotinib-induced increases in radial invasion are not 
affected by treatment with a MEK-1 and MEK-2 inhibitor. Spheroids derived from 
U87MG cells were imbedded in collagen containing either SFM & DMSO vehicle 
control (Veh) or 10 µM U0126, with either DMSO control (C), 10 µM imatinib, or 1 µM 
nilotinib. After 48 hours spheroids were fixed in 4% PFA and invasion was 
determined by measuring the area corresponding to the invasion rim minus the area 
of the core for at least 3 different spheroids per condition. Data from three independent 
experiments are presented as relative area units (RU) (means +/− s.e.m.). *p < 0.05 
compared to control DMSO vehicle.  
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4.4 Src activity does not mediate increases in tyrosine 
phosphorylation in response to treatment with 
imatinib or nilotinib 
Src directly phosphorylates p130Cas, FAK and PXN in response to growth factor 
stimulation, and  provides a link between multiple signalling pathways that regulate 
invasion (Barrett et al., 2013). Imatinib has also been shown to bind Src, albeit at a much 
lower affinity, despite the fact that residues interacting with imatinib in crystal structures of 
ABL are conserved in Src (Deininger et al., 2005, Seeliger et al., 2007). The role of Src in 
mediating imatinib- and nilotinib-induced increases in tyrosine phosphorylation was 
investigated using PP2, a potent tyrosine kinase inhibitor selective for the Src family of 
tyrosine kinases (Hanke et al., 1996). U87MG cells were pre-treated with PP2 prior to 
treatment with imatinib or nilotinib. PP2 treatment leads to a complete abrogation of both
basal and drug induced tyrosine phosphorylation of p130Cas, FAK and PXN (Fig. 4.4.1). 
This finding is not surprising given that Src exists at focal adhesions complexed with FAK 
and p130Cas, and that Src phosphorylates p130Cas and FAK (Sharma and Mayer, 2008). 
Because Src is required for p130Cas phosphorylation and Src phosphorylation at Y861 site 
enhances FAK binding to p130Cas, Src inhibition will intervene with basal levels of 
tyrosine phosphorylation of FAK and p130Cas. An alternative approach for assessing 
whether Src may be mediating observed drug-induced effects is to examine the effect of 
drug stimulation on levels of phosphorylation of the Src activating tyrosine residue Y416. 
Stimulation of U87MG cells with imatinib or nilotinib did not result in changes in the levels 
of Y416 phosphorylation, suggesting that imatinib and nilotinib are not affecting the 
activation of Src (Fig. 4.4.2). 
The overall sequences of Src family kinases (SFKs), with the exception of the N-terminal 
~50 residues, is highly conserved among the nine family members. Full activation of SFKs 
requires dephosphorylation at the exposed tyrosine Y527 residue, which stabilises the active 
conformation. Subsequent autophosphorylation at tyrosine Y416 locks the catalytic pocket 
in its active conformation. The activated SFK can then phosphorylate substrates, such as 
FAK and p130Cas. When the signalling response is terminated the SFKs are inactivated by 
phosphorylation at tyrosine residue Y527 (Okada, 2012). The NRTK CSK catalyses the 
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phosphorylation of the regulatory C-terminal tail tyrosine of Src, the tyrosine residue Y527, 
to inactivate Src. The negative regulation of Src is critical to cell survival and CSK is  
expressed in all mammalian cells (Roskoski, 2005). When Y527 is phosphorylated by CSK, 
Src adopts the inactive conformation which is stabilized by two intramolecular interactions 
that affect the configuration of the catalytic pocket: Y527 binds its own SH2 domain, and 
the SH2 domain binds to the SH3 domain (Okada, 2012). In addition to SFKs, several 
signalling proteins are reported to interact with CSK. These include FAK and PXN. In 
fibroblasts, PXN and FAK colocalise at focal adhesions and bind the CSK SH2 domain 
(Sabe et al., 1994). 
If imatinib and nilotinib were directly targeting CSK, this could provide a mechanism for 
increased Src activation, which would result in increased tyrosine phosphorylation of 
p130Cas, FAK and PXN. However, preliminary findings suggest that silencing CSK with 
siRNA does not affect drug-induced tyrosine phosphorylation of p130Cas, FAK and PXN 
(Fig.4.4.3).  
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Figure 4.4.1 p130Cas, FAK and PXN tyrosine phosphorylation are sensitive to 
treatment with a Src kinase inhibitor. U87MG cells (~80% confluent) were incubated in 
SFM for ~18hr prior to pre-incubation for 20 min with 10 µM PP2 or DMSO vehicle (Veh) 
prior to treatment with SFM & DMSO vehicle control (C), or 10 µM imatinib or 10 µM 
nilotinib for 20 minutes. Cell lysates were then prepared, blotted, and probed with the 
indicated antibodies.  
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Figure 4.4.2 Imatinib and nilotinib treatment does not affect tyrosine phosphorylation 
of Src at residue Y416. U87MG cells (~80% confluent) were incubated in SFM for ~18hr 
prior to treatment with either SFM & DMSO vehicle control (C), or 10 µM imatinib (I) for 
the specified amount of time. Cell lysates were then prepared, blotted, and probed with the 
indicated antibodies. 
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Figure 4.4.3 Knockdown of CSK does not affect imatinib and nilotinib 
stimulated increases in tyrosine phosphorylation. U87MG cells were transfected 
with siRNA targeting CSK (siCSK) at a concentration of 25 nM, or with 25 nM of a 
control scrambled siRNA (siScr). 48hr post transfection, cells were incubated in SFM 
for ~18hr prior to treatment with SFM & DMSO vehicle control (C), or 10 µM imatinib or 
10 µM nilotinib for 20 minutes. Cell lysates were then prepared, blotted, and probed 
with the indicated antibodies. Blots are representative of n=2 experiments.  
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4.5 Increased tyrosine phosphorylation is not affected 
by silencing integrins b1 and b3 and NCK 
Integrins are known to mediate p130Cas and FAK tyrosine phosphorylation through beta 1 
and beta 3 subunits. Integrin receptor activation leads to FAK autophosphorylation at 
tyrosine residue Y397, which recruits Src and p130Cas (Sharma and Mayer, 2008, Barrett et 
al., 2013). The possible involvement of integrin signalling in mediating imatinib and 
nilotinib stimulated tyrosine phosphorylation was investigated. U87MG cells were treated 
with two different siRNAs to either ITGB1 or ITGB3 integrins. Silencing resulted in a 
marked reduction in integrin protein expression, but had no effect on drug-induced tyrosine 
phosphorylation of p130, FAK and PXN (Figure 4.5.1). Knockdown of β1 and β3 integrins 
in this experiment did not positively confirm involvement of β1 and β3 integrins in 
mediating the effects of imatinib and nilotinib on tyrosine phosphorylation.
NCK (non-catalytic region of tyrosine kinase adaptor protein) is a ubiquitously expressed 
cytosolic adaptor protein made up of one SH2 domain and three SH3 domains. It plays an 
important role in mediating motility by linking RTKs and NRTKs to actin cytoskeleton 
reorganising proteins. The SH2 domain associates with phosphotyrosine residues of a 
number of proteins, including BCR-ABL, EGFR and PDGFR. The SH3 domain recruits 
proline-rich proteins to the plasma membrane (Buday et al., 2002). The possible 
involvement of NCK in mediating drug-induced effects was investigated. However, 
preliminary findings suggest that silencing NCK does not affect imatinib- and nilotinib-
induced increases in tyrosine phosphorylation (Appendix Fig. A3).
120	
Figure 4.5.1 Treatment with β1 or β3 siRNA does not affect drug-induced tyrosine 
phosphorylation of p130Cas, FAK and PXN. (A) U87MG cells were transfected with two 
siRNA targeting integrin b1 (siITGB1) at a concentration of 25 nM, or with 25 nM of a 
control scrambled siRNA (siScr). (B) U87MG cells were transfected with two siRNA 
targeting integrin b3 (siITGB3) at a concentration of 25 nM, or with 25 nM of a control 
scrambled siRNA (siScr). (A-B) 48hr post transfection, cells were incubated in serum-free 
medium (SFM) for ~18hr prior to treatment with SFM & DMSO vehicle control (C), or 10 
µM imatinib or 10 µM nilotinib for 20 minutes. Cell lysates were then prepared, blotted, 
and probed with the indicated antibodies. 
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4.6 Discussion 
The major known targets of imatinib and nilotinib are ABL, ABL2 (ARG), DDR1, PDGFR 
and c-Kit (Hantschel et al., 2008). The effect of silencing these targets on imatinib- and 
nilotinib-induced tyrosine phosphorylation was evaluated. Preliminary data suggests that the 
effects of imatinib and nilotinib on p130Cas, FAK and PXN tyrosine phosphorylation are 
unaffected by treatment with siRNA targeting ABL1, ABL2, DDR1 and PDGFRβ. 
Knockdown of ABL1, ABL2 or both ABL1 and ABL2 led to a decrease in total levels 
of p130Cas and PXN, making it difficult to evaluate the role of ABL1 and ABL2 
in mediating drug-induced tyrosine phosphorylation. Nevertheless, the data revealed 
that there is no significant effect of knockdown on imatinib and 
nilotinib induced tyrosine phosphorylation of p130Cas and PXN. The levels of 
phospho-p130Cas in the ABL1, ABL2 or both ABL1 and ABL2 siRNA-treated 
cells did not significantly differ from the siScr-treated cells. Silencing of ABL1 or 
both ABL1 and ABL2 did however lead to a significant reduction in 
phosphorylation of FAK. Interestingly no decrease in basal phosphorylation of FAK in 
the control treated cells was detected. It is proposed that the reduced p130Cas expression 
in cells treated with siRNA is sufficient to facilitate drug induced FAK phosphorylation. 
This is supported by the findings that varying levels of p130Case knockdown efficiency 
between two different siRNAs causes differences in the reduction of imatinib and 
nilotinib induced tyrosine phosphorylation of FAK and PXN (Fig. 4.2.1). 
Immunoprecipitation of p130Cas revealed the interdependence of p130Cas, FAK and PXN 
that constitutively complex together in U87MG cells. Importantly, imatinib and nilotinib 
did not affect this interdependence as drug stimulation did not have an effect on complexes.
There is evidence that PDGF autocrine loops contribute to the transformed phenotype of 
human astrocytomas. PDGF A and B ligand genes are expressed in almost all glioma cell 
lines and in isolates of human malignant astrocytoma (Kilic et al., 2000). Dominant-negative 
mutants of the PDGF ligands A and B have been found to inhibit growth of 
U87MG cells (Shamah et al., 1993). Imatinib was considered a rational drug 
candidate for the treatment of the GBM based on the evidence that PDGFR is implicated 
in driving  pathology (Raymond et al.,  2008). Imatinib has   previously been found  to 
generated 
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inhibit  PDGFR tyrosine phosphorylation in  tumours generated by  injecting U87MG cells 
into mice. Oral administration of imatinib was alsofound to reduce tumour growth in this 
mouse model of GBM (Kilic et al., 2000). Interestingly, findings here show that knockdown 
of PDGFRβ does not affect the imatinib- and nilotinib-induced tyrosine phosphorylation of 
p130Cas, FAK and PXN in U87MG cells. U87MG cells mainly express PDGFRβ, and the 
expression of PDGFRa is very weak (Gross et al., 2006).  Findings suggest that PDGFR does 
not mediate imatinib- and nilotinib-induced tyrosine phosphorylation in GBM cells. Imatinib 
has failed clinical trials for glioblastoma, where it shows no significant antitumour activity or 
extension of survival (Wen et al., 2006, Raymond et al., 2008). Findings here indicate 
unforeseen effects of imatinib and nilotinib on cell motility that may be independent of 
PDGFR, which could contribute to the lack of clinical efficacy observed in these trials.
Knockdown of DDR1, another major target of imatinib and nilotinib (Hantschel et al., 2008), 
did not affect drug-induced tyrosine phosphorylation either. The lack of expression of c-Kit 
in U87MG cells indicates that c-Kit is not mediating drug-induced tyrosine phosphorylation 
either. These findings reveal that alternative pathway(s) are being activated by the drugs that 
are not dependent on known targets. 
The possibility that imatinib and nilotinib signal via the RAS/RAF/MEK/ERK pathway to 
stimulate phosphorylation was investigated. Imatinib leads to increased ERK phosphorylation 
in U87MG cells, whereas nilotinib does not. This suggests that imatinib and nilotinib may be 
activating different signalling pathways in these cells. In healthy cells, the ERK pathway 
regulates survival, proliferation and differentiation. In cancer, ERK signalling downstream of 
Ras is associated with invasive growth and metastasis, whereby deregulated and constitutive 
activation promotes excessive proliferation and survival (Heidorn et al., 2010, Viala and 
Pouyssegur, 2004). Pharmacological inhibition of MEK with U0126 had no effect on 
imatinib- and nilotinib-stimulated tyrosine phosphorylation or migration. Treatment with 
BRAF or CRAF siRNA, either alone or together, did not affect increased tyrosine 
phosphorylation in response to drug treatment either. To confirm that knockdown of BRAF 
and CRAF was sufficient to block downstream signalling, lysates should be probed for 
phospho-ERK. However, preliminary results suggest that the RAS/RAF/MEK/ERK pathway 
does not mediate imatinib- or nilotinib-induced effects on tyrosine phosphorylation and 
migration in U87MG cells. 
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Imatinib and nilotinib have been reported to activate MEK and ERK in colorectal cancer, 
pancreatic cancer, lung cancer and melanoma cell lines at concentrations as low as 100nM. 
The study also revealed that in cells derived from patients with CML expressing the  BCR-
ABL T315I gatekeeper mutation, imatinib and nilotinib induced  BRAF binding to CRAF 
and induced activation of MEK and ERK (Packer et al., 2011). By contrast, findings here 
suggest that imatinib and nilotinib exert effects on the p130Cas-FAK pathway distinct from 
the MEK pathway, which is not required for drug-induced tyrosine phosphorylation or 
migration.  
The NRTK Src is the main kinase that phosphorylates p130Cas, FAK and PXN (Barrett et 
al., 2013). This is supported by findings in this study that inhibition of Src with PP2
abolished basal levels of p130Cas, FAK and PXN tyrosine phosphorylation. Imatinib and 
nilotinib treatment did not result in any changes in the levels of tyrosine phosphorylation of 
the activating Src residue tyrosine Y416, suggesting that Src activity is not affected by drug 
treatment. A possible mechanism of imatinib- and nilotinib-induced tyrosine 
phosphorylation of p130Cas, FAK and PXN, is the direct inactivation of an inhibitory 
kinase, which under physiological conditions inhibits a downstream kinase responsible for 
phosphorylation of the three proteins. When the Src inhibitory residue Y527 is 
phosphorylated by CSK, Src adopts the inactive conformation (Okada, 2012). If imatinib 
and nilotinib inhibit CSK, this would prevent the inhibition of Src, and could lead to 
increased downstream tyrosine phosphorylation of p130Cas, FAK and PXN. However, 
preliminary results suggest that silencing CSK does not have an effect on drug-induced 
phosphorylation. Findings suggest that although Src is required for basal phosphorylation of 
p130Cas, FAK, and PXN, it does not mediate imatinib- and nilotinib-driven 
phosphorylation. 
FAK inhibition with PF-228 led to a significant decrease in the basal level of radial invasion, 
supporting the role of FAK in mediating migration. Results show that imatinib- and 
nilotinib-induced tyrosine phosphorylation of p130Cas and PXN is sensitive to the inhibition 
of FAK kinase activity. Further experiments looking at the effect of treatment with 
additional pharmacological inhibitors and siRNA targeting FAK could be performed to 
confirm the role of FAK in mediating drug-induced phosphorylation.  
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Preliminary findings suggest that pharmacological modulation of FAK may ameliorate the 
clinical management of GBM and the clinical management of CML with imatinib / 
nilotinib. Several small-molecule FAK TKIs are currently undergoing pre-clinical and 
clinical testing. TAE-226 is a pre-clinical compound that acts as a potent ATP-competitive 
inhibitor of FAK and inhibits FAK autophosphorylation at Y397. It has demonstrated strong 
anti-tumour activities in glioma, where it induces a concentration-dependent decrease in 
cellular proliferation (Lee et al., 2014a, Shi et al., 2007, Liu et al., 2007b). 
Previous studies provide evidence of a role for FAK in promoting haematological 
malignancies. Aberrant expression of FAK and subsequent hyper-activation is detected in 
about half of acute myeloid leukaemias (Recher et al., 2004). FAK is constitutively 
activated in BCR-ABL-transformed cell lines and FAK silencing inhibits BCR–ABL-
mediated leukaemic cell survival and proliferation (Gotoh et al., 1995, Le et al., 2009, Yin, 
2011). The evidence that FAK silencing significantly reduces BCR-ABL-mediated cell 
survival in vitro provides compelling evidence that targeting FAK could provide therapeutic 
benefit. More recently it was found that TAE226 in combination with nilotinib 
provided greater growth inhibition than nilotinib alone in vivo in mice xenografted 
with Ph+ leukaemia cells (Hu and Slayton, 2014). Results here support previous 
findings that FAK inhibition in conjunction with imatinib or nilotinib treatment could 
ameliorate their clinical management.  
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5 The role of phosphatases in mediating 
drug effects 
5.1 Investigating the role of protein tyrosine 
phosphatases 
The phosphorylation of a particular residue can be affected by changing either the activity 
of a kinase, a phosphatase, or both (Fig. 5.1.1). One way in which imatinib and nilotinib 
treatment could lead to increased tyrosine phosphorylation could be via inhibition of an 
inhibitory tyrosine kinase, such as the example of CSK in relationship to Src as described in 
Chapter 4. However, drug treatment did not have an effect on Src activating residue Y416; 
and nor did knockdown of CSK have an effect on drug-induced tyrosine phosphorylation. 
Another possible mechanism by which imatinib and nilotinib induce tyrosine 
phosphorylation of p130Cas, FAK and PXN and enhance migration, may involve indirect 
inactivation of a protein tyrosine phosphatase (PTP). It is possible that imatinib and nilotinib 
are targeting a kinase that, under physiological conditions, activates one or more PTP. By 
direct inhibition of a kinase, the TKIs may be preventing the downstream activation of a 
phosphatase. By causing downstream inhibition of phosphatase activity, imatinib and 
nilotinib would prevent dephosphorylation and thus drive upwards the level of 
phosphorylation (Fig. 5.1.1). 
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Figure 5.1.1 Possible mechanism of imatinib- and nilotinib-induced tyrosine 
phosphorylation. The net level of protein tyrosyl activity is balanced by the opposing 
actions of protein tyrosine kinases and protein tyrosine phosphatases. A protein kinase 
transfers phosphates from ATP to tyrosine residues on numerous substrates, including 
p130Cas. A protein phosphatase removes phosphate groups from the substrate, thus 
inactivating it and directly opposing the action of the kinase (Paul and Mukhopadhyay, 
2004). Imatinib and nilotinib treatment leads to increased tyrosine phosphorylation of 
p130Cas (black dotted line). A possible mechanism by which imatinib and nilotinib exert 
effects is by the indirect inhibition a phosphatase (red dotted line); this could be achieved 
via inhibition of protein kinase (red solid line) that under physiological conditions activates 
a phosphatase (black solid line).  
+
- 
- 
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It is proposed that imatinib and nilotinib may be inducing their effects via indirect inhibition 
of a PTP. Dephosphorylation of p130Cas by PTP-PEST (encoded by PTPN12) is required 
for the disassembly of focal adhesions; SHP2 (encoded by PTPN11) is required for the 
activation of the Ras-ERK pathway in response to growth factors; PTP-1B (encoded by 
PTPN1) dephosphorylates the insulin receptor, EGFR and PDGFR (Ostman et al., 2006). 
The role of these PTPs in mediating drug-induced effects was investigated using siRNA.  
If a particular phosphatase is being inhibited indirectly by imatinib / nilotinib, silencing the 
phosphatase should lead to similar increases in tyrosine phosphorylation that are observed 
upon drug treatment. Silencing PTP1B and SHP2 provided inconsistent data. Two different 
siRNAs against SHP2 led to varying levels of knockdown, and knockdown of SHP2 
had different effects on p130Cas, FAK and PXN phosphorylation. SHP2 siRNA #6 led 
to an increase in tyrosine phosphorylation of FAK but not p130Cas. And although two 
different siRNAs against PTP1B both led to good knockdown, the two siRNA caused 
different effects on tyrosine phosphorylation: PTP1B siRNA #6 caused an 
increase in tyrosine phosphorylation of p130Cas, FAK and PXN, whereas siRNA #7 
did not affect tyrosine phosphorylation (Fig. 5.1.2A). Silencing PTP-PEST with two 
different siRNAs led to a good knockdown. Silencing PTP-PEST did not cause a 
significant increase in basal levels of p130Cas or PXN phosphorylation; nor did 
silencing have an effect on imatinib- and nilotinib-induced increases in 
phosphorylation. This suggests that PTP-PEST is not involved in mediating the 
observed drug-induced effects on tyrosine phosphorylation (Fig. 5.1.2B). 
The receptor protein tyrosine phosphatase α (PTPα; encoded by PTPRA) is implicated in 
integrin signalling, cell adhesion and proliferation. PTPα dephosphorylates Src at its 
inactivating residue Y527 and interacts with FAK (Ostman et al., 2006, Su et al., 1999). The 
potential involvement of PTPα was investigated by transfecting glioma cells with two 
different siRNAs. Knockdown efficiency was evaluated by immunoblotting for 
PTPRA tyrosine residue Y789, the residue whose phosphorylation has been shown to be 
required for targeting PTPα to focal adhesions (Lammers et al., 2000). Preliminary 
results show that although siRNA treatment led to good knockdown of PTPRA, it did not 
affect imatinib- and nilotinib-induced increases in tyrosine phosphorylation of p130Cas 
and PXN, suggesting that PTPα is not mediating drug-induced tyrosine phosphorylation 
(Appendix Fig. A4).  
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Figure 5.1.2 Effect of silencing PTP1B, SHP2 and PTP-PEST phosphatases on tyrosine 
phosphorylation. (A) U87MG cells were transfected with two different siRNAs 
targeting PTP1B (siPTP1B) and two different siRNAs targeting SHP2 (siSHP2) at a 
concentration of 25 nM, or with 25 nM of a control scrambled siRNA (siScr). 72hr post 
transfection, cell lysates were prepared, blotted, and probed with the indicated antibodies. 
(B) U87MG cells were transfected with two different siRNAs targeting PTP-PEST
(siPTPPEST) at a concentration of 25 nM, or with 25 nM of a control scrambled
siRNA (siScr). 48hr post transfection, cells were incubated in SFM for ~18hr prior to
treatment with SFM & DMSO vehicle control (C), or 10 µM imatinib or 10 µM nilotinib for
20 minutes. Cell lysates were then prepared, blotted, and probed with the indicated
antibodies.
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5.2 The involvement of PP2A serine phosphatase in 
mediating imatinib and nilotinib stimulation of 
tyrosine phosphorylation 
Protein phosphatase 2A (PP2A) is a ubiquitously expressed serine/threonine phosphatase 
which acts as a tumour suppressor and plays a crucial role in the regulation of cell cycle 
progression, survival, and differentiation. The loss of PP2A activity has been identified in 
some myeloid malignancies, including blast-phase CML and AML (Yang et al., 2012). It 
has been shown that PP2A is inactivated by long-term treatment (24h) with nilotinib in 
human hepatocellular carcinoma (HCC) cell lines (Yu et al., 2013). PP2A is known to 
interact and associate with p130Cas (Yokoyama and Miller, 2001b) and has been found to 
inhibit Src activity (Yokoyama and Miller, 2001a). The role of PP2A in imatinib- and 
nilotinib-induced tyrosine phosphorylation was examined using pharmacological 
modulators of PP2A activity. U87MG cells were treated with the potent PP2A activator 
FTY720 (Yang et al., 2012), and inhibitor okadaic acid (OA) (Garcia et al., 2002). 
Pharmacological inhibition of PP2A with OA significantly increased the tyrosine 
phosphorylation of p130Cas, FAK and PXN in vehicle control cells. Conversely, 
pharmacological activation of PP2A using FTY720 strongly inhibited imatinib and nilotinib 
stimulated tyrosine phosphorylation of p130Cas, FAK and PXN (Fig. 5.2.1). p130Cas and 
PXN have been previously reported to associate with the catalytic subunit of PP2A (Ito 
et al., 2000, Yokoyama and Miller, 2001b). Co-immunoprecipitation of p130Cas and PP2A 
in U87MG cells revealed that PP2A associates with p130Cas. Association of PP2A 
and p130Cas is constitutive, and was unaffected by imatinib or nilotinib treatment 
compared to vehicle control (Fig. 5.2.2).  The effect of modulating PP2A activity on 
imatinib- and nilotinib-induced 3D radial invasion was assessed. Treatment of U87MG 
spheroids with FTY720 caused a striking reduction in drug-induced 3D radial invasion 
(Fig. 5.2.3).   
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Figure 5.2.1 Drug-induced increases in tyrosine phosphorylation is mediated by PP2A 
activity. U87MG cells (~80% confluent) were incubated in SFM for ~18hr prior to pre-
incubation for 30 min with 10 µM FTY720 or 100 nM okadaic acid (OA) or DMSO vehicle 
control (Veh) prior to treatment with SFM & DMSO control (C), or 10 µM imatinib or 10 
µM nilotinib for 20 minutes. Cell lysates were then prepared, blotted, and probed with the 
indicated antibodies. Data from three independent experiments are presented as 
phosphorylation relative units (RU) (means +/- s.e.m.) normalised to total protein levels; 
*p<0.05, **p<0.01 compared to imatinib and nilotinib DMSO vehicle respectively. #p>0.05
compared to control DMSO vehicle.
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Figure 5.2.2 PP2A and p130Cas co-immunoprecipitation is not affected by imatinib 
and nilotinib treatment.  U87MG cells (~80% confluent) were incubated in SFM for ~18hr 
prior to treatment with either SFM & DMSO vehicle control (C), 10 µM imatinib or 10 µM 
nilotinib for 20 minutes. Cell lysates were then immunoprecipitated with anti-p130Cas 
antibody. Purified complexes were separated by SDS-PAGE, and probed with PP2A 
antibody. IgG control and a whole cell lysate (WCL) were also included.  
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Figure 5.2.3 Drug-induced increases in three-dimensional radial invasion is regulated 
by PP2A activity. Spheroids derived from U87MG cells were imbedded in collagen 
containing either SFM & DMSO vehicle control (Veh) or 10 µM FTY720 with either 
DMSO control (C) or 10 µM imatinib or 1 µM nilotinib for 48 hours. Spheroids were fixed 
in 4% PFA and invasion was determined by measuring the area corresponding to the 
invasion rim minus the area of the core for at least 3 different spheroids per condition. Data 
from three independent experiments are presented as relative area units (RU) (means +/- 
s.e.m.). **p < 0.01 compared to imatinib and nilotinib DMSO vehicle control respectively.
#p>0.05 compared to control DMSO vehicle.
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5.3 Discussion 
It is possible that imatinib and nilotinib inhibit one or more kinases, which 
under physiological conditions activate one or more phosphatase. In this context, drug-
induced inhibition of the kinase would lead to a reduction in phosphatase activity, and 
subsequent reduction in dephosphorylation. The net result would be increased tyrosine 
phosphorylation (Fig. 5.1.1). Interestingly, findings implicate the serine / threonine 
phosphatase, PP2A, in regulating the effects of the two tyrosine kinase inhibitors, imatinib 
and nilotinib, on glioma signalling and motility. PP2A has been reported to interact with 
p130Cas and it has been proposed that PP2A plays a role in regulating the cell cycle 
through de-phosphorylation of p130Cas (Ito et al., 2000). Although PP2A has been 
reported to de-phosphorylate p130Cas on serine residues (Yokoyama and Miller, 2001b), 
there are no reports of how PP2A activity affects p130Cas tyrosine phosphorylation. But it 
has been recently reported that long-term 24 hour treatment with nilotinib leads to PP2A 
inactivation in human HCC cells (Yu et al., 2013). Consistent with the possibility that 
inactivation of PP2A by imatinib or nilotinib treatment results in enhanced p130Cas, 
FAK and PXN tyrosine phosphorylation, treatment with the PP2A inhibitor, 
OA, significantly increased basal tyrosine phosphorylation of these molecules. If 
imatinib- and nilotinib-induced increased tyrosine phosphorylation is completely dependent 
on PP2A activity, then treatment with OA should result in similar increases in tyrosine 
phosphorylation. However, if the concentration of OA used was not sufficient to fully 
inhibit PP2A then combined treatment with both OA and drug should have an additive 
effect over single treatments. To fully understand this effect, dose response curves would 
need to be performed. Preliminary analysis of potential additive effects based on either 
imatinib or nilotinib alone, or in combination with OA, suggest that in some cases drug 
treatments were not additive, and in other cases they were additive. Nonetheless, the role of 
PP2A in mediating imatinib and nilotinib effects is confirmed by the results obtained from 
the treatment with FTY720. Pharmacological activation of PP2A, using FTY720, strongly 
inhibited both the increased tyrosine phosphorylation of p130Cas, FAK and PXN and radial 
spheroid invasion stimulated by imatinib and nilotinib. It is proposed that PP2A activity is 
playing a key role in modulating the effects of imatinib and nilotinib via regulation of 
tyrosine phosphorylation of p130Cas, FAK and PXN.
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PP2A is one of the few serine/threonine-specific phosphatases in the cell and one of the 
most abundant enzymes, accounting for up to 1% of total cellular protein in some tissues. 
PP2A plays an important role in development, cell proliferation, cell death, cell mobility, 
the control of the cell cycle, and the regulation of numerous signalling pathways (Shi, 
2009). PP2A is an important tumour suppressor, regulating the activity of at least 50 
different kinases and has been shown to antagonise the actions of Ras (Janssens et al., 2005, 
Mumby, 2007). Given the results here, it is proposed that modulating PP2A activity could 
provide an approach to improving the clinical outcome of imatinib and nilotinib. 
Stimulating PP2A activity could boost efficacy and could help circumvent the development 
of resistance to these drugs in CML and other cancers for which they are used. 
It has been shown that in BCR-ABL-transformed cells and CML blast crisis progenitors, the 
phosphatase activity of PP2A is inhibited by the BCR-ABL-induced expression of the PP2A 
inhibitor SET. PP2A activation resulted in growth suppression and enhanced apoptosis, and 
leukaemogenesis was found to be dependent on inactivation of PP2A (Neviani et al., 2005). 
FTY720 induces toxic effects in primary leukaemic cells from AML patients and in 
AML cell lines. (Yang et al., 2012). Results presented here support the role of PP2A as a 
tumour suppressor and suggest that pharmacological modulation of PP2A may help 
circumvent the development of resistance to imatinib and nilotinib. Findings 
highlight that specific molecular effects of imatinib and nilotinib in different cell types are 
not well defined.   
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6 Imatinib and nilotinib effects on serine 
phosphorylation 
6.1 Imatinib and nilotinib stimulate serine 
phosphorylation of p130Cas, FAK and PXN 
Tyrosine phosphorylation has emerged as a critical component of cellular regulation, 
predominantly because tyrosine kinases have been found to initiate many signalling 
pathways. However, signal transduction involves reversible phosphorylation of proteins not 
only on tyrosine residues, but also on serine / threonine residues (Hunter, 1995). Cell 
transformation can result from deregulated serine kinase activity, and serine kinases can also 
initiate signalling pathways. The identification of bifunctional protein kinases further 
complicates the interplay of tyrosine and serine / threonine phosphorylation; for example, 
ERK autophosphorylates itself on tyrosine and threonine residues, but phosphorylates 
substrates on serine or threonine residues (Posada and Cooper, 1992). 
The tyrosine phosphorylation of p130Cas, FAK and PXN in mediating cell motility has 
been widely studied. Src directly phosphorylates p130Cas, FAK and PXN at tyrosine 
residues in response to integrin activation and growth factor stimulation (Sharma and 
Mayer, 2008, Barrett et al., 2013). FAK is activated by growth factors, which leads to 
autophosphorylation at its tyrosine residue Y397 (Nakamura et al., 2001). Src 
phosphorylation of FAK tyrosine residue Y861 enhances FAK binding to p130Cas (Mitra et 
al., 2005). Tyrosine phosphorylation of PXN at tyrosine residues Y31 and Y118 occurs 
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during the formation of focal adhesions and generates two functional SH2-binding sites for 
members of the Crk family of SH2-SH3 adaptor proteins (Turner, 2000a, Petit et al., 2000). 
By contrast, serine-specific phosphorylation of p130Cas, FAK and PXN is not widely 
reported in the literature, nor has the involvement of serine phosphorylation in mediating 
motility and other cell functions been widely investigated. Several studies, however, suggest 
that not only tyrosine phosphorylation, but also serine phosphorylation, is important in 
driving the activity of p130Cas, FAK and PXN. Serine phosphorylation of p130Cas has 
been shown to be required for the coordinated disassembly of focal adhesion complexes 
during mitosis, and is associated with simultaneous serine phosphorylation of FAK and 
PXN (Yamakita et al., 1999). Serine phosphorylation of p130Cas correlates with oestrogen 
resistance and invasiveness of human breast cancer cells (Makkinje et al., 2009) 
The interplay between tyrosine phosphorylation and serine phosphorylation of p130Cas has 
not been widely studied. The NRTK Src was recently found to mediate serine 
phosphorylation of p130Cas at residue S639 in an in vivo feline model of pressure 
overloaded myocardium. Whereas kinase activity of Src was required for tyrosine 
phosphorylation of p130Cas at tyrosine residues Y165, Y249 and Y410, kinase inactive Src 
mutant with intact scaffold domains was able to phosphorylate p130Cas in hamster ovary 
cells overexpressing p130Cas at a serine residue corresponding to human S639 (Palanisamy 
et al., 2015). These findings demonstrate that Src can mediate serine phosphorylation of 
p130Cas at S639, and that this occurs independently of Src kinase activity that is required 
for tyrosine phosphorylation of the protein.  
Previous findings in this thesis show that the serine / threonine, PP2A, regulates the 
effects of imatinib and nilotinib on glioma cell signalling and motility. Inhibition of 
PP2A with okadaic acid significantly increased levels of tyrosine phosphorylation of 
p130Cas, FAK and PXN. Conversely, activation of PP2A with FTY720 strongly 
inhibited drug-induced tyrosine phosphorylation of the three molecules (Fig. 5.2.1), and 
radial invasion (Fig. 5.2.3). Based on the findings that a serine / threonine phosphatase is 
involved in mediating imatinib- and nilotinib-induced tyrosine phosphorylation of 
p130Cas, FAK and PXN, the effect of drug treatment on serine phosphorylation of the 
three proteins was investigated.  
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There are no commercially available serine-specific p130Cas antibodies. To assess whether 
imatinib and nilotinib may be affecting serine phosphorylation of p130Cas, cell lysates were 
treated with imatinib or nilotinib, immunoprecipitated with anti-phosphoserine antibody and 
blotted for total p130Cas. Findings reveal that 20-minute treatment with 10 µM imatinib or 
10 µM nilotinib causes a significant increase in the amount of p130Cas detected (Fig. 
6.1.1).  
FAK contains four serine phosphorylation sites within its C-terminal domain, S722, S843, 
S846 and S910 (Ma et al., 2001), that are in close proximity to important protein-protein 
interaction sites, such as the p130Cas binding site (Fig. 1.2.2.2.1). Serine phosphorylation at 
S722 may play a role in modulating FAK binding to p130Cas  (Ma et al., 2001), and FAK 
has been found to undergo Src-dependent S910 phosphorylation, which is important for cell 
spreading (Chu et al., 2011). The effect of imatinib and nilotinib on FAK serine 
phosphorylation was investigated by treating cells with imatinib or nilotinib, 
immunoprecipitating cell lysates with an anti-phosphoserine antibody, and blotting for total 
FAK. Preliminary findings suggest that more total FAK is detected in response to 20-minute 
treatment with 10 µM imatinib or 10 µM nilotinib, than in response to control (Fig. 6.1.2).  
In addition to tyrosine phosphorylation sites, serine phosphorylation sites have also been 
identified on PXN. Serine residues S188 and S190 were found to be phosphorylated 
following integrin activation (Bellis et al., 1997). More recently, PXN serine S126 and S130 
residues were identified as two major ERK-dependent phosphorylation sites in Raf 
transformed fibroblasts (Woodrow et al., 2003). Serine residue S126 was subsequently 
found to be stimulated in response to lipopolysaccharide (LPS) in murine macrophage cells. 
LPS stimulation was accompanied by cell spreading that was partially inhibited in cells 
expressing the PXN S126A/ S130A mutant (Cai et al., 2006). LPS is a component of the 
outer membrane of Gram-negative bacteria that strongly activates macrophage migration 
from blood vessels into surrounding tissue (Kleveta et al., 2012).  
Based on the previous finding that PXN serine phosphorylation mediates macrophage cell 
spreading, the effect of imatinib and nilotinib treatment on PXN serine phosphorylation was 
examined using a phospho-specific antibody. Before treatment with imatinib and nilotinib, 
U87MG cells were treated with LPS for 60-minute and lysates were probed with phospho-
specific S126 antibody. Consistent with the literature, LPS treatment led to an increase in 
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the amount of S126 detected by Western blot (Appendix Fig. A5). U87MG cells were 
subsequently treated with 10 µM imatinib or 10 µM nilotinib for 20 minutes, and cell lysates 
were probed with phospho S126 antibody. Results indicate that treatment with nilotinib 
leads to a significant increase in serine phosphorylation of PXN at residue S126 (Fig. 6.1.3). 
Results show a trend towards increased serine phosphorylation with imatinib treatment, 
although this was not significant. 
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Figure 6.1.1 Imatinib and nilotinib stimulate p130Cas serine phosphorylation in 
U87MG cells. U87MG cells (~80% confluent) were incubated in SFM for ~18hr prior to 
treatment with either SFM & DMSO vehicle control (C), 10 µM imatinib or 10 µM nilotinib 
for 20 minutes. Cell lysates were then immunoprecipitated with anti-phosphoserine 
antibody. Purified complexes and corresponding total cell lysates were separated by SDS-
PAGE. IgG control and a whole cell lysate (WCL) were also included. Data from five 
independent experiments are presented as phosphorylation relative units (RU) (means +/- 
s.e.m.) normalised to the loading control (the heavy chain); *p<0.05, **p<0.01.
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Figure 6.1.2 Imatinib and nilotinib stimulate FAK serine phosphorylation in U87MG 
cells. U87MG cells (~80% confluent) were incubated in SFM for ~18hr prior to treatment 
with either SFM & DMSO vehicle control (C), 10 µM imatinib or 10 µM nilotinib for 20 
minutes. Cell lysates were then immunoprecipitated with anti-phosphoserine antibody. 
Purified complexes and corresponding total cell lysates were separated by SDS-PAGE. IgG 
control and a whole cell lysate (WCL) were also included. Blots are representative of n=2 
experiments. 
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Figure 6.1.3 Imatinib and nilotinib treatment of U87MG cells leads to increased PXN 
serine phosphorylation. U87MG cells (~80% confluent) were incubated in SFM for ~18hr 
prior to treatment with either SFM & DMSO vehicle control (C), 10 µM imatinib or 10 µM 
nilotinib for 20 minutes. Cell lysates were then prepared, blotted, and probed with the 
indicated antibodies. Data from three independent experiments are presented as 
phosphorylation relative units (RU) (means +/- s.e.m.) normalised to total PXN protein 
levels; *p<0.05 compared to control. 
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6.2 Discussion 
Findings reveal that imatinib and nilotinib treatment results in increased serine 
phosphorylation of p130Cas. Furthermore, nilotinib treatment results in a significant 
increase in serine phosphorylation of PXN S126 residue. Preliminary findings suggest that 
imatinib and nilotinib may also be stimulating serine phosphorylation of FAK. This is the 
first study that implicates tyrosine kinase inhibitors in driving serine phosphorylation. 
Findings in Chapter 5 identify serine / threonine PP2A activity in mediating imatinib- and 
nilotinib-induced tyrosine phosphorylation. It could be speculated that PP2A modulates 
serine phosphorylation of p130Cas, FAK and/or PXN, a possibility that would require 
further work to confirm. It has previously been shown that PP2A associates with p130Cas in 
mouse embryo fibroblasts. Furthermore, p130Cas immunoprecipitates treated with OA 
showed an increase in serine phosphorylated p130Cas (Yokoyama and Miller, 2001b). In 
this study PP2A was found to associate with p130Cas in U87MG cells (Fig. 5.2.2). In order 
to investigate whether PP2A mediates p130Cas serine phosphorylation in U87MG, cells 
could be pre-incubated with FTY720 prior to treatment with imatinib and nilotinib. Cell 
lysates immunoprecipitated with anti-phosphoserine antibody could be probed for p130Cas. 
If PP2A is implicated in imatinib- and nilotinib-induced serine phosphorylation of p130Cas, 
treatment with FTY720 would stimulate PP2A activity and should inhibit drug-induced 
phosphorylation. This would mean that less total p130Cas is detected by Western blot. 
Similar experiments could be performed to look at the effect of modulating PP2A activity 
on FAK and PXN serine phosphorylation.  
Both tyrosine and serine phosphorylation of p130Cas are implicated in modulating the 
activity of p130Cas. Src scaffold activity mediates serine phosphorylation of p130Cas at 
serine residue S639, distinct from Src kinase-dependent tyrosine phosphorylation of 
p130Cas (Palanisamy et al., 2015). BCAR3-mediated serine phosphorylation of p130Cas in 
breast cancer cells has also been identified and is associated with an aggressive 
phenotype.  BCAR3 is a member of the NSP family of adaptor proteins, which bind 
Crk-associated substrate (CAS) family of adaptor proteins, including p130Cas, to link CAS 
proteins to cell surface receptors. NSP proteins affect p130Cas protein expression levels, 
phosphorylation state, and subcellular localization, affecting migration and invasion. 
Augmented motility and aggressiveness of breast cancer cells is dependent on the 
association of BCAR3 with 
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p130Cas (Wallez et al., 2012, Makkinje et al., 2012). BCAR3 has been found to mediate 
p130Cas serine phosphorylation at serine residues S139, S437 and S639 in breast cancer 
cells. p130Cas serine phosphorylation was found to accumulate over several hours after 
adhesion of breast cancer cells to fibronectin and was dependent on BCAR3 expression. 
BCAR3 knockdown altered p130Cas localization and inhibited the formation of cellular 
projections (Makkinje et al., 2009). The BCAR3-mediated serine phosphorylation of 
p130Cas identified in breast cancer cells is distinct from the rapid FAK- and Src-mediated 
tyrosine phosphorylation of p130Cas.  
 
Data from this study provide evidence that imatinib and nilotinib modulate both tyrosine 
and serine phosphorylation of motility-related proteins. The potential involvement of serine 
phosphorylation of p130Cas, FAK and PXN in modulating U87MG motility, and the 
potential involvement of PP2A in mediating serine phosphorylation, warrants further 
investigation. 
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7 Clinical relevance 
7.1 Imatinib and nilotinib treatment of human-derived 
GBM stem cells leads to increased p130Cas, FAK 
and PXN tyrosine phosphorylation and increased 
three-dimensional migration 
Cancer cell lines have enabled the study of GBM tumour biology for over 30 years, and 
have provided useful preclinical models for the screening of therapeutics. However, there 
are limitations to cell models as the phenotypic characteristics and genetic abnormalities 
found within repeatedly passaged cell lines often do not resemble the corresponding primary 
tumour. The serum-containing medium in which cells are cultured alter their genomes and 
transcriptomes. Furthermore, tumours formed from these cells in mice xenograft models do 
not develop the typical morphological features of GBM, such as diffuse infiltration into 
surrounding tissue (Xie et al., 2015, Lee et al., 2006).  
There is now a body of evidence that exists to suggest that a sub-population of cancer stem 
cells exist within brain tumours that are capable of initiating and sustaining tumour growth 
in vivo (Wang and Dick, 2005). Glioma stem cells (GSCs) are now thought to be 
responsible for treatment resistance, and are implicated in recurrence after resection 
(Persano et al., 2013). Therefore, the incorporation of GSCs into research in vitro would 
provide a more biologically relevant model system for the study of GBM. 
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Research has shown that GSCs can be readily cultured as spheres, utilising the same 
conditions as for the isolation of normal neural stem cells (NSCs). NSCs were originally 
isolated using serum-free medium without the addition of substrate, and cultured on tissue 
culture plastic. The subsequent addition of EGF stimulated the proliferation of NSCs, 
resulting in the formation of clonal spheres, referred to as “neurospheres”, that show 
intraclonal heterogeneity in the expression of neural lineage-specific proteins, the defining 
characteristic of NSCs (Rahman et al., 2015). This protocol, referred to as the “neurosphere 
assay”, can be applied for the isolation and expansion of GSCs (Ignatova et al., 2002).  
The neurosphere assay has become the standard for maintaining GSCs in culture, providing 
a more clinically relevant model for the study of GBM biology and the effects of 
therapeutics on GBM. We were kindly given GSCs by Professor Sebastian Brandner at the 
UCL Institute of Neurology, which were derived from patient biopsies using the 
neurosphere assay protocol as described in Materials and Methods. The relevance of 
previous findings using GBM cell lines as outlined in Chapter 3 were assessed by 
investigating the effects of imatinib and nilotinib on GSCs isolated from patient biopsies. 
Treatment of patient-derived GSCs with 10 µM imatinib or 10 µM nilotinib led to a 
significant increase in tyrosine phosphorylation of p130Cas, FAK and PXN (Fig. 7.1.1A). 
Furthermore, treatment of spheroids generated from the GSC line, and two additional GSC 
lines, with 10 µM imatinib or 1 µM nilotinib led to a significant increase in 3D radial 
invasion (Fig. 7.1.1B). 
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Figure 7.1.1 Imatinib and nilotinib treatment of stem cells from human GBM biopsies 
leads to increased tyrosine phosphorylation and increased 3D radial invasion. (A) Stem 
cells established from a human GBM biopsy (cell line: NH10-1124) (~80% confluent) were 
incubated in SFM for ~18hr prior to treatment with either SFM & DMSO vehicle control 
(C), 10 µM imatinib or 10 µM nilotinib for 20 minutes. Cell lysates were then prepared, 
blotted, and probed with the indicated antibodies. Data is representative of n=3 experiments. 
(B) Spheroids derived from the indicated stem cell lines established from human GBM
biopsies were imbedded in a collagen gel and incubated in either SFM & DMSO vehicle
control (C), or 10 µM imatinib or 1 µM nilotinib for an additional 48 hours. Spheroids were
fixed in 4% PFA and invasion was determined by measuring the area corresponding to the
invasion rim minus the area of the core for at least 3 different spheroids per condition. Data
from three independent experiments are presented as relative area units (RU) (means +/-
s.e.m.). *p<0.05, **p<0.01 compared to control (C).
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7.2 Imatinib and nilotinib treatment of human 
gastrointestinal stromal cells leads to increased 
p130Cas, FAK and PXN tyrosine phosphorylation 
Gastrointestinal stromal tumour (GIST) is the most common mesenchymal tumour of the 
digestive tract. The most common early event in oncogenesis is gain-of-function mutations 
in KIT or PDGFRA genes which are present in the majority of GISTs and render 
the proteins constitutively activated. Imatinib was approved for GIST in 2008, and 
achieves a partial response or stable disease in most patients, with the response lasting 
more than 5 years in over 20% of patients. However, complete responses are rare, and 
half of patients develop disease progression after two years. The response to imatinib is 
dependent on the presence and variety of KIT or PDGFRA gain-of-function mutations 
(Joensuu, 2007, Guo et al., 2009). Nilotinib has not been approved for GIST, and instead the 
second-line therapy for imatinib-resistant patients is sunitinib, a TKI that is able to inhibit a 
proportion of imatinib-resistant c-Kit mutants. However, sunitinib only extends survival by 
a median of 6 months, as compared to placebo following discontinuation of imatinib 
(Joensuu, 2007).  
To assess whether imatinib and nilotinib may be driving adverse events in GIST, the effect 
of drug treatment on two GIST cell lines was examined. Currently, there is no suitable GIST 
model for the study of drug resistance or metastasis, and research relies largely on 
GIST cells lines obtained from patients. We were kindly provided imatinib-sensitive 
GIST882 and imatinib-resistant GIST48 cells by Professor Bart Vanhaesebroeck at the 
UCL Cancer Institute. The cell lines were initially obtained from patients undergoing 
surgical resection following their consent. The imatinib-sensitive GIST882 human cell 
line was established from an untreated GIST with a primary homozygous missense 
mutation in KIT exon 13. The cells do not express wildtype c-Kit, and instead the 
protein is constitutively tyrosine phosphorylated (Tuveson et al., 2001). The imatinib-
resistant GIST48 cell line was 
established from a GIST patie t whose cancer had progress d fter an initial response to 
imatinib. I  cells hav  a mutation in the activation loop of KIT that renders the protein 
imatinib-resistant (Bauer et al., 2006). 
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Imatinib-sensitive GIST882 cells were treated with 10 µM imatinib and 10 µM nilotinib. 
Preliminary findings suggest that 20-minute treatment with 10 µM nilotinib may lead to an 
increase in tyrosine phosphorylation of p130Cas and FAK. 20-minute treatment with 10 µM 
imatinib did not have an effect on tyrosine phosphorylation of p130Cas, FAK or PXN. Both 
10 µM imatinib and 10 µM nilotinib treatment resulted in reduced phosphorylation of ERK 
compared to control (Fig. 7.2.1A). 
A preliminary dose-dependency experiment suggests that whereas treatment with 10 µM 
imatinib has no effect on tyrosine phosphorylation, treatment with 20 µM imatinib may be 
increasing tyrosine phosphorylation of p130Cas. Preliminary findings suggest that nilotinib 
treatment causes an increase in tyrosine phosphorylation of p130Cas in a dose-dependent 
manner, with nilotinib concentration as low as 1 µM leading to increased phosphorylation. 
The results for FAK and PXN tyrosine phosphorylation are difficult to interpret requiring 
further investigation, with possible increases in tyrosine phosphorylation of FAK and PXN 
upon treatment with 20 µM nilotinib. Results suggest that treatment with imatinib as low as 
1 µM, and nilotinib as low as 10 µM, inhibits the phosphorylation of ERK (Fig. 7.2.1B). 
Unfortunately, the GIST882 cells stopped responding to cell culture conditions required for 
proliferation. Several unsuccessful attempts were made to raise cells from freeze-down 
vials. We contacted our collaborators who advised that this is an inherent problem of 
human-derived GIST cells. It was not possible to perform additional experiments using 
GIST882 cells to better identify the effects of imatinib and nilotinib treatment on tyrosine 
phosphorylation, nor was it possible to perform functional spheroid assays using these cells.  
However, the imatinib-resistant GIST48 cells responded to cell culture conditions and 
proliferated. Subsequent experiments looking at the effect of imatinib and nilotinib on GIST 
were performed using these cells. Based on the finding that 20 µM imatinib may be having 
an effect on tyrosine phosphorylation of p130Cas in GIST882 cells (Fig. 7.2.1B), imatinib-
resistant GIST48 cells were treated with 20 µM imatinib or 10 µM nilotinib for 20 minutes. 
Treatment with both imatinib and nilotinib led to a significant increase in tyrosine 
phosphorylation of p130Cas, FAK and PXN. Interestingly, imatinib and nilotinib treatment 
did not affect levels of phosphorylated ERK (Fig. 7.2.2). This is in contrast to imatinib-
sensitive GIST882 cells where imatinib and nilotinib treatment leads to a decrease in the 
phosphorylation of ERK (Fig. 7.2.1). 
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The effect of imatinib and nilotinib treatment on radial invasion in GIST48 cells was 
examined. GIST48 spheroids were generated and embedded in collagen plugs supplemented 
with serum free medium containing either DMSO (control), 10 µM imatinib, 20 µM 
imatinib or 1 µM nilotinib. Treatment with either imatinib or nilotinib alone for 48 hours
resulted in a significant increase in radial invasion compared to treatment with vehicle 
control (Fig. 7.2.3). 
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Figure 7.2.1 Imatinib and nilotinib treatment of imatinib-sensitive GIST882 cells. 
GIST882 cells (~80% confluent) were incubated in SFM for ~18hr prior to treatment with 
(A) SFM & DMSO vehicle control (C), 10 µM imatinib (I) or 10 µM nilotinib (N) for 20
minutes; (B) SFM & DMSO vehicle control (C), or imatinib or nilotinib at indicated
concentrations for 20 minutes. Cell lysates were then prepared, blotted, and probed with the
indicated antibodies. Blots for (A) are representative of n=2 experiments.
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Figure 7.2.2 Imatinib and nilotinib treatment of imatinib-resistant GIST48 cells leads 
to increased p130Cas, FAK and PXN tyrosine phosphorylation. GIST48 cells (~80% 
confluent) were incubated in SFM for ~18hr prior to treatment with either SFM & DMSO 
vehicle control (C), 20 µM imatinib or 10 µM nilotinib for 20 minutes. Cell lysates were 
then prepared, blotted, and probed with the indicated antibodies. Data from three 
independent experiments are presented as phosphorylation relative units (RU) (means +/- 
s.e.m.) normalised to total protein levels; *p<0.05, **p<0.01 compared to control (C).
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Figure 7.2.3 Imatinib and nilotinib treatment of human GIST cells leads to increased 
3D radial invasion. Equal amounts of GIST48 cells were used to generate spheroids as 
described in Materials and Methods. 24 hours after spheroid production, spheroids were 
imbedded in a collagen gel and incubated in SFM supplemented with vehicle (control), 10 
µM imatinib, 20 µM imatinib or 1 µM nilotinib for 48 hours. Spheroids were fixed in 4% 
PFA and invasion was determined by measuring the area corresponding to the invasion rim 
minus the area of the core for at least 3 different spheroids per condition. Data from three 
independent experiments are presented as relative area units (RU) (means +/- s.e.m.); 
*p<0.05, **p<0.01 compared to control.  
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7.3 Imatinib and nilotinib treatment of hepatocellular 
liver carcinoma cells leads to increased p130Cas, 
FAK and PXN tyrosine phosphorylation 
To examine whether increases in tyrosine phosphorylation in response to imatinib and 
nilotinib are specific to GBM and GIST cancer cells, the effect of drug treatment on 
hepatocellular carcinoma (HCC) was investigated. HEPG2 cells previously used by our lab 
were treated with imatinib and nilotinib. Findings reveal that a 20-minute treatment with 10 
µM imatinib or 10 µM nilotinib leads to a significant increase in tyrosine phosphorylation
of p130Cas. Treatment with 10 µM nilotinib also leads to a significant increase in tyrosine
phosphorylation of FAK and PXN (Fig. 7.3.1). These results show that imatinib- and 
nilotinib-induced increases in tyrosine phosphorylation are not restricted to GBM and GIST 
cancer cells.  
154	
Figure 7.3.1 Imatinib and nilotinib treatment of human liver carcinoma HEPG2 cells 
leads to increased p130Cas, FAK and PXN tyrosine phosphorylation. HEPG2 cells 
(~80% confluent) were incubated in SFM for ~18hr prior to treatment with vehicle control 
(C), or 10 µM imatinib or 10 µM nilotinib for 20 minutes. Cell lysates were then prepared, 
blotted, and probed with the indicated antibodies. Data from three independent experiments
are presented as relative units (RU) (means +/- s.e.m.); *p<0.05, **p<0.01 compared to 
control.  
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7.4 Imatinib and nilotinib treatment of non-cancer 
cells leads to increased p130Cas, FAK and PXN 
tyrosine phosphorylation 
 
Imatinib and nilotinib are described as well-tolerated drugs that cause few major adverse 
effects, with common reported adverse effects restricted largely to skin rash, diarrhoea, 
headache, nausea and fatigue (Druker et al., 2006, Quintas-Cardama et al., 2010, Waller, 
2010). However, adverse cardiovascular effects in response to imatinib or nilotinib 
treatment have been reported in several independent studies, more commonly identified in 
patients receiving higher doses (600-800 mg/day). One study identified imatinib treatment 
as a cause of left ventricular dysfunction in CML patients treated with 400-800 mg/day 
imatinib. Healthy mice treated with imatinib at doses comparable to those in the clinic also 
developed significant deterioration in contractile function and moderate left ventricular 
dilation after 3-4 weeks of treatment. Moreover, the study found that imatinib caused cell 
death in rat ventricular myocytes (Kerkela et al., 2006). In one study looking at 24 CML 
patients treated with nilotinib, adverse vascular events occurred in 8 of the 24 patients 
(~33%). Three patients developed rapidly progressive peripheral arterial disease (PAD), 
requiring repeated angioplasty and/or multiple surgeries within a few months. An additional 
one less severe case of PAD was identified in the remainder of the cohort, as well as one 
myocardial infarction, one spinal infarction and one haematoma (Aichberger et al., 2011). 
Adverse vascular events, including accelerated atherosclerosis, PAD and coronary artery 
disease, have also been documented in other studies (Tefferi and Letendre, 2011, Coon et 
al., 2013). 
 
To assess whether the activation of p130Cas, FAK and PXN by imatinib and nilotinib is a 
general effect or a disease-specific effect, primary non-tumour human umbilical vein 
endothelial cells (HUVECs) and human coronary artery smooth muscle cells (HCASMCs) 
were treated with imatinib and nilotinib. These experiments were performed by other 
members of our lab, Dr. Ian Evans and Miss Lisa Im (both at the Centre of Cardiovascular 
Biology and Medicine, UCL). Our lab has previously shown that VEGF stimulates tyrosine 
phosphorylation of p130Cas Y410 and FAK Y397 in HUVECs (Evans et al., 2011). 
HUVECs were treated with 10 µM imatinib or 10 µM nilotinib followed by incubation with 
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VEGF or vehicle control. Preliminary findings suggest that 10 µM imatinib and 10 µM 
nilotinib treatment of HUVECs leads to a rapid increase in tyrosine phosphorylation of 
p130Cas at Y410, FAK at its activating residue Y397, and PXN at Y118 (Appendix Figure 
A6A). Even in the absence of VEGF stimulation, 20-minute treatment with 10 µM imatinib 
or 10 µM nilotinib resulted in an increase in tyrosine phosphorylation of all three residues.  
Our lab has previously shown that PDGF stimulation of HCASMCs leads to increased 
tyrosine phosphorylation of p130Cas (Pellet-Many et al., 2011). HCASMCs were treated 
with nilotinib for 30 minutes followed by incubation with PDGF or vehicle control. 
Preliminary findings suggest that treatment with1 µM, 5 µM or 10 µM nilotinib leads to an 
increase in tyrosine phosphorylation of p130Cas, FAK, and PXN, even in the absence of 
PDGF (Appendix Figure A6B). The effects of imatinib on p130Cas, FAK and PXN in 
HCASMCs were inconclusive and are currently being investigated further in our lab.  
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7.5 Discussion 
Only a minority population of brain tumour cancer stem cells have the ability to self-renew, 
and these glioma stem cells are thought to drive tumour growth and spread. An important 
finding of this study is that imatinib and nilotinib treatment of GBM stem cells derived from 
patient biopsies led to increased tyrosine phosphorylation of p130Cas, FAK and PXN. 
Imatinib and nilotinib were also found to potently increase 3D radial spheroid invasion. 
These findings validate the clinical significance of results identified in U87MG, U118MG 
and U251MG glioma cell lines. It can be concluded that imatinib and nilotinib stimulate 
pro-invasive activity in a disease relevant model, providing evidence for the first time of 
why imatinib may have failed clinical trials for GBM. 
The effects of imatinib and nilotinib treatment in imatinib-sensitive GIST882 cells were 
inconclusive. Preliminary findings suggest that imatinib at 20 µM causes an increase in 
tyrosine phosphorylation of p130Cas. Preliminary findings also suggest that nilotinib 
induces as stronger activation of tyrosine phosphorylation of p130Cas than imatinib, with 
nilotinib exerting effects in a dose-dependent manner. Results suggest that nilotinib may 
cause increases in FAK and PXN tyrosine phosphorylation, although this requires further 
investigation. In the future an effort should be made to identify a new source of imatinib-
sensitive GIST cells that can be cultured. Importantly, imatinib and nilotinib were found to 
stimulate tyrosine phosphorylation in imatinib-resistant GIST48 cells. Both drugs were 
also found to stimulate 3D radial invasion in GIST48 cells. Imatinib and nilotinib 
were found to induce a stronger effect on tyrosine phosphorylation in the imatinib-
resistant cells compared to the imatinib-sensitive cells, suggesting that the p130Cas, 
FAK and PXN pathways may be activated in response to the development of resistance 
to imatinib. Findings here provide evidence that imatinib and nilotinib treatment cause 
undesirable adverse effects in GIST, a cancer for which imatinib is approved. Only a small 
number of GIST patients (10-20%) exhibit primary resistance to imatinib. However, 
most responding patients develop secondary resistance after a median of two years (Bauer et 
al., 2007). The activation of the motility-related proteins in GIST48, and possibly 
GIST882, suggest that p130Cas, FAK, and PXN activity may contribute to 
resistance and/or tumorigenesis, and that targeting this pathway in GIST patients may prove 
therapeutically beneficial.  
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Imatinib and nilotinib caused a reduction in phosphorylated ERK in the GIST882 cells, but 
not the imatinib-resistant GIST48 cells. These findings implicate the c-Kit receptor in 
driving downstream activation of ERK. In the imatinib-sensitive cells inhibition of c-
Kit leads to inhibition of ERK. The c-Kit mutation in the GIST48 cells renders the 
receptor unresponsive to imatinib and it subsequently continues to activate the ERK 
pathway. These findings are consistent with previous findings that the ERK pathway is 
activated in untreated GISTs and that imatinib treatment causes a reduction in 
phosphorylated ERK, as identified in patient-derived imatinib-treated GIST biopsies 
compared to biopsies from untreated patients (Heinrich et al., 2006). These 
findings support the targeting of downstream signalling proteins as an approach to 
tackling imatinib resistance. Indeed, additive effects have been observed in GIST cells 
using imatinib together with the MEK inhibitor U0126 (Bauer et al., 2007). 
Findings here are consistent with previous findings by Rossi et al. that show increased 
tyrosine phosphorylation of p130Cas (Y410) and FAK (Y861) in response to imatinib 
treatment in a mouse model of GIST (Rossi et al., 2010). The researchers propose that 
targeting FAK and members of the Src family kinases, or their downstream effectors in 
addition to imatinib would provide added therapeutic benefit. Given that first and second 
generation drugs are not always effective, an alternative strategy to circumvent TKI-
resistance would be to target downstream pathways critical for transformation. Results of 
this project endorse the idea of a combinational approach and suggest that targeting FAK in 
conjunction with imatinib may add therapeutic benefit for the treatment of GIST. 
The ability of imatinib and nilotinib to induce tyrosine phosphorylation is further 
underscored by the finding that treatment with either drug stimulates rapid phosphorylation 
of p130Cas in HEPG2 cells. Nilotinib treatment also led to a rapid increase in tyrosine 
phosphorylation of FAK and PXN. Results highlight the necessity of screening TKIs of 
interest across different types of cancers. Importantly, imatinib has failed a phase II clinical 
study looking at the efficacy and safety of imatinib in patients with unresectable HCC. 15 
patients with HCC were enrolled and it was found that although single-agent imatinib was 
well-tolerated by all patients, imatinib did not show any clinical efficacy for the treatment of 
HCC (Lin et al., 2008).  
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Importantly, imatinib and nilotinib were found to stimulate tyrosine phosphorylation in non-
tumour cell lines suggesting that the drugs exert general effects that are not restricted to 
disease. Preliminary findings suggest that imatinib and nilotinib stimulate tyrosine 
phosphorylation of p130Cas, FAK and PXN in HUVECs. Endothelial cells lining the 
endothelium cover the inner surface of blood vessels and separate blood from tissues. The 
endothelium also regulates vascular smooth muscle cells, regulating relaxation / contraction, 
and therefore vasodilatation / vasoconstriction. Endothelial dysfunction contributes to 
atherosclerotic disease (Esper et al., 2006). The findings that imatinib and nilotinib may 
stimulate p130Cas, FAK and PXN phosphorylation in endothelial cells suggest that the 
activation of these proteins may contribute to the prevalence of cardiovascular side effects 
observed in the clinic. This is further supported by preliminary finding that nilotinib 
treatment leads to increased tyrosine phosphorylation of p130Cas, FAK and PXN in 
HCASMCs. Activation of the p130Cas, FAK and PXN pathway in smooth muscle may 
contribute to the development of adverse cardiovascular effects.  
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8 Concluding discussion 
 
 
 
 
8.1 The development of resistance to tyrosine kinase 
inhibitors  
 
The approval of the first small-molecule kinase inhibitor, imatinib, in 2001 for the treatment 
of chronic myeloid leukaemia was a breakthrough in targeted cancer therapy. It provided 
evidence that you can target an oncoprotein that is the main driver of disease to successfully 
treat patients without severe side effects. Imatinib has changed the landscape of CML 
therapy. For patients in chronic phase CML, the rate of complete hematologic response 
approaches 100%. However, for patients in accelerated phase and blast crises phase, the 
efficacy of imatinib is significantly lower. And although initial response rates to imatinib 
are high, the TKI fails in up to 40% of patients with prolonged treatment (Quintas-Cardama 
et al., 2010, Druker et al., 2006). 
 
Acquired resistance to anticancer therapy remains a significant barrier in reducing the 
mortality associated with malignancy. The clinical outcome of a TKI is genotype-dependent 
in regards to both primary and secondary mutations in the drug targets. In the case of CML, 
imatinib binds with high affinity and specificity to the ATP-binding site within the catalytic 
domain of BCR-ABL. Response to the drug is maintained by inhibition of the ATP binding 
domain, preventing signalling downstream of BCR-ABL. Most often acquired resistance 
occurs as a result of mutations in the BCR-ABL kinase domain which prevent imatinib from 
binding the ATP-binding site (Quintas-Cardama et al., 2010). Although second-generation 
nilotinib is effective against many mutations that render BCR-ABL resistant to imatinib, it 
is not effective against the gatekeeper T315I mutant (Weisberg et al., 2006), which accounts 
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for 4-20% of mutations that are associated with TKI resistance (Xu et al., 2016). Treatment 
with the third-generation ponatinib results in a major cytogenetic response in 70% of 
chronic patients with the T315I mutation. However, the major cytogenetic response drops to 
29% for those patients in the blast crisis phase (Cortes et al., 2013). 
Acquired resistance to imatinib and nilotinib occurs over months or years, usually as a result 
of genomic instability which produces sub-clones with mutations in the kinase domain. In 
addition, non-genetic mechanisms of drug resistance have also been identified. It has 
recently been suggested that tumour cells can become dependent on non-amplified and non-
mutated RTKs to evade targeted treatment, in a phenomenon referred to as “RTK-
switching”. RTK switching has been identified as a mechanism of resistance to EGFR 
inhibition in GBM. Akhavan et al. generated mice xenografted with U87MG cells 
expressing the EGFRvIII gain-of-function mutation. As expected, erlotinib treatment slowed 
tumour growth relative to control; however, tumours retained a considerable growth rate 
despite continued treatment. Inhibition of EGFR was found to promote PDGFRβ 
upregulation. Immunoblots of tumour lysates revealed upregulation and activation of 
PDGFRβ in response to pharmacological or genetic inhibition of EGFRvIII. Erlotinib 
treatment of human-derived EGFRvIII-expressing GBM neurospheres also resulted in 
upregulation of PDGFRβ expression. A strong inverse correlation between EGFR and 
PDGFRβ expression was observed in patient glioma tissues, with high levels of EGFR 
correlating with a low level of PDGFRβ. Erlotinib treatment of human-derived EGFRvIII-
expressing GBM neurospheres resulted in upregulation of PDGFRβ expression. This 
provides evidence that highly active EGFR signalling can negatively regulate PDGFRβ 
expression, and that inhibition of EGFR signalling results in an RTK switch to PDGFRβ. 
Importantly, combinational pharmacological inhibition of PDGFR and EGFR in patient-
derived GBM neurospheres with high levels of EGFR significantly suppressed tumour cell 
proliferation (Akhavan et al., 2013). Upregulation of the hepatocyte growth factor pathway 
has also been documented in response to EGFR kinase inhibitors in lung cancer via focal 
amplification of the c-Met receptor (Engelman et al., 2007).  
Changes in the tumour microenvironment caused by an anticancer drug can affect the 
response of tumour cells to therapy. One study found that although BRAF-mutant 
melanoma cells initially respond to the BRAF inhibitor PLX4720, they rapidly develop 
resistance. PLX4720 leads to matrix remodelling, which promotes integrin β1/FAK/Src 
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signalling and causes ERK re-activation downstream of BRAF. As expected, combined 
MEK and BRAF inhibition led to a reduction of ERK signalling. FAK inhibition alone did 
not lead to reduced ERK activity. Importantly, BRAF inhibition in combination with FAK 
inhibitor PF-228 prevented the re-activation of ERK in cultured melanoma spheroids 
embedded in collagen (Hirata et al., 2015). This study highlights that inhibition of a target 
can generate a drug-tolerant microenvironment prior to the emergence of a genetic cell 
intrinsic mechanism of drug resistance.  This provides an example of how the development 
of combinational therapies can help circumvent drug-tolerance. 
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8.2 Combinational therapeutic approach 
The preliminary results here highlight the presence of unforeseen effects of imatinib and 
nilotinib on cellular signalling, implicating the activation of p130Cas and FAK pathways. 
Imatinib and nilotinib treatment leads to a rapid increase in tyrosine phosphorylation and 
localisation to the membrane of p130Cas, FAK and PXN. Consistent with increases in 
tyrosine phosphorylation of motility-related proteins, imatinib and nilotinib stimulate two-
dimensional and three-dimensional migration. Findings demonstrate for the first time that 
imatinib and nilotinib, two tyrosine kinase inhibitors, also stimulate serine phosphorylation 
of p130Cas, FAK and PXN. Preliminary findings suggest that drug-induced effects may 
not be dependent on the targets to which the drugs bind to with high specificity. 
By contrast, results demonstrate that drug-induced effects are dependent on 
p130Cas, and may be dependent on FAK kinase activity. 
A possible mechanism of resistance to imatinib and nilotinib is the upregulation 
of alternative pathways. As discussed above, studies looking at EGFR inhibition 
provide evidence of non-genetic adaptive mechanisms of resistance and show how a 
tumour can become “addicted” to a non-amplified and non-mutated RTK to evade 
targeted treatment. The study looking at BRAF inhibition in melanoma cells provides 
evidence that a drug can induce changes to the tumour microenvironment, which results 
in drug-tolerance. In this context, multiple targets need to be targeted simultaneously. The 
results here suggest that a combinational approach targeting PP2A and / or FAK in 
combination with imatinib or nilotinib could have a beneficial therapeutic effect.  
Findings in this study implicate the serine / threonine phosphatase, PP2A, in mediating 
effects of imatinib and nilotinib on glioma signalling and motility. Consistent with 
the possibility that inactivation of PP2A by imatinib or nilotinib treatment results in 
tyrosine phosphorylation, pre-treatment with okadaic acid, a PP2A inhibitor, significantly 
increased basal tyrosine phosphorylation of p130Cas, FAK and PXN. Conversely, 
pharmacological  activation of  PP2A with FTY720 strongly  reduced both the drug-induced 
increase in tyrosine phosphorylation of p130Cas, FAK and PXN, and radial invasion. In Ph+ 
leukaemias, FTY720 promotes the inactivation of BCR-ABL and apoptosis of Ph+ blasts; 
and   FTY720  treatment leads to  long-term survival in a mouse model of BCR-ABL-driven
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leukaemia (Neviani et al., 2007). Similar findings were observed in AML cells harbouring 
gain-of- function mutated c-Kit (c-Kit+). Pharmacological activation of PP2A by FTY720 
reduced proliferation and induced apoptosis of mutant c-Kit+ cells (Roberts et al., 2010). 
Findings here support the role of PP2A as a tumour suppressor and suggest that 
pharmacological modulation of PP2A may add therapeutic benefit when used in 
conjunction with imatinib/nilotinib. 
Given the findings by Roberts et al. that FTY720 promotes apoptosis of c-Kit+ 
leukemia cells, it is possible that reactivation of PP2A may be of therapeutic benefit in 
other c-Kit+ cancers (Roberts et al., 2010). The effect of FTY720 in GIST has not been 
widely studied, and based on findings from this project that imatinib and nilotinib also 
induce tyrosine phosphorylation of p130Cas, FAK and PXN in GIST cells, the effect of 
FTY720 in GIST cells warrants investigation. Preliminary findings show that 
FTY720 is significantly cytotoxic in GIST cells (Dumont et al., 2011). However, 
Dumont et al. found that the concentration of FTY720 required to reduce GIST cell 
viability by 50% at 72 hours in GIST cells was between 2.9 and 3.9 µmol/L, which 
translates to high oral dosing for patients, and exceeds the concentrations used in clinical 
trials. The effect of lower doses and long-term treatment of FTY720 should be 
considered, as well as the potential of a combinational approach alongside imatinib.  
FAK inhibition has been found to synergise with nilotinib to reduce Ph+ CML growth 
in vivo (Hu and Slayton, 2014). Findings from this study suggest that FAK inhibition 
in conjunction with imatinib / nilotinib may also provide therapeutic benefit for the 
treatment of GBM. Treatment of U87MG cells with the FAK inhibitor PF-228 
significantly reduced the imatinib and nilotinib stimulated increases in p130Cas 
and PXN tyrosine phosphorylation, and drug-induced 3D radial invasion. FAK 
inhibition with PF-228 also resulted in a significant decrease in the basal level of radial 
invasion, supporting the role of FAK in mediating migration. Consistent with the 
possibility that targeting FAK may be beneficial for the treatment of GBM, FAK 
inhibition has been found to decrease cellular proliferation, adhesion and migration in 
glioma cells (Shi et al., 2007). Furthermore, FAK inhibition was found to increase survival 
of mice in an intracranial glioma xenograft model (Liu et al., 2007b).  
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In addition to combinational therapy that targets several pathways, the therapeutic potential 
of multiple TKIs targeting a single kinase needs to be considered in the context of acquired 
resistance resulting from secondary mutations. In CML, acquired resistance to TKIs occurs 
most often as a result of mutations in the BCR-ABL kinase domain which prevent drug 
binding (Quintas-Cardama et al., 2010). Nilotinib and dasatinib are approximately ~30-fold 
and ~325-fold respectively more potent for BCR-ABL than imatinib, and are effective 
against most imatinib-resistant BCR-ABL mutants except the gate-keeper mutation T315I. 
An experimental drug, SGX393 (SGX Pharmaceuticals, Inc., San Diego) was found 
effective against a large range of mutations, including T315I, in cells recovered from 
patients that are resistant to dasatinib. However, SGX393 was ineffective against several 
other mutations that nilotinib and dasatinib could inhibit. Importantly, SGX393 in 
combination with nilotinib or dasatinib was able to entirely abrogate the outgrowth of 
resistant subclones (O'Hare et al., 2008). The resistance profile of SGX393 complements the 
resistance profile of nilotinib and dasatinib. Neither of the drugs control all of the mutations; 
however, SGX393 in combination with either nilotinib or dasatinib was able to suppress 
resistance. These pre-clinical findings suggest that a rational combination of two kinase 
inhibitors that have different resistance profiles, could protect against resistance and provide 
significant therapeutic benefit in CML and GIST. 
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8.3 Possible mechanisms mediating the observed 
effects on phosphorylation and motility 
Downstream imatinib- and nilotinib-induced tyrosine phosphorylation could result from at 
least two different mechanisms: activation of an upstream signalling molecule(s) that 
activate(s) p130Cas, FAK and PXN, or indirect inhibition of one or more PTP that 
dephosphorylates the proteins. As discussed in Chapter 4, CSK is a non-receptor tyrosine 
kinase that inhibits Src via phosphorylation of the Src Y527 residue. Direct inhibition of 
CSK would result in the activation of Src and could promote downstream tyrosine 
phosphorylation of p130Cas, FAK and PXN. Although preliminary results suggest that CSK 
is not implicated in mediating imatinib- and nilotinib-induced phosphorylation, direct drug 
inhibition of an inhibitory kinase has not been ruled out as a possible mechanism.  
The second possible mechanism of action is the indirect inhibition of a phosphatase, which 
under physiological conditions dephosphorylates p130Cas, FAK and PXN. Zheng et al.  
recently found that Ras unexpectedly negatively regulates FAK via activation of the serine / 
threonine protein kinase ERK and PTP-PEST. Activated Ras induces serine phosphorylation 
of FAK S910 by ERK, which recruits the enzyme PIN1. PIN1 is an evolutionarily 
conserved enzyme that binds and isomerises specific phosphorylated motifs in a subset of 
proteins resulting in their conformational change (Lu and Zhou, 2007). PIN1 binding and 
isomerisation of FAK causes PTP-PEST to interact with and dephosphorylate FAK at 
tyrosine residue Y397. Inhibition of FAK mediated by this pathway promotes Ras-induced 
cell migration, invasion, and metastasis (Zheng et al., 2009). These findings highlight the 
sequential modification of FAK by Ras involving serine phosphorylation, isomerisation, and 
tyrosine dephosphorylation, and provides an example of indirect kinase-mediated activation 
of a PTP. 
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8.4 Target specificity 
It will be important to further investigate which target(s) and downstream signalling 
pathways are being activated by imatinib and nilotinib. Imatinib and nilotinib are ATP-
competitors initially designed to bind to the ATP binding site of BCR-ABL. In addition to 
BCR-ABL, these drugs target ARG, PDGFR, DDR1 and c-Kit with high specificity 
(Hantschel et al., 2008). Imatinib and nilotinib bind their targets in the inactive 
conformation, with the activation loop folded in towards the active site, preventing substrate 
binding (Zhang et al., 2009). The target(s) via which the observed effects are mediated is 
presumed to be one or more kinase with an ATP-binding site against which the inhibitors 
were developed. The ATP nucleotide-binding pocket is located within the catalytic domain 
of of the kinase. The activation loop is located at the amino-terminal of the ATP-binding 
site, and controls catalytic activity by switching between different states in a 
phosphorylation-dependent manner. Both the ATP-binding site and the activation loop are 
highly conserved regions across most kinases (von Bubnoff et al., 2002). The traditional 
approach to identifying TKI targets is through in vitro assays that utilise a panel of 
recombinant kinases to measure inhibitor binding (Lee and Wang, 2009). It is possible that 
imatinib and nilotinib bind other kinase target(s) which have not been detected in in vitro 
kinase screens. Even the largest kinase panels contain only a proportion of all 518 kinases of 
the human kinome, and the kinases not included in such screens would not be investigated 
for potential binding to TKIs (Hantschel et al., 2008). The pre-selection of kinase targets 
limits the traditional approach to kinase screening. Another limitation of these cell free 
screens is that they do not take into consideration in vivo protein interactions. Understanding 
the full spectrum of drug targets would enable the development of combinational therapies. 
Furthermore, the multi-target specificity of imatinib and nilotinib means that if their full 
target-spectrum is identified, the drugs could be re-purposed for other diseases.  
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8.5 Importance of motility-related screening for TKIs 
during drug development  
 
Kinases have become one of the most important classes of proteins for drug discovery and 
oncology has benefited significantly from the development of small-molecule inhibitors. 
But acquired resistance to TKIs remains a major challenge for personalised cancer therapy. 
Identifying the full range of intracellular targets of a small-molecule inhibitor is extremely 
difficult, but vital for our understanding of toxicity, for the ability to predict how tumours 
may respond to particularly therapy, and for the prevention of resistance.  Findings highlight 
that the precise molecular outcomes of imatinib and nilotinib treatment are not well defined, 
providing insight as to why their clinical management remains challenging.  
 
Imatinib and nilotinib stimulate tyrosine phosphorylation of p130Cas, FAK and PXN in 
multiple settings, including non-transformed primary cell lines, and established and patient-
derived cancer cell lines. These results highlight the necessity for screening imatinib, 
nilotinib and other TKIs for their effects on multiple modes of cell motility in specific 
cancers and other diseases where therapeutic efficacy is being investigated.  
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Appendix 
Figure A1 Imatinib and nilotinib treatment leads to increased tyrosine 
phosphorylation of additional p130Cas and FAK tyrosine residues. U87MG cells 
(~80% confluent) were incubated in SFM for ~18hr prior to treatment with (A) either SFM 
& DMSO vehicle control (C), or 10 µM imatinib or 10 µM nilotinib for 5, 10 or 20 minutes 
(’); (B) either SFM & DMSO vehicle control (C), or 10 µM imatinib or 10 µM nilotinib for 
20 minutes. Cell lysates were then prepared, blotted, and probed with the indicated 
antibodies. 
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Figure A2 Imatinib and nilotinib treatment leads to increased 2D cell motility of 
U87MG cells. Transwell cell culture inserts were inserted into a 24-well plate. SFM 
supplemented with 10 µM imatinib or vehicle were placed in the bottom chamber, and 
U87MG glioma cells in suspension (1.5 x 105 cells/well) were added to the top chamber and 
incubated at 37˚C for 6h. Cells that had not migrated or had only adhered to the upper side 
of the membrane were removed before membranes were fixed and stained. Cells that had 
migrated to the lower side of the membrane were counted in four random fields per well. 
Data from three independent experiments are presented as means ± s.e.m, expressed as the 
number of cells migrating per field; *p<0.01 compared to vehicle treated control. These 
experiments and quantification were performed by Dr. Paul Frankel, UCL. 
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Figure A3 Imatinib- and nilotinib-induced increases in p130Cas, FAK and PXN 
tyrosine phosphorylation are not dependent on NCK. U87MG cells were transfected 
with siRNA targeting NCK (siNCK) at a concentration of 25 nM, or with 25 nM of a 
control scrambled siRNA (siScr). 48hr post transfection, cells were incubated in SFM for 
~18hr prior to treatment with SFM & DMSO vehicle control (C), or 10 µM imatinib or 10 
µM nilotinib for 20 minutes. Cell lysates were then prepared, blotted, and probed with the 
indicated antibodies. 
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Figure A4 Silencing PTPRA does not affect imatinib and nilotinib stimulation of 
p130Cas and PXN tyrosine phosphorylation. U87MG cells were transfected with two 
different siRNAs targeting PTPRA (siPTPRA) at a concentration of 25 nM, or with 25 nM 
of a control scrambled siRNA (siScr). 48hr post transfection, cells were incubated in SFM 
for ~18hr prior to treatment with SFM & DMSO vehicle control (C), or 10 µM imatinib 
or 10 µM nilotinib for 20 minutes. Cell lysates were then prepared, blotted, and probed 
with the indicated antibodies. 
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Figure A5 LPS treatment of U87MG cells. U87MG cells (80% confluent) were incubated 
in SFM for ~18hr prior to treatment with vehicle control (-), or 1 µg/mL LPS (+) for 60 
minutes. Cell lysates were then prepared, blotted, and probed with the indicated antibodies. 
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Figure A6 Imatinib and nilotinib treatment of non-cancerous cells leads to increased 
tyrosine phosphorylation of p130Cas, FAK and PXN. (A) HUVECs (80% confluent) 
were incubated in SFM for ~18hr prior to treatment with vehicle control, or 10 µM imatinib 
or 10 µM nilotinib for 20 minutes. Cells were then incubated for 10 minutes with 25ng/ml 
of VEGF (+) or vehicle control (-). Cell lysates were then prepared, blotted, and probed with 
the indicated antibodies. (B) HCASMCs were incubated in SFM for ~18hr prior to 
treatment with vehicle control, or different concentrations of nilotinib for 30 minutes. Cells 
were then incubated for 10 minutes with 50ng/ml of PDGF (+) or vehicle control (-). Cell 
lysates were then prepared, blotted, and probed with the indicated antibodies. These 
experiments were performed by (A) Dr. Ian Evans, UCL; (B) Miss Lisa Im, UCL. 
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Imatinib and Nilotinib increase 
glioblastoma cell invasion via 
Abl-independent stimulation of 
p130Cas and FAK signalling
Antonina Frolov1, Ian M. Evans1, Ningning Li2, Kastytis Sidlauskas2, Ketevan Paliashvili1, 
Nicola Lockwood1,3, Angela Barrett1, Sebastian Brandner2, Ian C. Zachary1 & Paul Frankel1
Imatinib was the first targeted tyrosine kinase inhibitor to be approved for clinical use, and remains 
first-line therapy for Philadelphia chromosome (Ph+)-positive chronic myelogenous leukaemia. We 
show that treatment of human glioblastoma multiforme (GBM) tumour cells with imatinib and the 
closely-related drug, nilotinib, strikingly increases tyrosine phosphorylation of p130Cas, focal adhesion 
kinase (FAK) and the downstream adaptor protein paxillin (PXN), resulting in enhanced cell migration 
and invasion. Imatinib and nilotinib-induced tyrosine phosphorylation was dependent on expression 
of p130Cas and FAK activity and was independent of known imatinib targets including Abl, platelet 
derived growth factor receptor beta (PDGFRβ) and the collagen receptor DDR1. Imatinib and nilotinib 
treatment increased two dimensional cell migration and three dimensional radial spheroid invasion 
in collagen. In addition, silencing of p130Cas and inhibition of FAK activity both strongly reduced 
imatinib and nilotinib stimulated invasion. Importantly, imatinib and nilotinib increased tyrosine 
phosphorylation of p130Cas, FAK, PXN and radial spheroid invasion in stem cell lines isolated from 
human glioma biopsies. These findings identify a novel mechanism of action in GBM cells for two well 
established front line therapies for cancer resulting in enhanced tumour cell motility.
Abnormal or dysregulated tyrosine kinase (TK) activity represents a large proportion of oncogenic activity across 
a broad range of cancers. TK mutation, enhanced expression and autocrine stimulation can lead to downstream 
signalling that is responsible for enhanced migration, proliferation, angiogenesis and survival of cancer cells1,2.
Given their cardinal role in tumourigenesis, TKs have been the target for the development of inhibitors as 
therapeutics. The constitutively active oncoprotein BCR-ABL tyrosine kinase is the driver of Philadelphia chro-
mosome (Ph+ )-positive chronic myeloid leukaemia (CML)3. Imatinib, a BCR-ABL inhibitor (Gleevec, Novartis 
Pharmaceuticals Corporation, East Hanover, NJ), was the first selective tyrosine-kinase inhibitor (TKI) to be 
approved for the treatment of a cancer in 20024. Imatinib is currently first-line therapy for Ph+ -CML leading to 
remission in the majority of CML patients, and is also used for treatment of other malignancies including gas-
trointestinal stromal tumours (GIST). Imatinib was developed to bind to the ATP-binding pocket of BCR-ABL, 
competing with ATP, and thus blocking kinase activity1,2. Nilotinib, a second generation TKI, shares a very similar 
target spectrum with imatinib and was approved in 2010 to provide second-line treatment in case of resistance or 
intolerance to imatinib5. However, a considerable amount of CML patients do not respond favourably to nilotinib 
after imatinib treatment6.
Despite encouraging clinical results for CML, and for GIST7, imatinib has failed clinical trials for glioblas-
toma, where it shows no significant inhibition of tumour growth or extension of survival8,9 Imatinib and nilotinib 
potently inhibit tyrosine kinases including ARG, c-KIT, PDGFR and DDR1. Moreover, imatinib and nilotinib are 
reported to cause activation of intracellular kinases including the PI3K, Akt and ERK pathways3,7,10. Inhibition 
of other TKs and co-activation of signalling pathways may account both for the development of imatinib resist-
ance in Ph + CML and GIST, and imatinib’s lack of efficacy in glioblastoma. The functional consequences of 
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imatinib and nilotinib treatment on enhanced signalling in tumour cells remain poorly understood. In particular, 
their effects on cell functions modulating tumour behaviour are essential for understanding critically important 
aspects of drug treatment including non-responsiveness, the development of resistance, and the occurrence of 
side-effects.
The acquisition of enhanced cell motility provides tumour cells with the capacity to invade their surrounding 
tissue and metastasise, and is considered one of the “hallmarks of cancer”11. In this study, we demonstrate that 
imatinib and nilotinib treatment of glioblastoma and patient-derived glioblastoma stem cells results in increased 
tyrosine phosphorylation of several signalling proteins centrally important for cell motility including p130Cas, 
focal adhesion kinase (FAK), and paxillin (PXN), and strikingly increases tumour cell and stem cell migration 
and invasion. Surprisingly, these effects are independent of the known imatinib and nilotinib targets, ABL, ABL2 
(ARG), c-KIT, PDGFRβ and DDR1.
Our findings point to a novel and important effect of imatinib and nilotinib upon tumour cell motility. 
These data may provide insight as to why imatinib has failed clinical trials for glioma, and have implications for 
understanding mechanisms underlying the development of imatinib and nilotinib resistance in other human 
malignancies.
Experimental
Cell culture. U87, U251, and U118 glioma cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 10% (vol/vol) foetal calf serum (FCS) supplemented with Pen/Strep (1:100; P4333-Sigma).
Derivation of Human GBM stem cell lines. All patients gave informed consent before the surgical inter-
vention. The storage of human tissue is governed by the Human tissue Act (UK; HTA License #’s 12054). The 
use of tissue and cells has been approved by the National Hospital Ethics Committee (LREC 08/0077) and all 
methods were carried out in accordance with the approved guidelines. All tumours were diagnosed as glioblas-
toma (WHO grade 4) by neuropathologists. The samples were taken directly from the operating theatre and 
placed in cold Dulbecco’s modified Eagle’s medium/Ham’s F12 (DMEM/F12). The samples were finely minced, 
erythrocytes lysed by ACK buffer (Invitrogen) and tissue dissociated using Trypsin/EDTA. The resulting suspen-
sion was centrifuged and pellets re-suspended in DMEM/F12 medium supplemented with B27, bFBF, EGF and 
penicillin-streptomycin. Fresh medium was added to the cell suspensions every 3–5 days. When neurospheres 
formed, the suspension was transferred to flasks coated with laminin (Sigma). Adherent monolayer cells were 
sub-cultured by treatment with Trypsin/EDTA and plating them onto laminin coated plates for western blotting 
experiments or directly used for spheroid formation as described below.
Antibodies, reagents and small interfering RNAs (siRNAs). Antibodies to Phospho-p130Cas (Y410), 
DDR1, ABL1, ERK, Phospho-ERK (T202/Y204), Phospho-Paxillin (Y118), and Phospho-PDGF-R β (Y751) were 
from Cell Signalling Technology Inc., (Danvers, MA, USA). Antibodies to PDGFR-β , focal adhesion kinase (FAK; 
A-17), β 1 Integrin, β 3 Integrin, c-RAF, B-RAF, Paxillin (H-114), and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH; V-18) were from Santa Cruz Inc., (Heidelberg, Germany). Secondary antibodies to mouse, goat and
rabbit were also from Santa Cruz Inc. Antibody to Phospho-FAK (Y861) was purchased from Life Technologies
(Carlsbad, USA). Antibody to p130Cas antibody was from BD Transduction Laboratories (Oxford, UK). The anti-
body to ABL2 (N1N3) was from GeneTex (Irvine, USA). The Fak/Pyk2 inhibitor PF573228 was purchased from
Tocris Bioscience (Bristol, UK). PDGF-BB was purchased from Peprotech (London, UK). Dimethyl sulphoxide 
(DMSO) was purchased from Sigma. U0126, Imatinib and Nilotinib were purchased from Source Bioscience
(UK). The pH2B-GFP plasmid, encoding histone H2B fused to the green fluorescent protein, was obtained from
Professor Sibylle Mittnacht (UCL Cancer Institute).
The following small interfering (si) RNAs were purchased from Dharmacon (GE Healthcare, UK):
si ITGB1-1: 5′-GAACAGAUCUGAUGAAUGA‐3′
si ITGB1-2: 5′-CAAGAGAGCUGAAGACUAU‐3′
si ITGB3-1: 5′-CUCUCCUGAUGUAGCACUUAA-3′
si ITGB3-2: 5′-CACGUGUGGCCUGUUCUUCUA-3′
si p130Cas #2: 5′‐GGUCGACAGUGGUGUGUAU‐3′
The following siRNA was purchased from Life Technologies (Carlsbad, USA):
si p130Cas #1: 5′ ‐GAGUUUGAGAAGACCCGATT‐3′
The following siRNAs were purchased from Qiagen (Crawley, UK):
AllStars Negative Control
siPDGFR-β 5′-GGAACGTGCTCATCTGTGA-3′
siABL1 (#10) 5′-ACGCACGGACATCACCATGAA-3′
siABL2 (#8) 5′-AACCCTGTCCTTAATAACTTA-3′
siCRAF (#5) 5′-AAGACGTTCCTGAAGCTTGCC-3′
siBRAF (#1) 5′-AACATATAGAGGCCCTATTGG-3′
siDDR1 (#9) 5′-ACGGTGTGAATCACACATCCA-3′
siRNA Transfection. U87 and U251 glioma cells at 60% confluence were transfected with Lipofectamine 
2000 (Invitrogen) using 25 nM final concentration of siRNA as described12.
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Immunoblotting. For immunoblotting, cells were lysed in a solution containing 50 mM Tris-HCl (pH 7.5), 
1% Triton X-100, 150 mM NaCl, 5 mM EDTA, complete protease inhibitor (Roche) and phosphatase inhibitors I 
& II (Sigma) and analysed by SDS-PAGE using 4 to 12% Bis-Tris gels (NuPAGE; Invitrogen), followed by electro-
transfer onto Invitrolon polyvinylidene difluoride membranes (Invitrogen). Membranes were blocked with 5% 
(wt/vol) non-fat dry milk and 0.1% (vol/vol) Tween-20 in Tris-buffered saline for 1 hour at room temperature, 
before being probed with the primary antibody by overnight incubation at 4 °C, followed by incubation for 1 hour 
at room temperature with a horseradish peroxidase-linked secondary antibody (Santa-Cruz) and detection using 
ECL reagents (Bio-Rad, Hercules, USA), following the manufacturer’s protocol. Immunoblots were quantified by 
scanning of films with a calibration strip and analysis by densitometry using Image J (US National Institutes of 
Health; http://rsb.info.nih.gov/ij).
Immunofluorescent staining and Confocal Imaging. For immunofluorescent staining, cells were 
fixed in 4% paraformaldehyde in PBS for 60 min followed by permeabilisation in 0.2% Triton X100 for 30 min. 
Antibody incubations were performed overnight at 4 °C in 1% BSA, 0.1% Tween20 in PBS. Confocal imaging 
was performed using a LEICA SPE2 upright microscope running LEICA-LAS software using sequential imaging 
capture.
Transwell chemotactic migration assay. This assay was performed as described previously12. Briefly, 
Transwell cell culture inserts (Falcon; BD Biosciences, Oxford, UK), were inserted into a 24-well plate. Serum free 
media supplemented with or without imatinib or vehicle were placed in the bottom chamber, and U87 glioma 
cells in suspension (1.5 × 105 cells/well in serum free DMEM) were added to the top chamber and incubated at 
37 °C in for 6 h. Cells that had not migrated or had only adhered to the upper side of the membrane were removed 
before membranes were fixed and stained with a Reastain Quik-Diff kit (IBG Immucor Ltd, West Sussex, UK). 
Cells that had migrated to the lower side of the membrane were counted in four random fields per well at 20× 
magnification using an eyepiece indexed graticule.
Cell Proliferation assay. Proliferation of U87MG cells (stably expressing H2B-GFP) was determined in 
96-well plates (seeding density of 2000 cells per well) by assessing total cell fluorescence intensity per well in living
cells using an IncuCyte Zoom (Essen Bioscience) for up to 96 hours.
Three dimensional (3D) spheroid invasion assay. Spheroids were generated using the metho-cellulose 
technique as previously described13,14. siRNA transfection were carried out on cells as described above. Following 
24 hours transfection, cells were trypsinised, and 5 × 104 cells/ml were suspended in a medium containing a 4:1 
(v/v) mixture of 10% FCS in DMEM and methylcellulose. Spheroids were produced by pipetting 100 µ l of the 
cell suspension into a well of a 96-well round bottomed non-tissue culture plate and incubating for 24 hours 
(37 °C, 5% CO2). Spheroids were collected and embedded in Collagen I plugs (2.1 mg/ml) prepared from fibrillar 
bovine collagen I (3.1 mg/ml; PureCol) by dilution in DMEM in accordance with the manufacturer’s protocol 
(Nutacon, The Netherlands). The collagen I solution was supplemented with either DMSO or 10 uM imatinib or 
1 uM nilotinib. Spheroids were allowed to invade for 48 hours followed by fixation in 4% formaldehyde. Spheriod 
Invasion was determined by measuring the circular area of the spheroid core and the rim of Invasion using Image 
J. The rim of invasion was determined by the circular distance from the edge of the core to the edge of contiguous
invading cells13,15.
Scratch wound assay. Cells were seeded to confluence, scratched evenly at the centre, and treated with 
imatinib, nilotinib, or vehicle control. Rate of wound closure was measured using an Incucyte Zoom (Essen 
Bioscience, UK). Images were captured every hour for 30 hours.
Immunoprecipitation. Cells were washed with PBS, lysed in NP40 (50 mM Tris–HCl at pH 8, 150 mM 
NaCl, 0.5% NP40) containing protease and phosphatase inhibitors and centrifuged for 15min at high speed 
(16000 g at 4 °Cmin). Immune complexes were collected when 1mg of cell lysate was immunoprecipitated with 
2 µ g of antibody or with control IgG. Lysis buffer was used to wash the beads three times before a final wash using 
0.6M lithium chloride was performed. These samples or 20 µ g lysate was then supplemented with sample buffer 
(Tris at pH 6.8, 20% glycerol, 5% SDS, β -mercaptoethanol and bromo-phenol blue), separated by SDS–PAGE, 
transferred to a nitrocellulose membrane and then immunoblotted.
Statistical analysis. The data displayed on graphs are means, with error bars representing the standard error 
of the mean (SEM). Statistical analysis was performed by two-way analysis of variance (ANOVA), or T-test where 
appropriate. P < 0.05 was considered significant.
Results
We treated the human glioblastoma multiforme (GBM) cell line U87MG with either imatinib or nilotinib and 
investigated their effects on key signalling components required for tumour cell motility and invasion. Tyrosine 
phosphorylation of p130Cas at Tyr410, FAK at Tyr861 and PXN at Tyr118 play important roles in cell migration 
and invasion and were used as readouts of activation of these signalling pathways12,16,17. Treatment with 10 µ M 
imatinib or nilotinib caused a striking increase in tyrosine phosphorylation of p130Cas, Focal Adhesion Kinase 
(FAK) and Paxillin (PXN) (Fig. 1A). These effects were dose-dependent, with a significant increase detected at 1 µ M 
and a maximal response at 10 µ M for both imatinib and nilotinib in U87MG cells (Fig. 1B). Because the peak 
plasma/serum concentrations of imatinib and nilotinib, are approximately 5 µ M and 4 µ M, respectively18,19, our 
data indicate that these effects occur at clinically relevant concentrations. The effects of imatinib and nilotinib on 
www.nature.com/scientificreports/
4Scientific RepoRts | 6:27378 | DOI: 10.1038/srep27378
Figure 1. Imatinib and nilotinib treatment of human GBM cells leads to increased p130Cas, Focal Adhesion 
Kinase (FAK) and Paxillin (PXN) tyrosine phosphorylation. Cells (~80% confluent) were incubated in SFM for 
~18 hr prior to treatment with either SFM & DMSO vehicle control (C), or imatinib or nilotinib at the indicated 
concentrations and times. Cell lysates were then prepared, blotted, and probed with the indicated antibodies. 
Blots shown here and in all subsequent figures unless indicated are representative of at least three separate 
experiments. (A), U87MG cells were treated with vehicle control (C), or 10 µ M imatinib or 10 µ M nilotinib for 
20 minutes. (B), Dose dependency of imatinib or nilotinib treatment for 20 minutes in U87MG cells. (C), Time 
course of U87MG cells treated with vehicle control (C), or 10 µ M imatinib or 10 µ M nilotinib. Quantitation 
of tyrosine phosphorylation was performed by densitometry using Image J. In each panel, data from at least 
www.nature.com/scientificreports/
5Scientific RepoRts | 6:27378 | DOI: 10.1038/srep27378
tyrosine phosphorylation of p130Cas, FAK and PXN were also rapid and sustained with a significant increase 
observed at 10 min, reaching a maximum at 30 min, which was maintained for up to 1 hour (Fig. 1C). After 
4 hours, p130Cas tyrosine phosphorylation declined to near basal level, whereas FAK and PXN tyrosine phos-
phorylation remained strongly elevated. These results were further supported by the finding that imatinib and 
nilotinib induced p130Cas, FAK and PXN tyrosine phosphorylation in the glioma cell line, U251MG (Fig. S1).
We also examined the effect of imatinib and nilotinib treatment on the localisation of phosphorylated p130Cas 
in U87MG cells by performing immunofluorescence confocal microscopy. As expected the levels of phosphoryl-
ated p130Cas (Tyr 410) increased in both imatinib and nilotinib treated cells after 20 min. We also observed a 
striking redistribution of phoso-p130Cas to the cell membrane, localising along what appear to be membrane 
ruffles (Fig. 1D).
Imatinib and nilotinib are both inhibitors of the Abl family tyrosine kinases, ABL1 and ABL2 (also called 
ARG). Furthermore, since Abl has been reported to regulate p130Cas tyrosine phosphorylation20, we reasoned 
that ABL1 and/or ABL2 could be mediating the effects of imatinib and nilotinib treatment in these glioma cell 
lines. We treated U87MG cells with siRNA to ABL1 and ABL2 either individually or in combination in the pres-
ence of imatinib, nilotinib or vehicle control. Knockdown of ABL1 or ABL2 alone or together had no effect on 
p130Cas, FAK and PXN tyrosine phosphorylation in control treated cells. Furthermore ABL1 and ABL2 silenc-
ing had no effect on imatinib and nilotinib mediated increases in p130Cas and PXN tyrosine phosphorylation, 
whereas tyrosine phosphorylation of FAK was reduced. Interestingly, knockdown of ABL1 and to a lesser extent 
ABL2 caused a decrease in total p130Cas and total PXN expression, whilst total FAK levels were unaffected 
(Fig. 2A). Imatinib and nilotinib inhibit additional tyrosine kinases, including platelet derived growth factor 
receptor beta (PDGFRβ ), stem cell growth factor receptor (c-KIT), and discoidin domain receptor tyrosine kinase 
1 (DDR1). However, silencing of PDGFRβ and DDR1 had no effect on increased tyrosine phosphorylation in 
response to imatinib and nilotinib (Fig. 2B & S2A). We were unable to detect c-KIT in U87MG cells, whereas we 
could readily detect c-Kit in human coronary artery smooth muscle cells (HCASMCs), indicating that c-Kit is not 
significantly expressed in U87MG cells (Fig. S2B).
The SRC tyrosine kinase is well known to play a role in the regulation of p130Cas, FAK and PXN tyrosine 
phosphorylation20. We therefore looked at the effect of using the SRC kinase inhibitor, PP2, in imatinib and 
nilotinib treated U87MG cells. We found that PP2 treatment leads to a complete abrogation of both basal and 
imatinib/nilotinib induced tyrosine phosphorylation of p130Cas, FAK and PXN (Fig. S3). This result led us to 
look at the levels of tyrosine 416 phosphorylation in SRC. We found that imatinib and nilotinib treatment did not 
result in any changes in the levels of Y416 phosphorylation (data not shown).
It has recently been reported that imatinib and nilotinib treatment leads to activation of MEK and ERK in 
several human tumour cell lines3, and ERK signalling has been implicated in meditating signalling pathways 
required for migration of glioma cells21,22. We therefore examined the effect of imatinib and nilotinib treatment on 
ERK activation in U87MG cells. Although imatinib treatment increased levels of phosphorylated ERK, nilotinib 
treatment had no effect (Fig. S4A). Furthermore, whereas the MEK inhibitor, U0126, completely abolished levels 
of phosphorylated ERK in all samples treated, it had no effect on imatinib and nilotinib stimulation of p130Cas, 
FAK, and PXN tyrosine phosphorylation (Fig. S4A). It was recently reported that imatinib and nilotinib can bind 
to B-RAF and C-RAF leading to the formation of RAF hetero- and homo-dimers, and stimulate paradoxical 
activation of BRAF and CRAF in the presence of activated RAS3. We therefore considered the possibility of a 
RAF-dependent, MEK/ERK-independent pathway leading to increased tyrosine phosphorylation of p130Cas, 
FAK and PXN. However, silencing of B-RAF or C-RAF either alone or together had no effect on imatinib and 
nilotinib stimulated increases in tyrosine phosphorylation (Fig. S4B). Because imatinib treatment was able to 
increase levels of ERK phosphorylation (Fig. S4A) we looked at the effect of imatinib and nilotinib treatment 
on U87MG cell proliferation. As shown in Fig. S7, drug treatment has no significant effect on cell proliferation.
Integrins are known to mediate p130Cas and FAK tyrosine phosphorylation through beta 1 & beta 3 
subunits20,23. To test the possibility that imatinib and nilotinib stimulated tyrosine phosphorylation of p130Cas, 
FAK and PXN occurs via an integrin signalling pathway, we treated U87MG cells with siRNA to either beta 1 or 
beta 3 integrins. Knockdown resulted in a marked reduction in integrin protein expression, yet had no effect on 
increased p130Cas, FAK and PXN tyrosine phosphorylation (Fig. S4C,D).
Because p130Cas and FAK have been reported to exist in multi-protein complexes required for cell motility20, 
we examined the association of these molecules in glioma cells, and their interdependence in the response of 
U87MG cells to imatinib and nilotinib. Immunoprecipitation of p130Cas and subsequent immunoblotting 
showed that FAK and PXN were both constitutively complexed with p130Cas in U87MG glioma cells, and that 
these complexes were not affected by imatinib or nilotinib treatment (Fig. S5). However, targeted knockdown 
of p130Cas with two different siRNA significantly reduced tyrosine phosphorylation of FAK and PXN induced 
by imatinib and nilotinib (Fig. 3A). Furthermore, treatment of U87MG cells with the FAK inhibitor PF-573,228 
(PF-228) significantly reduced the imatinib and nilotinib stimulated increases in p130Cas and PXN tyrosine 
phosphorylation (Fig. 3B).
three independent experiments are presented as phosphorylation relative units (RU) (means + /− s.e.m.) 
normalized to total protein levels; * p < 0.05, ** p < 0.01 compared to vehicle control (C). #p > 0.05 compared 
to vehicle control (C). (D), U87MG cells were seeded on glass cover slips and incubated in SFM for ~18 h prior 
to for 20 min with vehicle control (C), or 10 µ M imatinib or 10 µ M nilotinib. Confocal imaging was performed 
as described in Materials and Methods, with phosphorylated p130Cas (Y410) staining in green, actin in Red 
and DAPI in purple. Images are representative of at least three separate experiments. Arrows point to areas of 
increased p130Cas (pY410) localisation to the membrane upon treatment.
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Signalling via p130Cas and FAK pathways plays crucial roles in the regulation of cellular motility13,20,24. 
We therefore investigated the effects of imatinib and nilotinib treatment on glioma cell motility using both a 
three dimensional (3D) spheroid assay and two dimensional (2D) assays of chemotaxis and wound healing. We 
Figure 2. Imatinib and Nilotinib target proteins are not required for increased p130Cas, FAK and PXN 
tyrosine phosphorylation. (A), U87MG cells were transfected with siRNA targeting ABL1 (siABL1), ABL2 
(siABL2) or together at a concentration of 25 nM, or with 25 nM of a control scrambled siRNA (siScr). (B) U87MG 
cells were transfected with siRNA targeting PDGFR Beta (siPDGFRB), cells were transfected at a concentration of 
25 nM, or with 25 nM of a control scrambled siRNA (siScr). 48 hr post transfection, cells were incubated in serum-
free medium (SFM) for ~18 hr prior to treatment with SFM & DMSO vehicle control (C), or 10 µ M imatinib or 
10 µ M nilotinib for 20 minutes. Cell lysates were then prepared, blotted, and probed with the indicated antibodies.
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generated spheroids from U87MG, U251 and U118MG GBM cell lines and embedded them in collagen I plugs 
supplemented with either serum free medium (SFM) and DMSO (Veh), or SFM containing imatinib or nilotinib. 
Treatment with either imatinib or nilotinib alone for 48 hours resulted in a striking increase in radial invasion 
compared to the vehicle control spheroids (Fig. 4A–C). In transwell assays of chemotactic cell motility, we found 
surprisingly that imatinib acted as a chemo-attractant agent and was able to stimulate increased migration in 
U87MG cells (Fig. S6A). Furthermore, in wound healing assays in U251MG cells we found that either imatinib 
or nilotinib treatment resulted in increased rates of wound closure compared to control vehicle-treated cells 
(Fig. S6B). We next investigated the role of p130Cas, FAK and the MEK/ERK pathway in imatinib and nilotinib 
Figure 3. Increased p130Cas, FAK and Paxillin tyrosine phosphorylation is dependent on p130Cas expression 
and FAK kinase activity (A) U87MG cells were transfected with siRNA targeting p130Cas (si p130Cas) at a 
concentration of 25 nM, or with 25 nM of a control scrambled siRNA (siScr). 48 hr post transfection, cells were 
incubated in serum-free medium (SFM) for ~18 hr prior to treatment with SFM & DMSO vehicle control (C), 
or 10 µ M imatinib or 10 µ M nilotinib for 20 minutes. (B) U87MG cells (~80% confluent) were incubated in 
SFM for ~18 hr prior to pre-incubation for 30 min with 5 µ M PF573228 or the vehicle (0.05% DMSO) (C) prior 
to treatment with SFM & DMSO vehicle control (C), or 10 µ M imatinib or 10 µ M nilotinib for 20 minutes. 
Cell lysates were then prepared, blotted, and probed with the indicated antibodies. Quantitation of tyrosine 
phosphorylation was performed by densitometry using Image J. In each panel, data from at least three 
independent experiments are presented as phosphorylation relative units (RU) (means + /− s.e.m.) normalized 
to total protein levels; * p < 0.05 compared to vehicle control (C).
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Figure 4. Imatinib and Nilotinib treatment of human GBM cells leads to increased 3D radial invasion of GBM 
cell spheroids (A) U87MG. (B) U251MG. (C) U118MG. (A–C) Equal amounts of cells were used to generate 
spheroids as described in Materials and Methods. 24 hours after spheroid production, spheroids were imbedded 
in a collagen gel and incubated in either SFM & DMSO vehicle control or 10 µ M imatinib or 1 µ M nilotinib 
for an additional 48 hours. ** p < 0.01 compared to SFM & DMSO vehicle control. (D) Spheroids derived from 
U87MG cells treated with siRNA to p130Cas (si p130Cas #1 & #2) or control scrambled siRNA (siScr) were 
imbedded in collagen containing either SFM & DMSO vehicle control or 10 µ M imatinib or 1 µ M nilotinib and 
treated as above. ** p < 0.01 compared to imatinib and nilotinib siScr respectively.(E) Spheroids derived from 
U87MG cells were imbedded in collagen containing either SFM & DMSO vehicle control, 5 µ M PF573228 
or 10 µ M U0126 and treated as above. ** p < 0.01 compared to imatinib and nilotinib DMSO vehicle control 
respectively. #p> 0.05 compared to SFM & DMSO vehicle control. Spheroids were fixed in 4% PFA and invasion 
was determined by measuring the area corresponding to the invasion rim minus the area of the core for at least 
3 different spheroids per condition. Data from three independent experiments are presented as relative area 
units (RU) (means + /− s.e.m.).
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stimulated spheroid invasion. Spheroids from U87MG cells treated either with siRNA to p130Cas or with phar-
macological inhibitors of FAK (PF-228) or MEK (U0126) were prepared and then treated with imatinib and 
nilotinib. Silencing of p130Cas, or treatment with PF-228 significantly reduced invasion induced by imatinib 
and nilotinib (Fig. 4D,E), whereas U0126 treatment had no significant effect on radial invasion in imatinib and 
nilotinib treated spheroids, although U0126 alone resulted in a small but significant increase in radial invasion 
compared with SFM vehicle control (Fig. 4E). The importance of cancer stem cells (CSCs) in tumour progression 
and their role in driving tumour relapse after treatment is emerging rapidly. GBM is one of the first tumours 
where (CSCs) were identified. Glioma stem cells (GSCs) are thought to be responsible for tumour maintenance 
and critically important in recurrence after resection25. We therefore examined the relevance of our findings in 
glioma cell lines to GSCs by investigating the effects of imatinib and nilotinib on GSCs isolated from human GBM 
biopsies. Imatinib and nilotinib treatment of a recently isolated GSC line significantly increased tyrosine phos-
phorylation of p130Cas, FAK and PXN (Fig. 5A). Furthermore, imatinib and nilotinib treatment of spheroids 
generated from the GSC line and two additional GSC lines significantly increased 3D radial invasion compared 
to the vehicle control (Fig. 5B).
Discussion
Here we show that treatment of human glioma cell lines with the tyrosine kinase inhibitors imatinib and nilotinib 
produces a rapid and striking increase in tyrosine phosphorylation of p130Cas, FAK and PXN, key signalling 
molecules required for cell motility20,24. These effects were induced at concentrations similar to clinically relevant 
drug concentrations. The finding that imatinib and nilotinib treatment stimulates tyrosine phosphorylation as 
early as 10 minutes indicates that this is an immediate response though a direct drug effect on signalling com-
ponents distal to p130Cas and FAK pathways. This is in contrast to the indirect result of longer-term effects on 
metabolism or gene expression3,26,27. Furthermore, localisation of tyrosine phosphorylated p130cas to the cell 
membrane in imatinib and nilotinib treated cells is in agreement with the previously reported roles for p130Cas 
in cell motility20.
A surprising result of this study is that the effects of imatinib and nilotinib on p130Cas, FAK and PXN tyrosine 
phosphorylation were independent of the major known tyrosine kinase targets for these drugs. Knockdown of 
ABL1, ABL2 or both ABL1 & ABL2 had no effect on imatinib and nilotinib stimulated tyrosine phosphorylation 
of p130Cas and PXN. We did however detect a significant reduction in imatinib and nilotinib stimulated tyrosine 
Figure 5. Imatinib and Nilotinib treatment of stem cells from human GBM biopsies leads to increased 
p130Cas, Focal Adhesion Kinase (FAK) and PXN tyrosine phosphorylation and increased 3D spheroid 
radial invasion. (A) Stem cells established from a human GBM biopsy (cell line: NH10-1124) (~80% confluent) 
were incubated in SFM for ~18 hr prior to treatment with either SFM & DMSO vehicle control (C), or imatinib 
or nilotinib for 20 minutes. Cell lysates were then prepared, blotted, and probed with the indicated antibodies. 
(B) Spheroids derived from the indicated stem cell lines established from human GBM biopsies were imbedded
in a collagen gel and incubated in either SFM & DMSO vehicle control (C), or 10 µ M imatinib or 1 µ M nilotinib
for an additional 48 hours. Spheroids were fixed in 4% PFA and invasion was determined by measuring the area
corresponding to the invasion rim minus the area of the core for at least 3 different spheroids per condition.
Data from three independent experiments are presented as relative area units (RU) (means + /− s.e.m.).
* p < 0.05, ** p < 0.01 compared to SFM & DMSO vehicle control (C).
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phosphorylation of FAK in cells treated with siRNA to ABL1, and both ABL1 & ABL2. This is most likely due 
to the reduction in total p130Cas expression observed in ABL1 and ABL1 & ABL2 treated cells. This is sup-
ported by our results showing that small changes in p130Cas knockdown efficiency between two different siRNAs 
exhibit differences in the reduced levels of imatinib and nilotinib stimulated tyrosine phosphorylation of FAK 
and Paxillin. Furthermore, knockdown of PDGFRβ , and DDR1 had no direct effect on imatinib and nilotinib 
stimulated tyrosine phosphorylation of p130Cas, FAK and PXN. Whilst the lack of expression of c-Kit in U87MG 
cells indicates it is not responsible for these effects. It is important to note that these experiments also preclude 
the possibility of kinase independent roles for these targets. SRC is the main kinase responsible for tyrosine phos-
phorylation of these proteins20. We found that pharmacological inhibition of SRC leads to a complete abrogation 
of both basal and imatinib/nilotinib induced tyrosine phosphorylation of p130Cas, FAK and PXN. However, 
imatinib and nilotinib treatment did not result in any changes in the levels of tyrosine 416 phosphorylation in 
SRC, making it difficult to interpret these data in the context of a direct role for SRC.
Another potential mechanism underlying the effects of imatinib and nilotinib on motility-associated tyrosine 
phosphorylation is increased signalling through the RAF/MEK/ERK pathway, which has recently been reported 
to occur in several human tumour cell lines in response to these drugs3. Whilst we observed increased ERK phos-
phorylation in response to imatinib treatment, nilotinib treatment did not lead to increased ERK phosphoryla-
tion, possibly pointing to engagement of different signalling pathways in glioma cells. Furthermore, inhibition of 
MEK/ERK signalling using U0126 had no effect on imatinib- and nilotinib-stimulated tyrosine phosphorylation. 
In addition, we observed no effect of silencing of B-RAF or C-RAF, either alone or together, on increased tyrosine 
phosphorylation in response to imatinib and nilotinib.
Many studies have shown a role for integrin receptors and integrin signalling in the regulation of p130Cas, 
FAK and PXN tyrosine phosphorylation either through “inside-out” or “outside-in” signalling20,24. We however, 
found no effect on increased tyrosine phosphorylation in cells which were depleted of integrin β 1 or Integrin β 3 
by gene silencing. This result is in agreement with our recent work showing that p130Cas tyrosine phosphoryla-
tion and 3D invasion were independent of integrin β 1 in U87MG cells28.
Both p130Cas and FAK have been shown to signal through multi-protein complexes, required for cell motility13,20, 
yet the individual contributions of these molecules in such complexes is not completely understood. Our previ-
ous studies show that platelet derived growth factor (PDGF-BB) or hepatocyte growth factor (HGF) stimulated 
tyrosine phosphorylation of p130Cas in U87MG cells was independent of FAK kinase activity12. However, we 
show here that both p130Cas expression and FAK kinase activity are required for the increased tyrosine phospho-
rylation of p130Cas, FAK, and PXN, and glioma cell spheroid invasion induced by imatinib and nilotinib. This 
supports the conclusion that imatinib and nilotinib impact upon p130Cas and FAK complexes via a signalling 
pathway distinct from that mediating PDGFRβ and c-Met signalling and motility in U87MG cells12.
An important finding of this study is that, consistent with increased tyrosine phosphorylation of p130Cas, 
FAK, and PXN induced by imatinib and nilotinib treatment, these drugs strikingly increased motility in 2D and 
3D models using multiple human glioma cell lines. The conclusion that the pro-invasive activity of imatinib and 
nilotinib is mediated through p130Cas and FAK signalling is supported by the finding that the response to these 
drugs was strongly reduced by silencing of p130Cas and inhibition of FAK, but not by the inhibition of MEK.
Imatinib and nilotinib are successfully used in the clinic as front line therapies for Ph+ CML. In this con-
text, Ph+ CML is the result of a single driver mutation and does not possess the genetic heterogeneity that is 
observed in GBM29. CML is a cancer of the white blood cells, resulting in increased and unregulated growth of 
predominantly myeloid cells in the bone marrow and the accumulation of these cells in the blood30. These cells 
are non-adherent and do not rely on adherent modes of cell motility for tumour progression. Imatinib-resistant 
Ph+ CML patients are either initially resistant (primary) or develop resistance over the course of treatment 
(acquired)31. Patients with advanced stage disease frequently have both32. The process involved in both primary 
and acquired imatinib-resistance can be divided into either BCR-ABL-dependent or BCR-ABL -independent 
mechanisms. BCR-ABL-dependent mechanisms include point mutations within the kinase domain resulting 
in reduced drug potency, while BCR-ABL -independent mechanisms are more varied and poorly understood. 
However, there are reports of imatinib-resistant Ph+ CML tumour cells undergoing a mesenchymal-like conver-
sion associated with increased levels of FAK tyrosine phosphorylation and increased adherence and invasiveness26. 
Furthermore, imatinib is used as an adjuvant therapy in patients with Gastrointestinal stromal tumour (GIST) 
and there are reports of imatinib treated GIST cells showing increased FAK tyrosine phosphorylation after long 
term treatment (6–24 hours)27,33. On the basis of our results, we also propose that pharmacological modulation 
of FAK activity could provide an approach to boost imatinib and nilotinib efficacy and limit resistance to these 
drugs in CML & GIST and other cancers in which imatinib is used, a possibility that warrants further investi-
gation. In this context, it is of interest that pharmacological inhibition of FAK using TAE226 can synergise with 
nilotinib in reducing Ph+ CML growth34,35. Furthermore, a FAK-selective inhibitor (TAG372) induced apoptosis 
of imatinib-resistant GIST-T1 cells and decreased the imatinib IC5033.
The results presented here suggest a potential adverse effect of the use of imatinib and nilotinib treatment in 
GBM tumours, which is dependent on augmented adherent tumour cell motility. The relevance of our study for 
human GBM is further underscored by the finding that imatinib and nilotinib treatment of stem cell lines derived 
from human GBM biopsies also increased p130Cas, FAK and PXN tyrosine phosphorylation and radial invasion 
of spheroids generated from these cell lines. Imatinib and nilotinib treatment resulting in enhanced invasion 
through increased p130Cas and FAK signalling could lead to selection of tumour cells with increased motility 
independent of c-ABL and PDGFRβ signalling pathways. Recently, imatinib was tested in a multi-centre phase III 
clinical trial for patients with recurrent GBM. The results indicated that there were no clinically meaningful dif-
ferences between mono therapies (Hydroxy Urea or Temozolimide) or combination therapies with imatinib36 and 
the primary study end point was not met. GBM is an extremely aggressive cancer due in part to its highly invasive 
nature. Our findings indicate important and unforeseen adverse effects of imatinib and nilotinib treatment on 
www.nature.com/scientificreports/
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tumour cell motility, which could be a significant contributor to the lack of clinical efficacy observed in these 
trials. These results point to the necessity for screening imatinib, nilotinib and other members of this class of TKI 
for their effects on multiple modes of cell motility in specific cancers and other diseases where therapeutic efficacy 
is being investigated.
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